Official Title of Study:  
A Global, Phase 2, Randomized, Double -Blind, Placebo -Controlled, Dose -Ranging Study of  
BMS- 986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or  
New Covert Brain Infarction in Patients Receiving Aspi[INVESTIGATOR_880404] (TIA)  
 
PROTOCOL: CV010- 031 
 
Study ID: [REMOVED]  
  
Document Date (Date in which document was last revised): October 9, 2020  
Page: 1
Protocol Number: CV010031
IND Number: 138,[ADDRESS_1230444] Number: 2017-005029-19
Date: 13-Jul-2018
Revised Date: 09-Oct-2020
Clinical Protocol CV010031
A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of 
BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarction in Patients Receiving Aspi[INVESTIGATOR_880405] (TIA)
AXIOMATIC-SSP
Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute 
Thromboembol ic events in Secondary Stroke Prevention
Revised Protocol 06
24-hr Emergency Telephone Number
[LOCATION_003]: 
International: 
Bristol-Myers Squibb Company
Route 206 & Province Line Road
Lawrenceville, NJ [ZIP_CODE]
Avenue de Finlande 4
B-1420 Braine-l ÕÉAlleud, Belgium
6-5-1 Nishi-Shinjuku, Shinjuku-ku,
Tokyo, 163-1327, Japan
Approved 8.0 v Approved 1.0 v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Revised Protocol No.: 06
Date: 09-Oct-2020 2BMS -986177 is being co- developed under a collaboration agreement between Bristol -Myers 
Squibb Company (BMS) and Janssen Pharmaceuticals, Inc. (Janssen)
This document is the confidential and proprietary information of B ristol -Myers Squibb and 
its global affiliates (BMS) , andco-development partner Janssen . By [CONTACT_52212], 
you agree to keep it confidential and to use and disclose it solely for the purpose of assessing 
whether your organization will participate in and/or the performance of t he proposed BMS -
sponsored study. Any permitted disclosures will be made only on a confidential "need to 
know" basis within your organization or to your independent ethics committee(s). Any other 
use, copying, disclosure or dissemination of this information is strictly prohibited unless 
expressly authorized in writing by [CONTACT_20444]. Any supplemental information (eg, amendments) 
that may be added to this document is also confidential and proprietary to BMS and Janssen 
and must be kept in confidence in the same manner as the contents of this document. Any 
person who receives this document without due authorization from BMS or Janssen is 
requested to return it to BMS or promptly destroy it. All other rights reserved. References 
to BMS in this protocol may also apply to partners to which BMS has transferred obligations, 
eg, a Cont ract Research Organization (CRO).
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Revised Protocol No.: 06
Date: 09-Oct-[ADDRESS_1230445] -2020 ÔÇ∑Increased NIHSS score inclusion criterion for qualifying 
event f rom ‚â§5 to ‚â§7.
ÔÇ∑Rem oved use of thrombolytic therapy/mechanical 
thrombectomy for treatment of the index event from 
exclusion criteria and added to inclusion criteria to be 
permitted under specified conditions.
ÔÇ∑Added intracranial artery stenosis requiring angioplasty 
within 90 days to the exclusion criteria.
ÔÇ∑Clarified that treated aneurysms without history of 
intracranial bleed are permitted.
ÔÇ∑Clarified that only complete occlusion of a cervical carotid 
artery  or an intracranial artery on the ipsilateral site and 
proximal to the index lesion are exclusionary for the study.
ÔÇ∑Clarified UFH or LMWH for DVT prophylaxis allowance 
prior to enrollment.
ÔÇ∑Updated INR exclusion requirement from INR >1.7 to INR 
>1.5.
ÔÇ∑Updated exclusion criteria to include history of 12-lead 
ECG findings requiring exclusion.
ÔÇ∑Added exclusion criterion of known SARS -CoV -2 infection 
within 4 weeks of scre ening and associated conditions .
ÔÇ∑Clarified that a clinical (standard -of-care) MRI scan can be 
used as the baseline MRI provided that the clinical MRI 
protocol and scanner have been pre -
approved by [CONTACT_11344].
ÔÇ∑Rem oved requirement of baseline MRI within 48 hours of 
index event and prior to randomization and provided 
instructio n regardi ng instances where the baseline MRI 
cannot be performed within 48 hours of the index event and 
before randomization.
ÔÇ∑Expanded the available window for the baseline MRI for 
instances where the MRI cannot be performed within 48 
hours of the index event and prior to randomization to up to 
72 hours after the onset of the index event and up to 24 
hours after randomization 
ÔÇ∑Rem oved +10 day visit window from Day 90 visit and 
added instruction regarding performance of the Day 90 
MRI when impacted by [CONTACT_25963] -19 pa ndemic.
ÔÇ∑Added statement that alternative measures can be 
considered to obtain required visit assessments for 
participants who are unable or not permitted to attend an 
onsite visit due to the COVID -19 pandemic as local 
regulato ry requirements permit.
ÔÇ∑Update d Day  [ADDRESS_1230446] 
requirement for participants who completed required 
assessments at Day 60 site visit and removed requirement 
of reviewing Day 60 clinical laboratory results with 
participant.
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Revised Protocol No.: 06
Date: 09-Oct-2020 4Document Date of Issue Summary of Change
ÔÇ∑Added statement that the DMC recommendation regarding 
the Day  60 clinical laboratory sample will be 
communicated to the investigator by [CONTACT_1034].
ÔÇ∑Updated the miles tone requirement for DMC review to 
decide on inclusion of the 200 -mg BID dose arm.
ÔÇ∑Rem oved contrast use restriction fo r the collection of the 
study MRIs to allow for contrast agent administration as per 
investigator discretion and local clinical practice.
ÔÇ∑Revised statement that study drug BMS -[ADDRESS_1230447] be 
permanently discontinued if thrombolytic therapy or 
thrombectomy is used for the treatment of a new stroke 
during the study to allow for only a temporary interruption 
and restart of BMS -986177 if pr e-specified conditions are 
met.
ÔÇ∑Modified required duration of SAE collection from 7 days 
after discontinuation of dosing to through the follow -up 
period.
ÔÇ∑Simplified pharmacokinetic and pharmacodynamic 
sampling schedules.
ÔÇ∑Added biomarkers related to SARS -CoV -2 infection status 
or related pathophysiological pathways to exploratory 
biomarker assessments. 
ÔÇ∑Provided sample size est imations for the study without 
inclusion of the 200- mg BID dose arm.
ÔÇ∑Updated Appendix 2 to specify that other means of remote 
monitoring approved by [CONTACT_880545].
ÔÇ∑Other changes made related to ty pographical errors, 
clarificatio ns, changes in terminology, and alignment to 
other key study documents.
Revised Protocol 05 24-Aug -2019 ÔÇ∑Rem oved 3 QD doses groups (lowest 25 mg QD dose is 
maintained); keepi[INVESTIGATOR_880406]. Accordingly, the sample 
size of the study  is reduced and primary objective is updated 
(dose -response trend is retained; MED and ED90 assessment 
is removed)
ÔÇ∑Primary  analy sis MCP -MOD (include placebo and [ADDRESS_1230448] dose)
oAdditional exploratory analyses using the 25 mg QD dose 
and c ontrol
ÔÇ∑Response -adapted randomization (RAR) initially proposed has 
been replaced with a non -RAR randomization schema
ÔÇ∑Title of the protocol was changed to reflect the new design
ÔÇ∑Rem oved RAR interim analyses, added administrative interim 
analy ses
ÔÇ∑Rem oved RNA and miRNA sample collection and testing
Revised Protocol 04 03-May -2019 ÔÇ∑Updated exclusion criteria to exclude participants with 
arteriovenous malformation (AVM)
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Revised Protocol No.: 06
Date: 09-Oct-2020 5Document Date of Issue Summary of Change
Revised Protocol 03 05-Apr -2019 ÔÇ∑Allow clopi[INVESTIGATOR_880407] 300 mg to 600 mg prior to
signing informed consent
ÔÇ∑Rem oval of aortic arch atheroma >4 mm in thickness from 
vascular imaging criteria and updated criteria for 
atherosclerotic plaque
ÔÇ∑Added exploratory objective to assess the incidence and 
characteristics of cerebral microbleeds (CMB s), hemorrhagic 
transformation of ischemic stroke and asymptomatic 
intracranial bleeding on Day 90
ÔÇ∑Added specifics regarding petechiae on brain imaging
ÔÇ∑Clarified that MRI is not required to determine study 
eligibility
ÔÇ∑Clarified assessments to be completed for participants who 
discontinue study treatment
ÔÇ∑Updated PK characteristics table to include estimate of renal 
clearance and impact of renal impairment
ÔÇ∑Added instructions for missed doses
ÔÇ∑Added details for brief physical exam
ÔÇ∑Provided guidance for the management of bleeding events
ÔÇ∑Modified the PK and PD sample collection window for the 
12-hour post - first dose time point and the requirement of a 12-
and 24- hour PK/PD sample collection for TIA subjects on 
Day 1.
ÔÇ∑Clarified assessments to be completed at sc reening vs.prior to 
dosing o n Day 1
ÔÇ∑Added scenarios where the DMC and the RAR vendor will 
receive unblinded data for safety assessment
ÔÇ∑Added new appendices for strong CYP3A inhibitors and 
inducers
ÔÇ∑Added guidance for use of thrombolytic therapy for the 
treatment of new stroke, including availability of unblinding
ÔÇ∑Reduced the window for collection of information on 
medications taken prior to study drug from 30 days to 7 days
ÔÇ∑Reduced the window for SAE collection after discontinuation 
of study medication f rom30 days to 7 days
ÔÇ∑Reorganized statistical analysis sections to tabular form 
matching endpoint with statistical method
ÔÇ∑Corrected/clarified discrepant items
Administrative Letter 01 27-Nov -2018 Correcting a typo in the summary of Change column of the 
document history
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Revised Protocol No.: 06
Date: 09-Oct-[ADDRESS_1230449] -2018 ÔÇ∑Appendix 3 updated for Adverse Events (AE) definitions and 
details
ÔÇ∑Day 60ÔÇ±7 central clinical laboratory sample collection added
ÔÇ∑DMC review for the first 450 and 600 subjects added to make 
recommendation re garding collection of clinical laboratory 
samples
ÔÇ∑Corrected/clarified items (IP designation, PK /PDsample time 
and collection window)
Revised Protocol 01 20-Sep-2018 ÔÇ∑Updated based on  Steering Committee 
feedback
ÔÇ∑Study Design changes for clopi[INVESTIGATOR_880408]
ÔÇ∑Corrected/clarified discrepant items
Original Protocol 13-Jul -2018 Not applicable
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
OVERALL RATIONALE FO R REVISED PROTOCOL 06:
The purpose of Revised Protocol  [ADDRESS_1230450] itute of Healt hStroke Scale (NIHSS) at randomization fro m ‚â§5 to ‚â§[ADDRESS_1230451] a broader popul ation that is cl oser t o 
clinical practice. In addition, the internat ional normalized ratio (INR) threshol d prior to study 
treatm ent administration has been lowered from ‚â§ 1.7 to <1.5 for all partici pants to ensure the 
safet y of the study  populati on, which is now permitted to receive thrombo lytic therapy and/or 
mechanical thrombectomy for acut e treatm ent of  the index stroke . To accommodate for potenti al 
instances where the baseline study  MRI cannot be completed within [ADDRESS_1230452] igator discret ion. Specific to COVID -
19, an exclusio n criterion was added for the safety  of study  participants and site personnel . In 
addition, exploratory  research was modified to include biomarkers rela
ted to severe acute 
respi[INVESTIGATOR_19960] 2 (SARS -CoV -2) infect ion to support advancing the 
understanding of the impact of SARS -CoV -[ADDRESS_1230453] ion ofother onsite
assessments that can be conducted remotely (eg,central  laboratory  tests), and rem otemonitoring 
considerations. 
Other changes are administrative changes such as typographical errors, clarificat ions, changes in 
termino logy, and alignment to other key  study  docum ents.
The changes made to the protocol are not anticipated to have a significant impact on the 
benefit -risk of  the tr ial parti cipants, and do not impact the integrit y of the study .
The table below highlights the key  changes made to the body  of the protocol . The changes made 
in the body  of the protocol  were al so implemented in the Synopsis, where applicable. 
Revised Protocol No.: 06
Date: 09-Oct-2020 7
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
SUMMARY OF K EY CHANGES FOR REVIS ED PROTOCOL 0 6
Section Number & Title Description of Change Brief Rationale
Title page Revised Sponsor contact 
[CONTACT_3031].Toupdate clinical team members .
Section 2 (Schedule of
Activities), Table 2 -1
(Screening Period Procedural
Outline)Clarified that100-mg aspi[INVESTIGATOR_880409] D ay [ADDRESS_1230454] of care on the 
same day as randomization .To accommodate for regional or 
institutional practices regarding 
aspi[INVESTIGATOR_880410]/TIA.
Section 2 (Schedule of
Activities), Table 2 -1
(Screening Period Procedural 
Outline)Clarified that following a 
standard-of-care clopi[INVESTIGATOR_880411], the standard-of-care 
clopi[INVESTIGATOR_880412] 75 mg 
may be ta ken prio r to 
randomization .To accommodate for regional or 
institutional practices regarding 
clopi[INVESTIGATOR_880413]/TIA.
Section 2 (Schedule of
Activities), Table 2 -1
(Screening Period Procedural 
Outline)Added note: A clinical (standard-
of-care) MRI scan can be used as 
the baseline MRI provided that 
the clinical MRI protocol and 
scanner have been pre -approved 
by [CONTACT_11343] . 
Rem oved note: Study -specific, 
pretreatment (Day 1) MRI must 
be performed within [ADDRESS_1230455] -of-care
MRI protocol as the baseline MRI. 
The timing of the baseline MRI 
relative to the onset of the index event 
and ra ndomizatio n is outlined in the 
study-specific MRI row on Table 2-2. 
Section 2 (Schedule of
Activities), Table 2 -1
(Screening Period Procedural 
Outline)Specified the anatomical location 
where complete occlusion of a 
cervical carotid or an intracranial 
artery  will require exclusion 
(proximal to the index lesion). To clarify the required evidence for 
exclusion of participants with 
complete occlusion of a cervical 
carotid or an intracranial artery. 
Section 2 (Schedule of
Activities), Table 2 -1
(Screenin g Period Procedural 
Outline)Updated the notes to include a list 
of screening laboratory tests that 
are required be performed locally 
to assess eligibility .To provide clarification to sites as to 
what screening labs need to be 
performed locally to assess eligibility .
Section 2 (Schedule of
Activities), Table 2 -1
(Screening Period Procedural 
Outline)Modified required duration of 
SAE collection from [ADDRESS_1230456] -randomization NSAE 
collection.
Section 2 (Schedule of
Activities), Table 2 -1
(Screening Period Procedural 
Outline)Added guidance as to where 
results of local labs performed for 
assessment of SAEs should be 
sent.To provide clarification to sites as to 
where results of local labs performed 
for assessment of SAEs should be 
sent.
Section 2 (Schedule of
Activities), Table 2 -2Updated ‚Äúbrief physical 
examination‚Äù to ‚Äúbrief physical 
assessment.‚ÄùTo enable performance of the physical 
assessment by [CONTACT_880546] -
physician study  staff on Day  21.
Revised Protocol No.: 06
Date: 09-Oct-2020 8
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
SUMMARY OF K EY CHANGES FOR REVIS ED PROTOCOL 0 6
Section Number & Title Description of Change Brief Rationale
(Post -Screening Period Procedural 
Outline)
Section 2 (Schedule of
Activities), Table 2 -2
(Post -Screening Period Procedural 
Outline)Provided instruction regarding
instances where the baseline MRI 
cannot be performed within 48 
hours of the index event and 
before randomization. Removed 
study-specific MRI sequences and 
referenced that sequences will be 
defined in imaging manual.To enable flexibility without delaying 
randomization. The required MRI 
sequences are defined in the imaging 
manual.
Section 2 (Schedule of
Activities), Table 2 -2
(Post -Screening Period Procedural 
Outline)Added instructio n regarding 
performance of the Day 90 MRI 
when impacted by [CONTACT_880547] -19
pandemic .To enable flexibility and preserve 
collection of the Day 90 MRI when 
impacted by [CONTACT_25963] -19pandemic .
Section 2 (Schedule of
Activities), Table 2 -2
(Post -Screening Period Procedural 
Outline)Clarified that participants may not 
be taking study medication past 
Day 96.To accurately reflect consideration of 
study medication supply relative to 
obtaining theDay 90 MRI. 
Section 2 (Schedule of
Activities), Table 2 -2
(Post -Screening Period Procedural 
Outline)Clarified that [ADDRESS_1230457] of care on the 
same day as randomization.To accommodate for regional or 
institutional practices regarding 
aspi[INVESTIGATOR_880410]/TIA. 
Section 2 (Schedule of
Activities), Table 2 -2
(Screening Period Procedural 
Outline)Clarified that following a 
standard-of-care clopi[INVESTIGATOR_880411], the standard-of-care 
clopi[INVESTIGATOR_880412] 75 mg 
may be taken prio r to
randomization .To accommodate for regional or 
institutional practices regarding 
clopi[INVESTIGATOR_880413]/TIA.
Section 2 (Schedule of
Activities), Table 2 -2
(Post -Screening Period Procedural 
Outline)NIHSS score for qualifying event 
was increased from ‚â§5 to ‚â§7.The NIHSS score for qualifying event 
was increased based on review of 
aggregate safety data to date and 
Steering Committee feedback.
Section 2 (Schedule of
Activities), Table 2 -2
(Post -Screening Per iod Procedural 
Outline)Updated the notes to include 
pregnancy requirements.To provide clarity to the sites on the 
pregnancy testing expectations.
Section 2 (Schedule of
Activities), Table 2 -2
(Post -Screening Period Procedural 
Outline)Modified required duration of 
SAE collection after 
discontinuation of dosing from [ADDRESS_1230458] -randomization NSAE 
collection.
Revised Protocol No.: 06
Date: 09-Oct-2020 9
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
SUMMARY OF K EY CHANGES FOR REVIS ED PROTOCOL 0 6
Section Number & Title Description of Change Brief Rationale
Section 2 (Schedule of
Activities), Table 2 -2
(Post -Screening Period Procedural 
Outline)Added guidance as to where 
results of local labs performed for 
assessment of SAEs should be 
sent.To provide clarification to sites as to 
where results of local labs performed 
for assessment of SAEs should be 
sent.
Section 2 (Schedule of
Activities), Table 2 -2
(Post -Screening Period Procedural 
Outline)Provided instruction to clarify 
that the timing of first dose of 
study medication remains 
unchanged in ins tances when the 
baseline MRI is completed after 
[ADDRESS_1230459] dose 
requirements relative to onset of the 
index event even when study -specific 
MRI cannot be completed within 
48hours from the onset o f the index 
event. 
Section 2 (Schedule of Activities), 
Table 2-2
(Post -Screening Period Procedural 
Outline)Modified table footnotes to reflect 
changes in the table and protocol 
body.To accurately reflect protocol body 
content. 
Section 3.2.1 (Phase 1 and 2a 
studies with BMS -986177), Table 
3.2.1-1 (Highlights of Clinical 
Pharmacology)Clarified that Tmax was in fasted 
state and that Accumulation Index 
was for QD dosing only.To provide clarification on the 
conditio ns where the PK properties 
were determi ned.
Section 5.1 (Overall Design) Rem oved ¬±10-day  visit window 
and a dded instruction regarding 
performance of the Day 90 MRI 
when impacted by [CONTACT_25963] -19 
pandemic .To enable flexibility and preserve 
collection of Day 90 MRI when 
impacted by [CONTACT_25963] -19pandemic .
Section 5.1 (Overall Design) Updated enrollment period 
duration from [ADDRESS_1230460] updated enrollment 
projections. 
Section 5.1 (Overall Design, 
Screening Period)Provided instruction regarding 
instances where the baselin e MRI 
cannot be performed within 48 
hours of the index event and 
before randomization. To enable flexibility without delaying 
randomization.
Section 5.1 (Overall Design, 
Screening Period)Specified the anatomical location 
for the assessment of complete 
occlusion of a cervical carotid or 
an intracranial artery (proximal to 
the index lesion).To clarify the required evidence for 
exclusion of participants with 
complete occlusion of a cervical 
carotid or an intracranial artery. 
Section 5.1 (Overall Design,
Double -Blind Treatment Period)Restructured order of activities to 
be performed during the double -
blind treatment period.To clarify the sequence of activities to 
be performed during the double -blind 
treatment period.
Section 5.1 (Overall Design, 
Double -Blind Treatment Period)Added statement that the DMC 
recommendation regarding the 
Day [ADDRESS_1230461] igator
without the need for a protocol 
amendment.
Revised Protocol No.: 06
Date: 09-Oct-2020 10
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
SUMMARY OF K EY CHANGES FOR REVIS ED PROTOCOL 0 6
Section Number & Title Description of Change Brief Rationale
Section 5.1 (Overall Design, 
Double -Blind Treatment Period, 
and Figure 5.1-1 Study Design 
Schematic )Updated the milestone 
requirement for DMC review 
prior to decision on inclusion of 
the 200 -mg BID dose a rm. In light of modifications to the 
inclusion/exclusion criteria, the DMC 
milesto ne requirements were updated 
to enable safety evaluation of study 
populatio n prior to the inclusion of the 
200-mg BID arm.
Section 5.1 (Overall Design, 
Double -Blind Treatme nt Period)Clarified that following a 
standard-of-care clopi[INVESTIGATOR_880411], the standard-of-care 
clopi[INVESTIGATOR_880412] 75 mg 
may be taken prio r to 
randomization.To accommodate for regional or 
institutional practices regarding 
clopi[INVESTIGATOR_880413]/TIA.
Section 5.1 (Overall Design, 
Double -Blind Treatment Period)Clarified that [ADDRESS_1230462] of care on the 
same day as randomization.To accommodate for regional or 
institutional practices regarding 
aspi[INVESTIGATOR_880410]/TIA.
Section 5.1 (Overall Design, 
Double -Blind Treatment Period)Added statement that alternative 
measures can be considered to 
obtain required visit assessments 
for participants who are unab le or 
not permitted to attend an onsite 
visit due to the COVID -19 
pandemic as local regulatory 
requirement spermit. To preserve study assessment 
collection for participants who are 
unable or not permitted to attend an 
onsite visit due to the COVID -
19 
pandemic.
Section 5.1 (Overall Design, 
Double -Blind Treatment Period)Updated Day [ADDRESS_1230463] 
all required assessment at Day 60 site 
visit.
Section 5.1 (Overa ll Design, 
Double -Blind Treatment and 
Follow -UpPeriod)Clarified when the Day 97 end -
of-study  follow -up pho ne visit 
should occur for participants not 
completing treatment or not 
obtaining the Day 90 MRI.To provide clear instruction on the
requirement of the Day 97 end -of-
study follow -up phone visit.
Section 5.1 (Overall Design, 
Double -Blind Treatment Period)Added statement encouraging 
sites to perform follow -up phone 
call [ADDRESS_1230464] is 
made wi th participants who 
permanently discontinue study 
medication. 
Revised Protocol No.: 06
Date: 09-Oct-2020 11
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
SUMMARY OF K EY CHANGES FOR REVIS ED PROTOCOL 0 6
Section Number & Title Description of Change Brief Rationale
Section 5.1.1 (Data Monitoring 
and Other External Committees)Updated the milestone 
requirements for DMC review 
prior to decision on inclusion of 
the 200 -mg BID dose arm. In light of modifica tions to the 
inclusion/exclusion criteria, the DMC 
milesto ne requirements were updated 
to enable safety evaluation of study 
populatio n prior to the inclusion of the 
200-mg BID arm.
Section 5.1.1 (Data Monitoring 
and Other External Committees )Added statem ent that the DMC 
recommendation regarding the 
Day 60 clinical laborato ry sample 
will be communica ted to the 
investigator by [CONTACT_941] S ponsor.To provide clarity regarding 
communication of the DMC 
recommendation to the investigator
without the need for a protoco l 
amendment .
Section 5.1.1 (Data Monitoring 
and Other External Committees)Rem oved statement: 
‚ÄúRecommendations for criteria to 
stop the clinical trial for safety 
concerns will be defined in the 
DMC charter.‚Äù
Added statement: ‚Äú The DMC will 
use their clinical and statistical 
judgment to evaluate pertinent 
trial data and may recommend 
early  termination of an individual 
study arm or the entire trial for 
important safety concerns that are 
felt to outweigh potential benefits. 
Details of the DMC activities will 
be described in a DMC charter.To clarify that the Sponsor will not 
provide trial stoppi[INVESTIGATOR_880414] -risk.
Section 6.1 (Inclusion Criteria) NIHSS score for qualifying event 
was increased from ‚â§5 to ‚â§7 .The NIHSS score for qualifying event 
was increased based on review of 
aggregate safety data to date and 
feedback from Steering Committee.
Section 6.1 (Inclusion Criteri a) Specified the anatomical location 
where complete occlusion of a 
cervical carotid or an intracranial 
artery  will require exclusion 
(proximal to the index lesion).To clarify the required evidence for 
exclusion of participants with 
complete occlusion of a cervical 
carotid or an intracranial artery. 
Section 6.1 (Inclusion Criteria) Rem oved language regarding 
performance of baseline MRI 
within [ADDRESS_1230465] baseline MRI requirements 
in line with Section 9.2.12 .
Revised Protocol No.: 06
Date: 09-Oct-2020 12
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
SUMMARY OF K EY CHANGES FOR REVIS ED PROTOCOL 0 6
Section Number & Title Description of Change Brief Rationale
Section 6.1 (Inclusion Criteria) Permitted the use of thrombolytic 
therapy/mechanical 
thrombectomy for treatment of 
the index ev entunder specified 
conditio ns.Based on aggregate safety data to date 
and feedback from Steering 
Committee, thrombolytic 
therapy /mechanical thrombectomy are 
now permitted provided that specified 
conditio ns are met in order to study a 
broader population t hat is closer to 
clinical practice.
Section 6.2 (Exclusion Criteria) Added intracranial artery stenosis
requiring angioplasty within 90 
days to the exclusion criteria .To clarify exclusion criteria regarding
planned vascular treatment of 
intracranial artery stenosis .
Section 6.2 (Exclusion Criteria) Rem oved use of thrombolytic 
therapy/mechanical 
thrombectomy from exclusion 
criteria .Based on aggregate safety data to date
and feedback from Steering 
Committee, thrombolytic 
therapy/mechanical thrombectomy are
now permitted provided that specified 
conditio ns are met in order to study a 
broader population that is closer to 
clinical practice.
Section 6.2 (Exclusion Criteria) Clarified that treated aneurysms 
without history of intracranial 
bleed a re permitted. To allow for enrollment of participants 
who present with treated aneurysms 
without history of intracranial bleed. 
Section 6.2 (Exclusion Criteria) Clarified UFH or LMWH for 
DVT prophylaxis allowance prior 
to enrollment.To provide clear in struction on UFH 
or LMWH for DVT prophylaxis 
allowance prior to enrollment.
Section 6.2 (Exclusion Criteria) Updated classification of strong 
CYP3A4/P -gp inhibitors and 
strong CYP3A4/P -gp inducers to 
combined P -gp and strong 
CYP3A4 inhibitors and combined
P-gp and strong CYP3A4 
inducers, respectively.To reflect current classification of 
compounds with combined P -gp and 
CYP3A modulation properties.
Section 6.2 (Exclusion Criteria) Updated INR exclusion 
requirement from INR >1.7 to 
INR >1.5.The INR thresh old was lowered for 
the safety of the study population that 
may receive thrombolytic therapy
prior to randomization while also 
aligning laboratory exclusion 
requirements for all study participants.
Section 6.2 (Exclusion Criteria) Updated criteria to include history 
of [ADDRESS_1230466] an increased risk for detection of 
an ECG finding during the study 
which may prompt early  drug 
discontinuation.
Revised Protocol No.: 06
Date: 09-Oct-2020 13
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
SUMMARY OF K EY CHANGES FOR REVIS ED PROTOCOL 0 6
Section Number & Title Description of Change Brief Rationale
Section 6.2 (Exclusion Criteria) Addition of SARS -CoV -2 
infection within 4 weeks of 
screening and associated 
conditio ns regarding symptom 
resolution, investigator 
assessment , and consultation with 
Medical Monitor/Clinical Tria l 
Physician.To ensure safety of study participants 
and site personnel.
Section 7.2 (Method of Treatment 
Assignment)Updated the milestone 
requirement for DMC review 
prior to decision on inclusi on of 
the 200 -mg BID dose arm .In light of modifications to the 
inclusion/exclusion criteria, the DMC 
milesto ne requirements were updated 
to enable safety evaluation of study 
populatio n prior to the inclusion of the 
200-mg BID arm.
Section 7.3 (Selection and Timing 
of Dose for Each P articipant)Clarified that foll owing a 
standard-of-care clopi[INVESTIGATOR_880411], the standard-of-care 
clopi[INVESTIGATOR_880412] 75 mg 
may be taken prio r to 
randomization.To accommodate for regional or 
institutional practices regarding 
clopi[INVESTIGATOR_880413]/TIA.
Section 7.3 (Selection and Timing 
of Dose for Each P articipant )Restructured language regarding
clopi[INVESTIGATOR_880415].To clarify 3scenarios for 
administration of the clopi[INVESTIGATOR_880416] .
Section 7.3 (Selection and T iming 
of Dose for Each P articipant )Clarified that [ADDRESS_1230467] of care on the 
same day as randomization.To accommodate for regional or 
institutional practices regarding 
aspi[INVESTIGATOR_880410]/TIA.
Section 7.3 (Se lection and Timing 
of Dose for Each P articipant )Provided instruction to clarify 
that the timing of first dose of 
study medication remains 
unchanged in instances when the 
baseline MRI is completed after 
[ADDRESS_1230468] dose 
requirements relative to onset of the 
index event even when baseline MRI 
cannot be completed within 48 hours 
from the o nset of the index event. 
Section 7.3 (Selection and Timing 
of Dose for Each P articipant )Updated study medication 
duration of re supply on Day [ADDRESS_1230469] the study 
medication re -supply that participant 
is receiving. 
Section 7.3 (Selection and Timing
of Dose for Each P articipant )Updated the consideration that 
participant may not be taking 
study medication past Day [ADDRESS_1230470] ¬± 6-day window due to the 
COVID -[ADDRESS_1230471] consideration of 
study medication supply relative to 
obtaining Day 90 MRI when impacted 
by [CONTACT_25963] -19 pandemic.
Revised Protocol No.: 06
Date: 09-Oct-2020 14
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
SUMMARY OF K EY CHANGES FOR REVIS ED PROTOCOL 0 6
Section Number & Title Description of Change Brief Rationale
Section 7.4 (Blinding) Clarified that designated staff of 
Bristol-Myers Squibb Research & 
Development not involved in the 
study will provide assistance for 
analy ses needed for DMC in 
scope of the DMC charter. To provide clarification on unblinding 
of designated Bristol -Myer s Squibb 
staff not involved in the study who are 
performing analyses needed for DMC 
in scope of the DMC charter .
Section 7.7.1 (Prohibited and/or 
Restricted Treatments)Included all prohibited treatments 
from exclusion criteria .To provide clarity on the pro hibited 
treatments from exclusion criteria 
instead of referencing the section.
Section [IP_ADDRESS] (Imaging 
Restrictions and Precautions)Updated contrast restriction to 
allow for contrast administration 
as per investigator discretion and 
local clinical prac tice.To accommodate for regional or 
institutional practices regarding 
contrast administration for MRIs .
Section 8.4 (Emergency 
Procedures)Rem oved statement that study 
drug BMS -[ADDRESS_1230472] be interrupted and can be 
restarted if thrombolytic therapy is 
administered or thrombectomy is 
performed provided that specified 
conditio ns are allmet.
Section 8.5 (Other Reasons for 
Permanent Discontinuation from 
Study Treatment)Rem oved statement that study 
drug BMS -[ADDRESS_1230473] be
permanently discontinued if 
thrombolytic therapy or 
thrombectomy is used.Based on aggregate safety data and 
feedback from the Steering 
Committee, study drug BMS -986177 
can be restarted if thrombolytic 
therapy  or thrombectomy were used 
during the treatment period, provided 
that all specified conditions are met.
Section 8.6 (Discontinuation from 
Study)Clarified the Day [ADDRESS_1230474] eted.To provid e clear instruction to sites 
regarding participants who discon tinue 
early  and complete end -of-treatment 
visit requirements. Specifically, that 
for these participants only the Day 90 
MRI is required on the Day 90 visit 
and that the Day 97 visit should be 
completed.
Section 8.6 (Discontinuation from 
Study)Added statement encouraging 
sites to perform follow -up phone 
call [ADDRESS_1230475] is 
made with participants who 
permanently discontinue study 
medicati on. 
Section 8.6 (Discontinuation from 
Study)Clarified conditions when Day 97 
end-of-study  follow -up pho ne 
visit should occur.To provide clear instruction on 
requirement of Day 97 end -of-study  
follow -up phone visit.  
Revised Protocol No.: 06
Date: 09-Oct-2020 15
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
SUMMARY OF K EY CHANGES FOR REVIS ED PROTOCOL 0 6
Section Number & Title Description of Change Brief Rationale
Section 8. 7(Post -Study Treatment 
Follow -up)Added instruction regarding 
performance of the Day 90 MRI 
when impacted by [CONTACT_25963] -19 
pandemic.To enable flexibility and preserve 
collection of Day 90 MRI when 
impacted by [CONTACT_25963] -19 pandemic.
Section 9.1 (Efficacy A ssessments) Provided instruction regarding 
instances where the baseline MRI 
cannot be performed within 48 
hours of the index event and 
before randomization.To enable flexibility without delaying 
randomization. 
Section 9.1 (Efficacy Assessments) Provided instruction to clarify 
that the timing of first dose of 
study medication remains 
unchanged in instances when the 
baseline MRI is completed after 
[ADDRESS_1230476] dose 
requirements relative to onset of the 
index event even when baseline MRI 
cannot be completed within 48 hours 
from the o nset of the index event. 
Section 9.2.3 (Time Period and 
Frequency for Collecting AE and 
SAE information)Clarified that non serious AE 
collection should begin at 
randomi zation. To align with adverse event reporting 
in Table 2-2 (Post -Screening 
Procedural Outline).
Section 9.2.3 (Time Period and 
Frequency for Collecting AE and 
SAE information)Modified required duration of 
SAE collection after 
discontinuation of dosing from [ADDRESS_1230477] -randomization NSAE 
collection.
Section 9.2.3 (Time Period and 
Frequency for Colle cting AE and 
SAE information)Added guidance as to where 
results of local labs performed for 
assessment of SAEs should be 
sent.To provide clarification to sites as to 
where results of local labs performed 
for assessment of SAEs should be 
sent.
Section 9. 2.12 (Magnetic 
Resonance Imaging)Clarified that a clinical (standard -
of-care) MRI scan can be used as 
the baseline MRI provided that 
the clinical MRI protocol and 
scanner have been pre -approved 
by [CONTACT_11343]. To clarify conditions when it is 
acceptable to utilize a standard -of-care 
MRI protocol as the baseline MRI.
Section 9.2.12 (Magnetic 
Resonance Imaging)Provided instruction regarding 
instances where the baseline MRI 
cannot be performed within 48 
hours of the index event and 
before ra ndomizatio n.To enable flexibility without delaying 
randomization. 
Section 9.2.12 (Magnetic 
Resonance Imaging)Rem oved ¬±10 -day window and 
added instruction regarding 
performance of the Day 90 MRI 
when impacted by [CONTACT_25963] -19 
pandemic.To enable flexibility and preserve 
collection of Day 90 MRI when 
impacted by [CONTACT_25963] -19 pandemic.
Revised Protocol No.: 06
Date: 09-Oct-2020 16
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
SUMMARY OF K EY CHANGES FOR REVIS ED PROTOCOL 0 6
Section Number & Title Description of Change Brief Rationale
Section 9.2.12 (Magnetic 
Resonance Imaging)Updated the consideration that 
participant may not be taking 
study medication past Day [ADDRESS_1230478] ¬± 6- day window due to the 
COVID -[ADDRESS_1230479] consideration of 
study medication supply relative to 
obtaining Day 90 MRI when impacted 
by [CONTACT_25963] -19 pandemic.
Section 9.2.12 (Magnetic 
Resonance Imaging)Restructured language for clarity. To provide clear guidance on MRI 
requirements for investigators.
Section 9.2.13 Physical 
ExaminationsUpdated ‚Äúbrief physical 
examination‚Äù to ‚Äúbrief physical 
assessment.‚ÄùTo enable performance of the physical 
assessment by [CONTACT_880546] -
physician study staff on Day 21.
Section 9.3 (PK, PD, Biomarkers 
and PK/PD Assessments), Table  
[IP_ADDRESS] -1 (Pharmacokinetic 
Sampling Schedule)Simplified pharmacokinetic 
sampling schedule.To enable flexibility to sites for PK 
sampling based on feedback from 
invest igators.
Section 9.3 (PK, PD, Biomarkers 
and PK/PD Assessments), Section 
[IP_ADDRESS] (Exploratory Biomarker 
Assessments)Added biomarkers related to 
SARS -CoV -2infection status or 
related pathophysiological 
pathways.SARS -CoV -[ADDRESS_1230480] of SARS -CoV -2 on BMS -
986177 and cardiovascular disease. 
Section 9.3 (PK, PD, Biomarkers 
and PK/PD Assessments), Table 
[IP_ADDRESS] -1 (Biomarker sampling 
Schedule)Simplified biomarker sampling 
schedule. To enable flexibilit y to sites for 
biomarker sampling based on 
feedback from investigators.
Section 9.4 (Other Assessments), 
Section 9.4.1 (Assessment of Index 
Stroke and New Strokes)NIHSS score for qualifying event 
was in creased from ‚â§5 to ‚â§7.The NIHSS score for qualifying event 
was increased based on review of 
aggregate safety data to date and 
feedback from Steering Committee.
Section 10.1 (Sample Size 
Determination)Provided sample size estimations 
for the study withou t inclusion of 
the 200 -mg BID dose arm.Toprovide an additional statistical 
sample siz e determination in case the 
200-mg BID dose arm is not included 
in the randomization scheme.
Appendix 2 (Study Governance 
Considerations)Added statement to specify that 
other means of remote monitoring 
approve d by [CONTACT_880548].To clarify conditions where remote 
monitoring can be considered. 
Appendix 11 (Strong CYP3A 
inhibito r list)Updated classification in title and 
body to combined P -gp and 
strong CYP3A4 inhibitors.To reflect current classification of 
compounds with combined P -gp and 
CYP3A modulation properties.
Appendix 12 (Strong CYP3A 
inducer list)Updated classification in title and 
body to combined P -gp and 
strong CYP3A4 inducers.To reflect current classification of 
compounds with combined P -gp and 
CYP3A modulation properties.
Revised Protocol No.: 06
Date: 09-Oct-2020 17
Approved
8.0
v
Approved
1.0
v
TABLE OF CONTENTS 
TITLE PAGE ................................................................................................................ 
DOCUMENT HISTORY .............................................. ................................................ 
OVERALL RATIONALE FOR REVISED PROTOCOL 06: .................... ................. 
SUMMARY OF KEY CHANGES FOR REVISED PROTOCOL 06 ......................... 
TABLE OF CONTENTS .............................................................................................. 
1 SYNOPSIS .................................................... ............................................................. 
2 SCHEDULE OF ACTIVITIES.................................................................................. 
3 INTRODUCTION ................................................ ..................................................... 
3.1 Study Rationale ................................................................................................. 
3.1.1 Novel Antithrombotic Mechanism of BMS-986177 ................................. 
3.1.2 More Potent Antiplatelet Therapy ........................................................... 
3.1.3 Dual Mechanisms of Thrombosis Inhibition ............................................ 
3.1.4 Selection of Treatments ............................................................................ 
3.2 Background ................................................ ....................................................... 
3.2.1 Phase 1 and 2a Studies with BMS-986177 .............................................. 
3.3 Benefit/Risk Assessment ................................... ............................................... 
4 OBJECTIVES AND ENDPOINTS ........................................................................... 
5 STUDY DESIGN....................................................................................................... 
5.1 Overall Design ............................................ ...................................................... 
5.1.1 Data Monitoring and Other External Committees .................................. 
5.2 Participants ........................................................................................................ 
5.3 End-of-Study Definition ................................................................................... 
5.4 Justification for Doses....................................................................................... 
5.4.1 Identification of Effective Doses of BMS-986177 .................................... 
5.4.2 BMS-986177 with Aspi[INVESTIGATOR_248] + Clopi[INVESTIGATOR_7745] ................................................ 
6 STUDY POPULATION ............................................................................................ 
6.1 Inclusion Criteria .............................................................................................. 
6.2 Exclusion Criteria ........................................ ..................................................... 
6.3 Lifestyle Restrictions ........................................................................................ 
6.4 Screen Failures ........................................... ....................................................... 
6.5 Retesting During Screening or Lead-In Period .............. ................................... 
7 TREATMENT ................................................... ........................................................ 
7.1 Treatments Administered ................................... ............................................... 
7.2 Method of Treatment Assignment .................................................................... 
7.3 Selection and Timing of Dose for Each Participant ......... ................................. 
7.4 Blinding............................................................................................................. 
7.5 Preparation/Handling/Storage/Accountability ............... ................................... 
7.6 Treatment Compliance ...................................... ................................................ 
7.7 Concomitant Therapy........................................ ................................................ 
7.7.1 Prohibited and/or Restricted Treatments................................................. 
7.7.2 Other Restrictions and Precautions ......................................................... 
[IP_ADDRESS] Imaging Restriction and Precautions ............................................. 
7.8 Treatment After the End-of-Study .......................... .......................................... 
8 DISCONTINUATION OR IN TERRUPTION CRITERIA ...................................... 

































&OLQLFDO3URWRFRO
%06-1-&9
)DFWRU;,D,QKLELWRU
5HYLVHG3URWRFRO1R'DWH2FW 
Approved
8.[ADDRESS_1230481] Result Abnormalities ..................................................... 
9.2.10 Other Safety Considerations .................................................................. 
9.2.11 Potential Drug Induced Liver Injury (DILI) .......................................... 
9.2.12 Magnetic Resonance Imaging ................................................................ 
9.2.13 Physical Examinations ........................................................................... 
9.2.14 Vital Signs .............................................................................................. 
9.2.15 Electrocardiograms ............................................................................... 
9.2.16 Clinical Safety Laboratory Assessments ................................................ 
9.3 PK, PD, Biomarkers and PK/PD Assessments .................. ............................... 
9.3.1 PK Assessments ........................................................................................ 
[IP_ADDRESS] PK Sample Analyses ....................................................................... 
9.3.2 PD and Biomarker Assessments .............................................................. 
[IP_ADDRESS] Exploratory Biomarker Assessments .............................................. 
9.3.3 Additional Research Collection ............................................................... 
9.4 Other Assessments ......................................... ................................................... 
9.4.1 Assessment of Index Stroke and New Strokes .......................................... 
9.4.2 Assessment of Risk for Subsequent Stroke Associated with Index TIA .... 
9.4.3 Assessment of Clinical Severity of Stroke ................................................ 
9.4.4 Assessment of Cognitive Function ........................................................... 
9.4.5 Assessment of Bleeding Severity .............................................................. 
10 STATISTICAL CONSIDERATIONS ................................. ................................... 
10.1 Sample Size Determination ................................ ............................................. 
10.2 Populations for Analyses ................................. ............................................... 
10.3 Statistical Analyses ......................................................................................... 
10.3.1 Demographics and Baseline Characteristics......................................... 




































&OLQLFDO3URWRFRO
%06-1-&9
)DFWRU;,D,QKLELWRU
5HYLVHG3URWRFRO1R'DWH2FW 
Approved
8.0
v
Approved
1.0
v
10.3.2 Efficacy Analyses ................................................................................... 
10.3.3 Safety Analysis ....................................................................................... 
10.3.4 Pharmacokinetic Analysis ...................................................................... 
10.3.5 Pharmacodynamic and Biomarker Analysis .......................................... 
10.3.6 Exposure-Response Analyses ................................................................. 
10.3.7 Interim Analyses ..................................................................................... 
11 REFERENCES ................................................. ....................................................... 
12 APPENDICES ................................................. ........................................................ 
APPENDIX 1 ABBREVIATIONS AND TRADEMARKS ....................... ................. 
APPENDIX 2 STUDY GOVERNANCE CONSIDERATIONS .................... ............. 
APPENDIX 3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, EVALUATING, 
FOLLOW UP AND REPORTING ....................................... .................................. 
APPENDIX 4 WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION ...................................... ............................... 
APPENDIX 5 NATIONAL INSTITUTES OF HEALTH STROKE SCALE (NIHSS)
................................................................................................................................. 
APPENDIX 6 ABCD2 SCORE ASSESSMENT TOOL......................... ..................... 
APPENDIX 7 MODIFIED RANKIN SCORE .............................. ............................... 
APPENDIX 8 MONTREAL COGNITIVE ASSESSMENT (MOCA) ........................ 
APPENDIX [ADDRESS_1230482] ...... . 
 















&OLQLFDO3URWRFRO
%06-1-&9
)DFWRU;,D,QKLELWRU
5HYLVHG3URWRFRO1R'DWH2FW 
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
1 SYNOPSIS
Protocol Title:
A Global,Phase 2, Rando mized, Doubl e -Blind, Placebo -Controlled ,Dose -Ranging Study  of 
BMS -986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New 
Covert Brain Infarct ion in Pat ients Receiving Aspi[INVESTIGATOR_880417] (TIA)
AXIOMATIC- SSP: Antithrombotic Treatment with F actor XIa Inhibit ion to Optimize 
Management of Acute Thromboembo lic Events in Secondary  Stroke Prevention
Study Phase:
2
Rationale:
Bleeding, especially intracranial hemorrhage (ICH) , is the major concern am ong clinicians when 
considering antithro mbotic therapy in patients with stroke and threatened stroke. A major advance 
of the past decade in anticoagul ation has been the introduction of selective oral direct thrombin 
and Factor Xa inhibitors (DOACs). The risk of ICH with DOACs is sharply  reduced compared 
with warf arin.
BMS-986177 (also known as JNJ-70033093) is a small molecule that binds and inhibit s the 
activated form of human coagul ation Factor XI (Factor XIa) wit
h high affini ty and select ivity. 
According to the scientific evidence accumulated to date, the inhibit ion ofFXI may provide a 
novel mechanism for systemic antithrombotic effects without increasing the risk of clinically 
significant bleeding in a variet y of condi tions predisposing to high risk of thrombotic events.
The rationale for this study  is that Factor XIa inhibit ion has the potenti al to reduce thrombin 
generat ion enough to prevent vascular occlusio n and embo lism wit hout impairing hemostasis. The 
following observat ions support this concept: (1) the highest levels of Factor XI activit y are 
associ ated with a heightened risk of ischemic stroke; (2) lower levels of Factor XI activit y are 
associ ated with a reduced risk of ischemic stroke; (3) Factor XI deficiency is rarely associ ated with 
unprovoked major bleeding; (4) al though not done in participants with strok e, a Phase [ADDRESS_1230483] total knee replacement with another Factor XIa inhibitor 
provi des a proof -of-concept. The study  showed that reducing FXI levels to 20% or less than norm al 
with an antisense inhibitor of FXI synthesis reduced the risk of postoperative VTE compared to 
enoxaparin, without an increase in bleeding compared to enoxaparin .
The recent ly-reported POINT and CHANCE studies demonstrated that treatment with aspi[INVESTIGATOR_880418]. However, 
the residual risk for recurrent stroke remains high , even when patients are treated with combinat ion 
of aspi[INVESTIGATOR_8258], emphasizes the cont inuing need for a more effect ive therapeut ic option.  
Two possible strategi es for achieving better efficacy  aremore potent antiplatelet therapy  or dual 
pathway  inhibi tion of  thrombus formati on.
Revised Protocol No.: 06
Date: 09-Oct-2020 21
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230484] ive
than anti platelet therapy  alone. Arecently co mpleted drug- drug interaction (DDI) studyin healt hy 
volunteers was conducted to assess the safet y and tolerabili ty of multiple-dose BMS -986177 
200mg given twice daily (BID) for 5 days with and without dual antiplatelet therap y. Clopi[INVESTIGATOR_880419] 300 mg on Day 1 followed by 4 days of 75 mg clopi[INVESTIGATOR_7745], and aspi[INVESTIGATOR_248] 325 mg was 
administered once daily [QD] for 5 days. There were no ser ious bleeding events reported from any 
of the 113 healthy participants , including 37 participants treated with DAPT + BMS -986177, in 
the DDI study .There were afew minor bleeding events , which showed no trend toward any 
treatm ent group . These preliminary findings are consistent wi th the noti on that FXIa inhibit ion is 
associ ated wi th a low risk of  bleeding, and support the proposed clinical tri al wi th BMS -986177, 
aspi[INVESTIGATOR_880420] .
Finally , the rationale for treating all patientswith aspi[INVESTIGATOR_248] +clopi[INVESTIGATOR_880421] t rial data to support a net clinical benefit of ant icoagulation alone over antiplatel et 
therapy  for secondary  prevent ion of non-cardi oembo lic strokes.  As noted above, this si tuation is 
reflected in guidelines recommending antiplatel et therapy for secondary stroke prevent ion in this 
popul ation. The data summarized above support the hypothesis that inhibit ion of Factor XIa could 
be a promising target for antithrombotic therapy for stroke, potentially providing sufficient  
inhibit ion of thrombin generati on to prevent thrombotic vascular occlusion or embolizatio n 
without impairing hemo stasis .
Study Population:
Approximately and up to 2350 participants , ‚â•40 years of age, ident ified wit hin 48 hours of onset 
ofsigns and/or symptom s of stroke or TIA will be included in this study.
Key Inclusion Criteria:
Type of Parti cipant and Target Disease Characteristics
ÔÇ∑ Ischemic stroke: a neurological defici t attributable to a non-lacunar , acute brain infarctio n 
detected by  [CONTACT_95425] (CT or MRI )and relevant to the clinical symptoms .
AND
National Inst itutes of Healt h Stroke Score (NIHSS) ÔÇ£7at time of rando mization
AND
Evidence of relevant intracranial or cervical arteri al atheroscl erotic plaque, ulcerat ion or 
thrombus in a feeding artery  docum ented by [CONTACT_9661] (either Doppl er ultrasound orCTA or
MRA or catheter angiography)
Note :Atheroscl erotic plaque does not need to be severe or stenotic, but must be visible .
Parti cipants with complete occlusion of a cervical caroti d or intracranial artery  that is 
proximal to the index lesio n shoul d be excluded.
AND
Modified Rankin Score (mRS) ÔÇ£3 before the index event (pre -morbid)
Revised Protocol No.: 06
Date: 09-Oct-2020 22
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
ÔÇ∑TIA: acute onset neurological defici t attri butable to focal ischemia of the brain by [CONTACT_880549], with complete resol ution of the deficit and no brain infarct ion on 
neuro imaging (CT or MRI)
AND
ABCD2 SCORE ‚â•6 or m otor symptoms
AND
Evidence of relevant intracranial or cervical arteri al atheroscl erotic plaque, ulcerat ion or 
thrombusin a feeding artery  docum ented by [CONTACT_9661] (either Doppl er ultrasound orCTA or
MRA or catheter angiography)
Note : Atherosclerotic plaque does not need to be severe or stenotic, but must be visible .
Parti cipants with complete occlusion of a cervical caroti d or intracranial artery  that is 
proximal to the index lesio n shoul d be excluded.
AND
Modified Rankin Score (mRS) ÔÇ£3 before the index event (pre -morbid)
ÔÇ∑Two MRI scans are requi red for parti cipat ion in this study . Therefore, parti cipants must have 
a body  habitus sui table for MRI and cannot have any contraindicati ons to the perf ormance of 
the MRI . (eg, weight limit, MRI -incompat ible implanted devices, infusio n pump that cannot 
be di scont inued temporarily for the scan).
ÔÇ∑No contraindicat ion to clopi[INVESTIGATOR_880422] [ADDRESS_1230485] 90 days .
ÔÇ∑Enrollment of subjects who have received  thrombolyt ic therapy or mechanical thrombectomy
(without stenting) for the treatm ent of the index event is permi tted if all of the following 
condi tions are m et:
oAt least [ADDRESS_1230486] elapsed between end of IV thro mbolyt ic use/thrombectomy and 
first dose of study  medicat ion.
oNeuroimaging (either clinical imaging or study  MRI) after IV thrombo lytic therapy/ 
post-thrombectomy  excludes any  hemorrhagic transform ation.
oNIHSS ‚â§[ADDRESS_1230487]-thrombo lytic therapy/post -thrombectomy INR ‚â§ 1.5, aPTT ‚â§1.[ADDRESS_1230488] igator would 
precl ude start of study medicat ion (eg,large infarct volume, procedure -related 
bleeding).
oAll other study  criteria are m et.
In addition, we recommend following local practice and considering fibrinogen > 150 mg/dL 
before init iation of study  treatm ent.
Revised Protocol No.: 06
Date: 09-Oct-2020 23
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Key Exclusion Criteria:
ÔÇ∑Predi cted inabilit y to swall ow study  medicat ion
ÔÇ∑Women who are pregnant or breastfeeding
ÔÇ∑Any condit ion that, in the opi[INVESTIGATOR_2511] i nvest igator, contraindicates ant icoagulant therapy  or 
woul d have an unacceptable risk of bleeding such as a large infarct volume (per invest igator 
discreti on) or uncontrolled hypertensio n.
ÔÇ∑Hem orrhage, tumor, arteri tis, large vessel  dissect ion, arteri ovenous malformation (AVM), or 
other pathology that could account for index symptom s must be excluded by [CONTACT_880550] l ocally.
ÔÇ∑Symptom atic caroti d stenosis or intracranial artery  stenosis for which endarterectomy  or 
angioplasty is planned within 90 days .
ÔÇ∑Any condi tion for which chronic anticoagul ation is indicated and expected to be initiated 
(eg,NVAF, DVT, PE )
ÔÇ∑Requi rement for continued use of dual antiplate let therapy  (DAPT) for more than 21 days or 
non-aspi[INVESTIGATOR_880423] 
(eg,prophylaxis for venous thromboembo lism).
Note : Treatment with clopi[INVESTIGATOR_7745] , aspi[INVESTIGATOR_248], dipyridamole or another P2Y12 inhibitor prior to 
enrollment is allowed. Treatment with aspi[INVESTIGATOR_9601] a different dose before enrollment is 
also allowed. All participants must transi tion to the protocol -defined treatm ents and 
doses at randomizat ion.No clopi[INVESTIGATOR_880424] a clopi[INVESTIGATOR_880425].Participants who report 
taking chronic clopi[INVESTIGATOR_880426] a 300-mg clopi[INVESTIGATOR_880427] [ADDRESS_1230489] receive the clopi[INVESTIGATOR_880428]-clopi[INVESTIGATOR_7745]  P2Y12 inhibitor or dipyridamo le/dipyridamo le-containing treatment.
ÔÇ∑History  of hemorrhage into the brain, subarachnoid hemorrhage, subdural hematoma or spi[INVESTIGATOR_880429] (CMB) and minor hemorrhagic transform ation 
of prior infarct manifest ing as scattered petechiae (Hemorrhagic Infarction Type 1 [HI1] 
according to Heidelberg classification ).
Note : CMBs are defined as rounded foci of <[ADDRESS_1230490] 
from vascular flow voids, leptom eningeal hemosiderosi s, or non-hemorrhagic 
subcorti cal mineralizat ion on T2* weighted MRI .
ÔÇ∑History  of clinically  meaningful hepat ic disease and/or clinically significant abnorm al liver 
funct ion.
ÔÇ∑Any of the following laboratory  results outsi de of the ranges specified below prior to study 
treatm ent administration, confirmed by  [CONTACT_7850]:
ÔÄ≠Hem oglobin <9 g/dL
ÔÄ≠Platelet coun t <100,000 mm 3
ÔÄ≠aPTT >1.4x upper limit of normal (ULN)
ÔÄ≠INR ÔÄæ1.5
ÔÄ≠AST or ALT >3x ULN
Revised Protocol No.: 06
Date: 09-Oct-2020 24
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
ÔÇ∑Intracranial tumor (except meningio ma, which is permitted) or aneurysm >5mm or AVM
(except treated aneurysm wit hout history  of intracranial bleed, which is permitted.)
ÔÇ∑History  of end-stage renal disease (ESRD) with eGFR <15 mL/min/1.73m2, or requiring 
dialysis 
ÔÇ∑Planned use of ant icoagulants including warfarin or other vitamin K antagonists, oral thrombin 
and Factor Xa inhibitors, bivalirudin, hirudin, argatroban, unfract ionated and low molecular 
weight heparins, with the except ion of hep arin or low mo lecular weight heparin (LMWH) used 
to maintain patency of indwelling catheters .
Note : Participants who received UFH or LMWH for DVT prophylaxis prior to randomizat ion 
can be enrolled. The use of anticoagulants for post-stroke DVT prophylaxis after 
rando mizat ion is prohibited. For post-stroke DVT prophylaxis, non-pharmaco logical 
prophylaxis (i.e. intermittent pneumat ic compression) is recommended .
ÔÇ∑Anticipated concomitant chronic (>14 days) use of systemic nonsteroidal anti-inflammatory 
drugs (N SAIDs). NSAID (including COX -2 inhibitors) use prior to randomizat ion is allowed.
ÔÇ∑Use of combined P-glycoprotein ( P-gp) and strong CYP3A4 inhibitors or combined P-gp and 
strong CYP3A4 inducers in the [ADDRESS_1230491] of combined 
P-gp and strong CYP3A4 inducers is attached as Appendix 12.
ÔÇ∑Planned c onco mitant use of om eprazo le or esomeprazole after randomization for the duration 
of clopi[INVESTIGATOR_880430](eg, H2 blockers [except cimet idine]and other PPIs are allowed) .
ÔÇ∑History  of or any of the fo llowing findings on 12- lead ECG prior to study drug administration: 
atrial fibrillat ion, atri al flutter, com plete heart block, or Mobitz 2 second -degree heart block .
ÔÇ∑Known SARS -CoV -[ADDRESS_1230492] ion within 4 weeks prior to screening
.
Note: To be considered for enrollment, symptoms must have completely resolved and based 
on invest igator asses sment in consultat ion with the Medical Moni tor/Clinical Tri al Physician, 
and there are no sequelae that woul d place the participant at a higher risk of receiving 
investigat ional treatm ent.
The following table outlines the objectives and endpo ints for the study .Definit ionsand details 
related to study  endpoints can be found in t he Study  Events Assessment Manual .
Objective Endpoints
Primary
To estimate thedose-response relationship of 
BMS -986177 in participants with ischemic stroke or 
TIA treated with aspi[INVESTIGATOR_880431] (FLAIR + DWI) 
detected by [CONTACT_66243] I at Day 90 (MRI assessed by[CONTACT_880551] )
Revised Protocol No.: 06
Date: 09-Oct-2020 25
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Objective Endpoints
Secondary
To assess the rate of major bleeding after treatment 
with BMS -986177 relative to placeboEvent rate based on bleeding according to Bleeding 
Academic Research Consortium ( BARC )Type 3 and 5
To assess the rate of all bleeding after treatment with 
BMS -986177 relative to placeboEvent rate based on BARC, ISTH and PLATO -defined 
criteria
To compare the rate of the composite of new ischemic
stroke and new covert brain infarction detected by 
[CONTACT_194704] 90 during treatment with BMS -986177 
compared to placeboRate of the composite of new ischemic stroke during the 
treatment period and new covert brain infarction 
(FLAIR + DWI) detected by [CONTACT_66577] [ADDRESS_1230493] of BMS -986177 on char acteristics 
ofbrain lesions on Day 90 MRILocation, number, and volume of new FLAIR + DWI 
lesions
To compare the rate of the c omposite of new ischemic
stroke, myocardial infarction ( MI)and all -cause 
mortality during treatment with BMS -986177 vs.
placeboEvent rates f or new ischemic , non -fatal stroke, non-fatal 
MI,and all -cause death during the treatment period
To assess stroke severity, neurological, and cognitive 
function following BMS -986177 treatment vs.
placeboNatio nal Institutes of Health Stroke Scale (NIHSS), 
Modified Rankin Scale (mRS), Montreal Cognitive 
Assessment (M oCA),and Digit Symbol Substitution 
Test ( subtest of WAIS -IV)at baseline, on Days 21 and 
90, and at the time of a new stroke event
To assess the safety and tolerability of BMS -986177 Adverse events, vital signs, physical exams, 
electrocardiogram ( ECG )and clinical laboratory results
To assess the pharmacokinetics ( PK)of BMS -986177 
and potential effects of covariates on exposureEstimated clearance ( CL)and volume of distribution 
(Vd)and effect of body weight, age, gender, race, renal 
function, liver function, concomitant medications
To assess the dose -response of BMS -986177 on 
pharmacodynamic (PD) biomarkers% change from baseline in aPTT and Factor XI clotting 
activity  during treatment
Exploratory
To assess the effect of BMS -986177 on characteristics 
of cerebral microbleeds (CMBs), hemorrhagic 
transformation of ischemic stroke and asymptomatic 
intracranial bleeding on Day 90 MRIIncidence and characteristics of CMBs, hemorrhagic 
transformation of ischemic stroke and asympt omatic 
intracranial bleeding on Day 90 MRI
To explore the exposure -response (E-R) relatio nship 
of BMS-986177 on efficacy endpointsNew ischemic , non -fatal stroke, non-fatal MI, and all -
cause death during the treatment period
To explore the E-Rrelationship of BMS -986177 on 
major bleedingBleeding according to BARC Type 3 and 5 definitions
To assess the PK of clopi[INVESTIGATOR_7745] (and metabolites) , 
aspi[INVESTIGATOR_880432] (and metabolites) , aspi[INVESTIGATOR_880433] E-Rrelationship of BMS -[ADDRESS_1230494], stroke, 
thrombosis/hemostasis, inflammation and 
cardiovascular diseases, and their relationship to 
BMS -986177 treatment and selected endpointsThese markers may include, but are not limited to: 
plasma D -dimer, PT, F1.2, and Factor XI antigen.
Revised Protocol No.: 06
Date: 09-Oct-2020 26
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Overall Design:
The study  is a m ulti-center, Phase 2, randomized, doubl e-blind, placebo -controlled, dose-ranging 
trial. Eligible participants will be screened for potent ial inclusio n into the study as soon as possible 
after presentati on and rando mized within 48 hours of the index event.
Following signing of informed consent, participants willbe rando mized to receive BMS -986177 
or placebo, plus open -label uncoated aspi[INVESTIGATOR_248] 100 mg in combinat ion with clopi[INVESTIGATOR_7745]  (a loading 
dose followed by [CONTACT_65119]) for the next 21 days. Participants will continue treatment 
from Day 22 through Day 90 with BMS-986177 or placebo, plus open -label 100-mg uncoated 
aspi[INVESTIGATOR_880434]. 
Aspi[INVESTIGATOR_880435] -label as a background therapy  according to the 
following scenarios:
1)Prior to signing informed consent :
ÔÇ∑Parti cipants who have received a single open -label  clopi[INVESTIGATOR_880436] 
300mg a nd [ADDRESS_1230495] -of-care pri
or to obtaining informed consent can be enro lled 
in the study . No addit ional loading dose of clopi[INVESTIGATOR_880437]. 
ÔÇ∑Following a standard -of-care clopi[INVESTIGATOR_880438], the standard -of-care clopi[INVESTIGATOR_880439] 75 m g will be taken the next day , and i t can be taken prior to randomizat ion. 
ÔÇ∑Parti cipants who report taking chronic clopi[INVESTIGATOR_880426] a 300-mg clopi[INVESTIGATOR_880440] i nvest igator can verify that the participant has taken the daily dose 
for at least the preceding 3 days.
2)Prior to randomizat ion and after signing informed consent :
ÔÇ∑Following si gning of informed consent, a 300 -mg loading dose of 
clopi[INVESTIGATOR_880441] 100 mg 
aspi[INVESTIGATOR_880442] (IRT), if considered 
clinically appropriate . Daily 75 mg clopi[INVESTIGATOR_123943] 100 mg da ily aspi[INVESTIGATOR_880443] .
3)After rando mizat ion:
ÔÇ∑A clopi[INVESTIGATOR_880444] [ADDRESS_1230496] dose of double -blind study medication (BMS -[ADDRESS_1230497] acebo) should
be taken as soon as possible after the baseline MRI assessment, preferably  within 2 hours, but no 
Revised Protocol No.: 06
Date: 09-Oct-2020 27
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230498] dose of study medicati on shoul d still be taken 
immediately  after randomizat ion and within 48 hours from  the onset of the index event.
BMS -986177 or placebo will be taken twice daily (BID), once in themorning (between
6AM -9AM) and again in the evening (between 6PM -9PM).
An MRI of the brain will be performed on Day 90 ¬± 6 days (based on randomizati on on Day 1) 
All participants shoul d remai n on study  treatm ent until theDay 90 MRI is performed up to Day 
96. 
Screenin g Period:
ÔÇ∑All study  assessments shoul doccur within the first 48 hours of the index event, following 
participant consent.
ÔÇ∑Within 48hours of the onset of  the index event, and prior to randomizat ion, participants will 
have a baseline MRI (may be same as clinical MRI) whenever possible .If the baseline MRI 
cannot be performed within [ADDRESS_1230499] dose of study medicat ion shoul d still be 
takenimmediately after rando mizat ionwithin 48 hours fro m the onset of the index event.
ÔÇ∑Within [ADDRESS_1230500] er ultrasound, CTA, MRA ,or catheter angiography to assess for the presence 
of intracranial or cervical arteri al atheroscl erotic plaque , ulcerati on, or thrombus that is 
proximal to th e index lesio n. Use of available vascul ar imaging showing a qualifying lesio n 
prior to the stroke event is allowed for participants who cannot complete the vascular imaging 
within 48 hours of the index event.
ÔÇ∑At screening, the following will be obtained: physical  examinat ion, physical measurements, 
local clinical laboratory  tests(including pregnancy test for WOCBP), vital signs, ECG, and 
medical history .
ÔÇ∑The following functional/disease severit y assessments are to be completed at screening : 
ABCD2, NIHSS, m RSfor eligibilit y assessment.
Double -blind Treatment Period:
ÔÇ∑The double -blind treatment period will be fro m Day 1 to Day  90.
ÔÇ∑During the init ial phase of the study, a minimum o f 800 participants will be ran domized to one 
of the following 4 doses of BMS -986177: 25 m g daily  (QD ), 25 m g, 50 m g,or 100 m g twi ce 
daily (BID) , or pl acebo. Twenty -five percent (25%) of the parti cipants will be rando mized to 
the placebo arm and the rest of participants will be rando mized equally to the 4doses of 
BMS -986177.
Revised Protocol No.: 06
Date: 09-Oct-2020 28
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
ÔÇ∑All participants will be treated with open -label uncoated aspi[INVESTIGATOR_248], 100 mg QD and clopi[INVESTIGATOR_51153] l, 
75 mg QD (after a single 300 mg clopi[INVESTIGATOR_880438] +aspi[INVESTIGATOR_248] 100 mg one day prior), 
for 21 days fo llowed by  [CONTACT_6149][INVESTIGATOR_880445] 22 to Day 90.
ÔÇ∑On Day 1, pri or to the init ial dose of study  medicatio n, the fo llowing will be obtained: centra l 
clinical laboratory  tests f or saf ety, PDsamples, expl oratory  biomarker samples, and optional 
pharmacogeno mic samples .
ÔÇ∑National Inst itutes of Healt h Stroke Sc ore(NIHSS), Modified Rankin Scale (mRS), Montreal 
Cogni tive Assessment (MoCA), and Digit Symbol Substi tution Test (DSST; subtest of 
WAIS -IV) will be collected a t baseline (at randomization for NIHSS) ,on Days [ADDRESS_1230501] (subset of WAIS-IV) will be read by a third-
party  central  laboratory  blinded to treatment.
ÔÇ∑A Day 60 visit is requi red for central  clinical safety  laboratory  sample within a ÔÇ±7-day visit 
window for a pproximately [ADDRESS_1230502] udy S ponsor.
ÔÇ∑A telephone contact [CONTACT_880552] [ADDRESS_1230503] not been 
completed onsite.
ÔÇ∑Onsitevisits will be requi red on Days 21 and 90 (end-of-treatm ent visit). At these visits, the 
following will be obtained: central  laboratory  tests for safet y, PK, PD,and exploratory 
biomarkers. 
ÔÇ∑In the event participants are unable or not permitted to attend an onsite visit due to the 
COVID -19 pandemic , alternat ive measures can be considered to obtain requi red visit 
assessments as loc al regulatory  requi rements permi t.
ÔÇ∑The randomization of participants to the [ADDRESS_1230504] acebo group will be used to achieve a 2:1 ratio rel ative to each treatm ent arm  by [CONTACT_93500] .Once a decisi on to add the 200-mg BID dose group has been made, 
rando mizat ion will be revised to achieve a target 2:1:1:1:1:1 (pl acebo: 25 mg QD: 25 mg BID: 
50 m g BID: 100 m g BID: 200 m g BID) by [CONTACT_880553] .
ÔÇ∑All participants will also have an MRI assessment on Day 90 ( ÔÇ±6 days) while cont inuing study 
drug treatment . 
In the event participants are unable or not permitted to attend the Day  [ADDRESS_1230505] Day  96.
Revised Protocol No.: 06
Date: 09-Oct-2020 29
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
ÔÇ∑A telephone contact [CONTACT_880554] y events will be requi red for all participants.  
For participants co mpleting treatment, this contact [INVESTIGATOR_1317] t imed wit hin [ADDRESS_1230506] scheduled 7 day s after the Day  90 
MRI; if for any reason a Day [ADDRESS_1230507] is to be 
perform ed at Day 97¬± 2.Participants who permanent ly discontinue study  treatment early 
shoul d complete the end-of-treatm ent assessments, except MRI, at time of study drug 
discontinuat ion. For these partici pants, the Day [ADDRESS_1230508] between discont inuat ion andDay 90 MRI i s encouraged for parti cipants 
who perman ently discont inue study  treatm ent early .
ÔÇ∑For participants who withdraw consent for follow-up, there shoul d be docum entati on of the 
reason for withdrawal. Study  staff should explici tly seek informat ion about the possible 
contribution of AEs to the participa nt‚Äôsdesire to withdraw and docum ent any AEs that are 
ident ified in the AEsection of the CRF.
ÔÇ∑Early permanent discont inuat ion ofstudy  medicat ionshoul d be distinguished fro m withdrawal 
of consent for follow-up visits, telephone contacts, or medical recor ds checks. Parti cipants 
requesting withdrawal  from the follow-up shoul d be informed that withdrawal of consent for 
follow-up will resul t in loss of important information about the benefits and risks of BMS-
986177.
Follow -upPeriod:
ÔÇ∑To be di scharged from  the study, atelephone contact [CONTACT_880555]. For participants compl eting treatment, this contact [CONTACT_880556] [ADDRESS_1230509] is to be performed at Day  97 ¬± 2.
Numb er of Participants:
Approximately  and up to 2350 participant s from approximately  30 countri es and approximately
380 clinical research sites will be rando mized using a compet itive enrollment approach.
Treatment Arms and Duration:
Study Drug
sfor CV010031
Medication Dose Strength IP/Non -IP
BMS -986177 Capsule25 mg IP
100 mg IP
Revised Protocol No.: 06
Date: 09-Oct-2020 30
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Study Drugs for CV010031
Medication Dose Strength IP/Non -IP
Placebo ForBMS -986177 Capsule NA IP
Clopi[INVESTIGATOR_880446] 75 mg IP
Uncoated Aspi[INVESTIGATOR_880447] 100mg IP
Study Design Schematic :
The enro llment period for this trial will last approximately 36months.
Data Monitoring Committee (DMC)
An independent DMC , whose activit ies will be described in a charter, will mo nitor the study . The 
DMC will be comprised of experi enced clinicians, tri alists and statistical experts. The DMC will 
review efficacy  andsafety  data at designated times during the trial wit h the purpose of each review 
defined in the DMC charter. After approximately [ADDRESS_1230510] ivities will be described in a DMC charter.
Revised Protocol No.: 06
Date: 09-Oct-2020 31
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Steering Committee (SC)
The SC will consist of the Lead Invest igator, who will serve as SC Chair. Other members will 
include: nationalleaders fro m othercoun tries, other experts ,and Sponsor representatives. The SC 
will be responsible for sci entific aspects of the study  and will  ensure that the study  executi on and 
manageme nt are of the highest qualit y. The SC will convene regul arly to discuss and report on 
ongoing supervisio n of the study .
Statistical Considerations
Sample Size : The primary endpo int for this study is the incidence of events within a co mposite of 
new ischemic stroke during the treatment period and ne w covert brain infarction (FLAIR + DWI) 
detected by [CONTACT_66577] [ADDRESS_1230511] with the MCP -MOD methodol ogy using simulat ions with the Dose -Finding 
package in Rstatistical analysis software . Simulations of 2500 clinical trials were performed, 
assuming a true incidence for placebo of 15%, a plateau shaped dose response relationship with 
maximum relat ive risk reduct ion of 32% for BMS -986177 100 or 200 mg BID relat ive to placebo, 
and reducti onsof 10%, 17.5%, and 27% for the 25 mg QD, 25 mg BID, and 50 mg BID doses, 
respectively . Candi date models included an Emax model, a logistic model, and an exponent ial 
model.
Using these assumpt ions, a total o f 2100 participants allocated in a 2:1:1:1:1:1 ra tio to placebo and 
BMS -986177, 25 -mg QD, 25 -mg BID, 50 -mg BID, 100 -mg BID, and 200 -mg BID groups provide 
approximately  80% power to demonstrate a dose -response relationship, with a 1- sided ty pe I error 
of 0.049. Without the 200-mg group, a total  of 1800 participants allocated in a 2:1:1:1:1 ratio to 
placebo and BMS 986177, 25-mg QD, 25-mg BID, 50-mg BID, and 100-mg BID groups woul d 
provi de approximately 79% power to demonstrate a dose-response relationship with similar 
pattern, but risk reducti on of 32% forBMS -986177 50- or 10-mg BID relative to placebo and 
reducti ons of 17.5%, and 27% for the 25 -mg QD and 25 -mg BID doses, respectively. Allowing up 
to 10% of participants who do not have a clinical event and also do not have a Day 90 imaging 
assessment, approximately andup to 2350 participants may be randomized. The frequency and 
reasons for missing data will be evaluated in blinded fashio n during the course of the study .
Statistical Analyses : Dose -response relat ionship will be analyzed based on a generalized Mult iple 
Com parisons and Modeling (gMCP -Mod) analysis for the BMS -
[ADDRESS_1230512] dose added to the ordered BID dose regimens. If a dose-
response relat ionship exists, then fitted estimates for the incidence of the primary endpo int will be 
calculated in each of the treatm ent groups using the selected dose-response models. An Emax 
model, a logistic model, and an exponent ial model will be used as the candi date models for the 
gMCP -Mod analysis.
Point estimates with 95% confidence intervals for the following event rates will be summarized 
by [CONTACT_1570].
ÔÇ∑Com posite of new ischemic stroke during the treatment period and new covert brain infarctio n 
detected by  [CONTACT_66577] 90 day s
Revised Protocol No.: 06
Date: 09-Oct-2020 32
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
ÔÇ∑Com posite of new ischemic non-fatal stroke, non-fatal MI,and all -cause m ortali ty
ÔÇ∑New ischemic stroke during the treatment period
ÔÇ∑New covert brain infarct ion detected by  [CONTACT_194704]  90
ÔÇ∑All-cause death
ÔÇ∑Non-fatal myocardial  infarct ion (MI)
Dose -response analysis for new ischemic non-fatal stroke and the composite of newnon-fatal 
stroke, non -fatal MI, and all -cause death will be assessed similar to the primary endpo int analysis.
Locati on, number, and vo lume of new FLAIR +DWI lesio ns will be summarized descript ively by 
[CONTACT_3227] .
Functional/disabilit y/cogni tivestatus assessed by [CONTACT_880557] 
(NIHSS), modified Rankin Score (mRS), Montreal Cogni tive Assessment (MoCA) and Digit
Symbol Subst itution Test ( DSST; subtest of WAIS -IV) will be summarized by [CONTACT_3227].
The event rates for all bleeding will be summarized by  [CONTACT_3227], including po int estimates 
with 95% confidence intervals within group. Bleeding events will be summarized by [CONTACT_880558] , ISTH (major and CRNM bleeding) , and PLATO criteria (major, including life-
threatening and other; minor, and minimal).
Adverse events, vital signs, ECG s,and clinical laboratory results will be summarized by [CONTACT_6490] .
Except as otherwise noted, descript ive summaries will use data from all rando mized groups, while 
dose-response analyses of primary and secondary  endpo ints will use data from participants 
rando mized to placebo, 25 m g QD ,and 25 mg, 50 mg, 100 mg, and 200 mg BID groups.
Revised Protocol No.: 06
Date: 09-Oct-2020 33
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
2 SCHEDULE OF A CTIVITIES
Study  assessments and procedures are presented in Table 2-1andTable 2-2.
Table 2-1: Screening Period Procedural Outline (CV010031)
ProcedureScreening
VisitNotes
Eligibility Assessments
Informed Consent X Must be signed before any study procedures are initiated. See Appendix 2.
Participant Enrollment X Contact [CONTACT_185686] (IRT ) for participant number assignment and treatment 
assignment .
Inclusion/Exclusion Criteria X SeeProtocol Section 6.1and 6.2.
Clopi[INVESTIGATOR_880448]/voic e response sy stem ( IRT) will dispense a [ADDRESS_1230513] the preceding 3 days.
Medical History X
Revised Protocol No.: 06
Date: 09-Oct-2020 34
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Table 2-1: Screening Period Procedural Outline (CV010031)
ProcedureScreening
VisitNotes
Assessment of Signs and Symptoms
Clinical MRI or CTfor Exclusionary 
PathologyXLocal assessment of magnetic resonance imaging (MRI )or computed tomography (CT)used to 
identify  exclusionary  pathology such aslacunar stroke, hemorrhage, arteriovenous malformation 
(AVM) or tumor .
Note: Aclinical (standard -of-care) MRI scan can be used as the baseline MRI provided that the clinical 
MRI protocol and scanner have been pre -approved by [CONTACT_11343].a
Clinical Vascular Imaging XDoppler Ultrasound, CTA, MRA or Catheter Angiography t oascertain the presence of intracranial or 
cervical arterial atherosclerotic plaque, ulceration or thrombus in feeding artery . Use of available 
vascular imaging showing a qualifying lesion prior to the stroke event is allowed for participant s who 
cannot complete the vascular imaging within 48 hours of the onset of t heindex event.
ÔÇ∑ Note : Atherosclerotic plaque does not need to be severe or stenotic, but must be visible. 
Participan ts with complete occlusion of a cervical carotid or an intracranial artery that is proximal 
to the index lesion should be excluded.
ABCD2for TIA X ABCD2 Score ‚â•6 ormotor symptoms (seeSection 9.4.2 and Appendix 6).
Modified Rankin Scale (m RS) X Pre-morbid mRSmust be ÔÇ£3 (ie, beforeindex event ); to assess degree of disability  or dependence in 
daily  activities (seeSection 9.4.3 and Appendix 7)
Full Phy sical Examination X SeeProtocol Section 9.2.13 .
Physical Measurements X Height (screening only) andweight .
Vital Signs X Seated blood pressure and heart rate measured after the participant has been resting quietly for at least 
5 minutes an d before blood collection (see Section 9.2.14 ).
Concomitant Medication Use X All medications within 7 days prior to randomization (see Section 7.7).
Revised Protocol No.: 06
Date: 09-Oct-2020 35
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Table 2-1: Screening Period Procedural Outline (CV010031)
ProcedureScreening
VisitNotes
Clinical Laboratory Tests XScreening clinical laboratory tests to assess eligibility ,per inclusion/exclusion criteria ,to be conducted 
locally and list edbelow (seeSection 6 and Section 9.2.16 ).Laboratory  samples collected as standard -
of-care after the o nset of the index event and prior to signing informed consent can be used to assess 
eligibility if meeting protocol -specified requirements . Results from the screening labs should be faxed 
or scanned and emailed to .
The following screening laboratory tests should be performed locally  to assess eligibility  and review 
should be documented prior to randomization:
eGFR ‚â• 15 ml/min/1.73m2
Hemoglobin ‚â• 9g/dL
Platelets count ‚â•100,000 mm3
aPTT ‚â§1.[ADDRESS_1230514]
INR <1.[ADDRESS_1230515] or ALT ‚â§ [ADDRESS_1230516] (WOCBP Only) XPregnancy test to be done locally at screening.
All WOCBP must have a negative pregnancy test every 30 days (seeProtocol Section 6.1and 
Appendix 4 ).
Electrocardiogram (ECG) X 12-lead ECG should be recorded after the participant has been supi[INVESTIGATOR_880449] 5 
minutes and bef ore blood collection (see
 Section 9.2.15) .
Serious Adverse Event (SAE) XAll SAEs should be collected from the date of written consent through the follow -upperiod (seeTable 
2-2, Section 9.2.2 ,and Appendix 3). L absperformed locally for assessment of SAEs should have 
reports faxed or scanned and emailed to .
Revised Protocol No.: 06
Date: 09-Oct-2020 36
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Table 2-2: Post-Screening Procedural Outline (CV010031)
ProcedureDay 1
Onsite
VisitDay 21
Onsite
Visita
(
ÔÇ±2days )Day 60
Onsite /Phone 
Visita,b
(ÔÇ±7days)Day 90 
Onsite Visita,c
(ÔÇ±6 days)
(End -of-
Treatment)Day 97
Phone Visitd
(ÔÇ±2 days)
(End -of-Study)Notes
Study -specific MRI Xe XThe baseline MRI should be acquired within 
[ADDRESS_1230517] be 
performed within 72 hours of the index event 
and up to 24 hours after randomization. In 
order to randomize a participant prior to the 
baseline MRI, other neuroimaging (CT or 
MRI) must be performed to assess eligibility.
The protocol -required MRI sequen ces will be 
defined in the imaging manual.
A second MRI will be performed on Day 90 
¬± 6 day s (based on randomization on Day 1) 
to accommodate scheduling and scanner 
availability . Sites are encouraged to schedule 
the Day  [ADDRESS_1230518] been pre -approved 
by [CONTACT_11343]. In the event 
Revised Protocol No.: 06
Date: 09-Oct-2020 37
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Table 2-2: Post-Screening Procedural Outline (CV010031)
ProcedureDay 1
Onsite
VisitDay 21
Onsite
Visita
(
ÔÇ±2days )Day 60
Onsite /Phone 
Visita,b
(ÔÇ±7days)Day 90 
Onsite Visita,c
(ÔÇ±6 days)
(End -of-
Treatment)Day 97
Phone Visitd
(ÔÇ±2 days)
(End -of-Study)Notes
the Day  90 MRI cannot be performed within 
the+ 6-day window, the Day 90 MRI can be 
performed after the +
6-day window using 
the study  site or an external facility MRI 
scanner. For these participants, it is 
understood that they may not be taking study 
medication past Day 96 (see Section 9.2.12 ).
Central Safety Laboratory  Tests XfX X X Safety labs: Serum chemistry and 
hematology (see Section 9.2.16 ).
Clopi[INVESTIGATOR_880450]. More specifically :
Clopi[INVESTIGATOR_880451] [ADDRESS_1230519] of care 
prior to obtaining informed consent canalso 
be enrolled in the study. No additional loading 
dose of clopi[INVESTIGATOR_880452]. Following a 
Revised Protocol No.: 06
Date: 09-Oct-2020 38
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Table 2-2: Post-Screening Procedural Outline (CV010031)
ProcedureDay 1
Onsite
VisitDay 21
Onsite
Visita
(
ÔÇ±2days )Day 60
Onsite /Phone 
Visita,b
(ÔÇ±7days)Day 90 
Onsite Visita,c
(ÔÇ±6 days)
(End -of-
Treatment)Day 97
Phone Visitd
(ÔÇ±2 days)
(End -of-Study)Notes
standard -of-care clopi[INVESTIGATOR_880453], the 
standard-of-care clopi[INVESTIGATOR_880454] [ADDRESS_1230520] be randomized within48 
hours of the onset of the index event .
Full Phy sical Examination X See Section 9.2.13 .
Brief Physical Assessment XIncludes organ systems pertinent to the 
participant ‚Äôs signs, symptoms, or adverse 
events, e.g., assessment of signs of 
thromboembolism and bleeding .
Physical Measurements X Weight only.
Revised Protocol No.: 06
Date: 09-Oct-2020 39
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Table 2-2: Post-Screening Procedural Outline (CV010031)
ProcedureDay 1
Onsite
VisitDay 21
Onsite
Visita
(
ÔÇ±2days )Day 60
Onsite /Phone 
Visita,b
(ÔÇ±7days)Day 90 
Onsite Visita,c
(ÔÇ±6 days)
(End -of-
Treatment)Day 97
Phone Visitd
(ÔÇ±2 days)
(End -of-Study)Notes
Vital Signs X XSeated blood pressure and heart ratemeasured 
after the participant has been resting quietly 
for at least 5 minutes ,and before blood 
collection (see Section 9.2.14).
Concomitant Medication Use X X X SeeSection 7.1.
Natio nal Institutes of Health 
Stroke Scale (NIHSS)g XeX XTo assess neurological impairment (see 
Section 9.4.1 and Appendix 5); must be ÔÇ£ÔÄ∑at 
time of randomization .
Modified Rankin Scale (mRS)g X XTo assess degree of disability  or dependence 
in daily activities (see Section 9.4.3 and 
Appendix 7 ).
Montreal Cognitive Assessment 
(MoCA)gXhX XTo assess cognitive dysfunction ,the MoCA 
instrument will be completed by [CONTACT_880559] a third -party central laboratory 
for evaluation (see Section 9.4.4 and 
Appendix 8).
Digit Symbol Substitution Test 
(subtest of WAIS -IV)gXhX XTo assess cognitive dysfunction, the DSST 
(subset of WAI S-IV )instrument will be 
completed by [CONTACT_880560] a 
third -party central laboratory for evaluation
(see Section 9.4.4 and Appendix 9).
Pregnancy Test
(WOCBP Only)X XAll WOCBP must have a negative pre gnancy 
test every 30 days (see Section 6.1and 
Appendix 4) .  
Revised Protocol No.: 06
Date: 09-Oct-2020 40
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Table 2-2: Post-Screening Procedural Outline (CV010031)
ProcedureDay 1
Onsite
VisitDay 21
Onsite
Visita
(
ÔÇ±2days )Day 60
Onsite /Phone 
Visita,b
(ÔÇ±7days)Day 90 
Onsite Visita,c
(ÔÇ±6 days)
(End -of-
Treatment)Day 97
Phone Visitd
(ÔÇ±2 days)
(End -of-Study)Notes
ECG X X12-lead ECG should be recorded after the 
participant has been supi[INVESTIGATOR_880455] 5 minutes an d before blood collection 
(see Section 9.2.15 ).
Adverse Event (AE) Reporting X X X X XNSAE collection begins after randomization 
through the follow -up period (seeSection 
9.2.2 and Appendix 3) .
Serious Adverse Event (SAE) 
ReportingX X X X XSAEs collection after written consent through 
the follow -up pe riod. SAEs must be followed 
up until resolution or stabilization (see 
Section s 9.2.2, 9.2.3 , and 9.2.5 and Appendix 
3). Labsperformed locally for assessment of 
SAEs should have reports faxed or scanned 
and emailed to .
Pharmacokinetic (P K)
Assessment for BMS -986177iX X X SeeSection 9.3.1 .
Pharm acokinetic (PK) 
Assessment for Clopi[INVESTIGATOR_880456] 9.3.1 .
Pharmacodynamic (PD) 
Biomarker Sampling (PT, aPTT ,
and FXI C lotting Activity)iXfX X SeeSection 9.3.2 .
Revised Protocol No.: 06
Date: 09-Oct-2020 41
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Table 2-2: Post-Screening Procedural Outline (CV010031)
ProcedureDay 1
Onsite
VisitDay 21
Onsite
Visita
(
ÔÇ±2days )Day 60
Onsite /Phone 
Visita,b
(ÔÇ±7days)Day 90 
Onsite Visita,c
(ÔÇ±6 days)
(End -of-
Treatment)Day 97
Phone Visitd
(ÔÇ±2 days)
(End -of-Study)Notes
Blood for F1.2 and D -dimer XfX X SeeSection 9.3.2 .
Plasma and Serum E xploratory 
Biomarker AssessmentsXfX X See Section 9.3.2 .
FXI A ntigen XfSee Section 9.3.2 .
Whole Blood for DNA XDay 1pre-dose. If sample is not collected on 
Day 1,it can be collected at any time during 
the study ; only one sample is require dper 
participant (see Section 9.3.2) .
Note: Collected only in participants in 
countries andsites where genetic 
testing is allowed and who opt in to 
genetic testing as captured on an ICF .
Study Medication Compliance X X X BMS -986177, placebo, clopi[INVESTIGATOR_880457] (see Section 7.6).
Dispense Study Medication X XkThe first dose of study medication (BMS -
986177 or placebo) should be taken as soon 
as possible after the baseline MRI 
assessment, preferably within [ADDRESS_1230521]-MRI window, the i nvestigator should 
call the Medical Monitor for guidance .
Ifthebaseline MRI is completed after 
48hours from the o nset of the index 
Revised Protocol No.: 06
Date: 09-Oct-2020 42
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Table 2-2: Post-Screening Procedural Outline (CV010031)
ProcedureDay 1
Onsite
VisitDay 21
Onsite
Visita
(
ÔÇ±2days )Day 60
Onsite /Phone 
Visita,b
(ÔÇ±7days)Day 90 
Onsite Visita,c
(ÔÇ±6 days)
(End -of-
Treatment)Day 97
Phone Visitd
(ÔÇ±2 days)
(End -of-Study)Notes
event,the first dose of study medication 
should still be take n immediately after 
randomization within 48 hours from the 
onset of the index event .
Study Medication Collection X Participant should return all study 
medication/supplies.
a  In the event participants are unable or not permitted to attend an onsite visit due to the COVID -19 pandemic, alternative measures can be considered to obtain required visit 
assessments as local regulatory requirements permit.
b  Day  60 site visit for central clinical safety laboratory testing can occur separate from the phone visit within the ¬±[ADDRESS_1230522] . The S ponsor will notify investigators on the dec ision of the DMC.
c  If study  treatment is discontinued early, the participant is expected to complete the end- of-treatment assessments, except MRI, at time of study drug discontinuation. For these 
participants, the Day 90 MRI (¬± 6 days) as well as Day 97 (¬± 2 days) visit must be completed at the planned visit days. Other Day [ADDRESS_1230523] is to be performed at Day 97 ¬± 2.
e To be conducted prior to randomization. Refer to notes regarding study -specific MRI for instances where the baseline MRI is performed outside of the [ADDRESS_1230524] dose of study medication.
g  In addition to the times specified in this table, assessments are to be obtained at the time of a new stroke (see Appendix 5, 7, 8, and 9).
h  May be collected within 48 hours of Day 1.
iSample should be obtained within 48 hours of new stroke or major bleeding event.
Revised Protocol No.: 06
Date: 09-Oct-2020 43
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230525] be re -dispensed at Day 21 .
Revised Protocol No.: 06
Date: 09-Oct-2020 44
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230526] 
commo n type of stroke (~80%). Primary brain hemorrhage is a less commo n cause of stroke 
(~20%) but is associ ated with considerable morbidity and mortalit y. Stroke incidence is strongly 
linked to age and stroke prevalence is increasing due to the ageing global population. 
Thromboembo lism is commo n to almost all types of ischemic stroke sso that inhibit ion of 
thrombosis is a pi[INVESTIGATOR_880458]. About 1.[ADDRESS_1230527] had a stroke or transient 
ischemic attack (TIA). The risk of recurrent stroke is particularly high during the initial 90 days 
following ischemic stroke or TIA. Pooled analyses of observat ional studi es completed in 2007,
suggested the early  risk of stroke was 9.9%, 13.4%, and 17.3% at 2, 30, and [ADDRESS_1230528] 
decreased the recurrence rate but it remains unacceptably high. In two recen t clinical trials that 
investigated pa tients with acute ischemic stroke, the risk of recurrent stroke was 7 to 12% despi[INVESTIGATOR_880459] n intervent ions.4,5In patients with acute TIA, 
the rate of subsequent ischemic s troke i s somewhat lower, but still high, 4 %to 9% at 90 day s.2,3,5
The clinical ,time
-based definit ion of TIA has been updated to now include imaging toexclude 
evidence of tissue damage ,but the traditional time-based definit ion is still commo nly used in 
practi ce.6Clinically defined TIA and stroke form part of a  risk continuum and risks of early 
recurrent stroke, MI and vascular de ath are similar .7,8,9
Accumulat ing evidence suggests that for patients wit
h strokes associated with large vessel 
atherosclerosis (CARESS10, CLAIR11) and for patients in who m treatm ent can be init iated wi thin 
12-24 hours after an acute minor stroke or TIA (CHANCE12, POINT13), treatm ent wit h aspi[INVESTIGATOR_880460].
A meta -analysis of data from the CARESS and CLAIR trials below (Figure 3-1) shows that the 
combinat ion of aspi[INVESTIGATOR_880461].
Figure 3-1: Meta -analysis Number of Patients with Recurrent Stroke in CARESS 
and CLAIR for Dual Antiplatelet Therapy vsMonotherapy
Revised Protocol No.: 06
Date: 09-Oct-2020 45
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
As shown in Table 3-1, t he risk of recurrent ischemic stroke at 90 days with aspi[INVESTIGATOR_880462].
Table 3-1: Rates of Ischemic Stroke and Bleeding in POINT and CHANCE 
Studies
Study
EventAspi[INVESTIGATOR_248] (%) Aspi[INVESTIGATOR_248] + Clopi[INVESTIGATOR_7745] (%)
CHANCE12
Ischemic Stroke 11.[ADDRESS_1230529] on thromboti c diseases through dose-
dependent inhibit ion of the tissue factor -activated coagulation process. Increasing doses of FXa 
inhibitors cause progressively more inhibit ion of hemostasis and efficac y, until bleeding risks limit  
further increases in FXa doses. Adding a FXa inhibitor to maximized antiplatelet treatm ent 
improves efficacy outcomes (as seen below wit h the COMPASS results) but ,again ,at the cost of 
additional bleeding which is a majo r concern among clinicians when consi dering antithrombotic 
therapy  in pat ients with stroke and threatened stroke .
3.1.1 Novel Antithr ombotic Mechanism of BMS -986177
BMS -986177 (also known as JNJ-70033093) is a small molecule that binds and inhibit s the 
activated form o f human coagulat ion Factor XI (Factor XIa) with high affinit y and select ivity. The
Revised Protocol No.: 06
Date: 09-Oct-2020 46
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230530] on hemostasis .14
The rationale for this study  is that Factor XIa inhibit ion has the potenti al to reduce thrombin 
generat ion enough to prevent vascular occlusion and embo lism without impairing hemostasis.
Whereas Factor Xa inhibitors block the tissue factor -activated coagulat ion process required for 
hemo stasis, Factor XIa inhibit ion blocks thrombus format ion through the ‚Äúcontact ‚Äùsystem, which
is not required for norm al hemostasis but appears to contribute to pathological thrombus formation.
The following observat ions support this concept : (1) the highest levels of Factor XIactivit y are
associ ated wi th a heightened risk of ischemic s troke15,16,17; (2) lower levels o f Factor XI activit y
are associated with a reduced risk of ischemic stroke18,19,20; (3) Factor XI deficiency israrely 
associ ated with unprovoked majo r bleeding21;(4) although not done in patients with stroke, a 
Phase 2study for VTE prophylaxis in patientspost total knee replacement provides a proof of 
concept. The study  showed that reducing FXI levels to 20% or less than normal wit h an ant isense 
inhibitor of FXI synthesis reduced the risk of postoperative VTE compared to enoxaparin, without 
an increase in bleeding compared to enoxaparin .14In patients with ESRD on hemodialysis, single 
doses of 100 mg and 300 mg BMS -986177 reduced clot formation in thehemodialysis circui ts, 
and was not associated with serious bleeding.22
The high residual risk for recurrent stroke seen in the POINT and CHANCE studies (see Table 3-
1),even when patients are treated withcombinat ion of aspi[INVESTIGATOR_8258] ,emphasize sthe 
continuing need for a more effective therapeut ic option. Two possible strategi esfor achieving 
better efficacy are: (1) more potent antiplatelet therapy. (2) dual pathway  inhibi tion of thrombo sis.
3.1.[ADDRESS_1230531] ive than treatment wi th aspi[INVESTIGATOR_880463]. The trial compared ticagrel or (a direct -acting P2Y12 receptor inhibitor 
antiplatelet agent) vs.aspi[INVESTIGATOR_248] 100 mg/day . The 11% reducti on in the primary outcom e (stroke, 
myocardial infarct ion, cardi ovascular death) with ticagrel or compared to aspi[INVESTIGATOR_880464] (p =0.07).
A pre-specified exploratory  subgroup analysis of the data from the SOCRATES tri a
l23showed a 
significant treatm ent-by-subgroup interacti on suggesting that the risk for the composite endpo int 
of stroke, myocardial  infarcti on, ordeath was lower with ticagrel or th an aspi[INVESTIGATOR_880465]. The invest igators suggested that this 
analysis provi des empi [INVESTIGATOR_880466]
3.1.3 Dual Mech anisms of Thrombosis Inhibition
Support for this strategy  was provided by [CONTACT_880561] (COMPASS24)trial in which 27,395
Revised Protocol No.: 06
Date: 09-Oct-2020 47
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
patients with stable coronary  artery  atheroscl erosis or peripheral artery  atheroscl erosis (but without 
recent stroke) were randomly assigned to receive rivaroxaban 5 mg twice daily (BID) , rivaroxaban 
2.[ADDRESS_1230532] ion of 49% (abso lute risk 
reducti on=0.7%) with low-dose rivaroxaban plus aspi[INVESTIGATOR_34265].aspi[INVESTIGATOR_264086] (nominal p<0.001). 
Major bleeding increased by 70% (abso lute risk increase =1.2%) with rivaroxaban 2.5mg BID 
plus aspi[INVESTIGATOR_880467].24
A recent ana lysis o f the patientsin CO MPASS who had a pri or stroke (3.8%=1,041) showed that 
the annual rate of ischemic stroke was reduced from 3.4% with aspi[INVESTIGATOR_880468] 0.7%
withrivaroxaban plus aspi[INVESTIGATOR_248] [HR =0.42 (0.19 -0.92), nominal p =0.03) ].25In addition to a 
reducti on in MACE , asubstant ialreduct ion in recurrent ischemic stroke in COMPASS was also 
observed indicat ingthat the combinat ionof antiplatelet therapy  with an anticoagulant has the 
potenti al to be more effective than antiplatelet therapy  or anticoagulat ion alone for secondary 
stroke prevention.
Although the combinat ion of a low dose of rivaroxaban combined with aspi[INVESTIGATOR_880469] , the risk of bleeding increased more than the risk reduction for ischemic stroke. This result 
is attributable to the mechanism by [CONTACT_880562] : dose -dependent inhibit ion of the tissue factor -activated coagulation process wh ich is 
requi red for hemostasis. Increasing doses of FXa inhibitors cause progressive lymore inhibit ion of 
hemo stasis which can predispose to bleeding. In contrast to FXa inhibit ion which impairs 
hemo stasis, FXIa inhibit ionblocks thrombus formation wi thout im pairing hemostasis. The rari ty 
of serious bleeding in people with severe FXI defici ency is consistent with the lack of a significant  
effect of severely reduced FXI activit y on hemo stasis.[ADDRESS_1230533] ion.
Revised Protocol No.: 06
Date: 09-Oct-2020 48
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230534] igated in a number of studies in humans including: (1) single 
ascending and multiple ascending dose study; (2) drug-drug interacti ons with itraconazole, 
diltiazem, rifampin ,aspi[INVESTIGATOR_248], and aspi[INVESTIGATOR_259941] ; (3) clinical pharmaco logy studies of 
special popul ations including participants with end-stage renal disease (ESRD) undergoing 
hemodialysis, participants with renal impairment, and participants with hepati c impairment; (4) 
relative bioavailabilit y and (5) Japanese PK study . To date, no dose -limiting safet y findings have 
been observed in these studies.
The first-in-human (FIH) study  withBMS -[ADDRESS_1230535]
igated single oral doses between 4 - 500 
mg and multiple oral doses between 5 - 500 mg over a 14-day period. In the single -dose portion 
of the study, dose-proporti onalit y was observed between 20 -200 mg QD with no greater increase 
in exposure observed at 300 mg, believed to be due to solubility
-limited absorpti on. 
Co-administration of a high- fat diet at 200 m g and 500 m g was associ ated wi th ~1.2 -fold and ~2-
fold increases in exposure, respectively. Table 3.2.1 -
1summarizes the clinical pharmaco logy of 
BMS -986177.
Table 3.2.1 -
1: Highlights of Clinical Pharmacology after Oral Administration of 
Single and Multiple Doses of BMS -[ADDRESS_1230536]
Half-life (T 1/2) ~11 hours (terminal T 1/2); supports BID or QD dosing
Accumulation 
Index (AI)Minimal accumulation: AI=1.13 to 1.40 for AUC (dose range 20 to 200 mg in MAD 
study; for QD dosing only)
ExposureÔÇ∑Average C max: 15.4 to 7595 ng/mL;
ÔÇ∑Average AUC:172 to [ZIP_CODE] ngÔÇ∑hr/mL
Dose 
Proportio nalityÔÇ∑Single oral doses: g reater than dose proportional from 4 to 20 mg; dose proportional 
between 20 and 200 mg
ÔÇ∑Multiple oral doses: g reater than dose proportional from 5 to 20 mg; dose proportional 
between 20 and 200 mg 
Renal Impairment
(normal renal 
function vs. 
moderate or severe 
renal dy sfunction)ÔÇ∑Renal Clearance: ~10 %
ÔÇ∑Similar C maxbetween all renal function groups
ÔÇ∑When compared to normal renal function (@ eGFR of 90 mL/min /1.73 m2):
-moderate impairment ( @ eGFR of 30 mL/min /1.73 m2): 39% ÔÇ≠in AUC (0-T);
41%ÔÇ≠ in AUC (0-INF)
-severe impairment ( @ eGFR of 15 mL/min /1.73 m2not o n dialysis ): 50% ÔÇ≠in AUC (0-T);
54%ÔÇ≠ in AUC (0-INF)
Revised Protocol No.: 06
Date: 09-Oct-2020 49
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Table 3.2.1 -1: Highlights of Clinical Pharmacology after Oral Administration of 
Single and Multiple Doses of BMS -986177 to Healthy Participants 
and Participant s with Renal or Hepatic Impairment
PK Properties BMS -
986177 Clinical PK Results
Hepatic 
Impairment 
(normal hepatic 
function vs mild or 
moderate hepatic 
impairment)ÔÇ∑Primarily  metabolized in the liver
ÔÄ≠Similar Cmaxand AUC (0-INF)between normal, mild and moderate hepatic impairment 
groups
ÔÇ∑Compared to normal participants
ÔÄ≠Mild hepatic impairment (Child Pugh A category): 18% ÔÇ≠in C maxand AUC (0-INF)
ÔÄ≠Moderate hepatic impairment (Child Pugh category B): 14% ÔÇ≠in Cmaxand no 
change in A UC (0-INF)
ÔÇ∑When accounting for changes in protein binding, the differences in normal participants 
compared to: 
ÔÄ≠Mild hepatic impairment (Child Pugh A category): 30% ÔÇ≠in Cmaxand 29% ÔÇ≠in 
AUC (0-INF)
ÔÄ≠Moderate hepatic impairment (Child Pugh category  B): 41% ÔÇ≠in C max and 24% ÔÇ≠
in AUC (0-INF)
Food Effect Small food e ffect at 200 mg (53% ÔÇ≠in Cmax; 39% ÔÇ≠for AUC )
Metabolites No major or active metabolites
CYP3A4 Inhibitors 
or Inducer DDIÔÇ∑Itraconazole: 150% ÔÇ≠in AUC; 28 %ÔÇ≠in C max
ÔÇ∑Diltiazem: 38%ÔÇ≠in AUC; 9%ÔÇ≠in C max
ÔÇ∑Rifampin : 85%ÔÇØin AUC ; 78%ÔÇØin C max
A multicenter, cross -over, randomized, Phase 2a proof -of-concept study  in participants
undergo ing hemodialysis for ESRD showed that single doses up to 300 mg of BMS -986177 were 
safe and well tol erated; no seri ous bleeding or other seri ous adverse events occurred. Exploratory 
efficacy  assessment showed that the extent of clot form ation in t he hemodialysis circuitwas similar 
with BMS -986177 and the active comparators (unfractionated heparin and enoxaparin). This result 
suggests that BMS -[ADDRESS_1230537] igator ‚ÄôsBrochure .[ADDRESS_1230538] ive 
than antiplatelet therapy  alone. Adrug-drug interacti on study  (CV010 [ZIP_CODE]) showed that 
BMS -
[ADDRESS_1230539] ion study  in healt hy participant s, BMS -986177 200 mg was given twi ce daily  (BID) for 5 
days, wit
h and without clopi[INVESTIGATOR_880470]. Clopi[INVESTIGATOR_880471] 300 mg on Day 1 
followed by 4 days of 75 mg clopi[INVESTIGATOR_7745] , and 325 mg aspi[INVESTIGATOR_880472] [QD] 
for 5 days. There were no serious bleeding events reported from any of the 113 healthy participants 
treated in this study28. A few minor bleeding events (e.g., contusion, venipuncture site bruise, 
gingival bleeding, and anal fissure bleeding) occurred in either subjects who received dual 
antiplatelet treatm ent plus BMS -986177, or in partici pants who received dual antiplatelet treatm ent 
Revised Protocol No.: 06
Date: 09-Oct-2020 50
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
without BMS -986177, or in participant swho received mono antiplatelet treatment (either 
clopi[INVESTIGATOR_880473]) alone, indicating no trend towards any  treatm ent arm s. These findings are 
consistent with the no tion that FXIa inhibit ion is a ssoci ated with a low risk of bleeding, and support 
the proposed clinical trial wit h BMS -986177, aspi [INVESTIGATOR_880420] .
3.3 Benefit/Risk Assessment
Anticoagulationhas the potenti al to cause majo r bleeding which has been demonstrated in all
clinical trials (SPI[INVESTIGATOR_61192]29, WARSS30, WASID31, ESPRIT32, ARISTOTLE33, RELY34, ROCK ET 
AF35, COMPASS). And the risk of bleeding associated with anticoagulation is heightened by 
[CONTACT_880563][INVESTIGATOR_880474] (ARISTOTLE33, APPRAISE -236, 
ATLAS -237, COMPASS24). Concern about bleeding is a major obstacle to use of ant icoagulation, 
even when clinical trial data show that the absolute risk of bleeding is lower than the risk of 
thromboembo lic events .38
A number of scores based on clinical factors (HEMORRHAGES39, ATRIA40, and HAS -BLED41) 
have been devel oped to predict the risk of major bleeding. However, none of the currently available 
scores aresufficient ly accurate in predi cting majo r bleeding in patients with non-valvular atrial 
fibrillat ion (NVAF) to be used as a rationale to withhol d anticoagulati onto reduce the risk of 
thromboembo lic events, especially stroke .42In addition, some clinical factors (hypertensio n, 
stroke, renal impairment) included in bleeding scores also increase the risk of throm boembo lic 
events.
DOACs are a majo r advance in improving the safety  of anticoagulati on. The risk of intracranial 
hemorrhage, the most devastating kind of bleeding, i s at l east 50% l ower withDOACs com pared 
to warfarin in pat ients with NVAF.43
A recent publication describes uniform  definit ions of cardiovascular and stroke outcom es 
developed by [CONTACT_880564] (SCTI) 
and the U.S. Food and Drug Administrati on (FDA) .44According to Hicks et al, ‚ÄúThe aim is for 
clinical trials to apply the stroke definit ion to assess the clinically relevant consequences of 
vascular brain injury‚Äù.
In the context of the SCTI definit ion, a clinically meaningful benefit of treatmen t is not only to 
decrease the number of strokes but also to mitigate the clinical consequences of ischemic brain 
infarction. Since no single outcome measure can describe all the dimensio ns of brain infarct ion45, 
we plan to usemultiple instruments to assess the clinical consequences of brain infarction: 
National Inst itute of Healt h Stroke Scale/Scor e (NIHSS), modified Rankin Scale (mRS), Montreal 
Cogni tive Assessment (M oCA), and Digit Symbo l Subst itution Test ( DSST; subtest of WAIS -IV).
The available preclinical and clinical evidence suggest that direct inhibit ion of Factor XIa by 
[CONTACT_20444] -986177 has the potential to reduce the risk of thromboembo lic events with a lower risk of 
major bleeding than currently available DOACs, even in combinat ion with aspi[INVESTIGATOR_248] +clopi[INVESTIGATOR_7745] , 
thus provid ing a favorable benefit/risk.
Revised Protocol No.: 06
Date: 09-Oct-2020 51
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230540] undergoing hemodialysis, there is a potenti al risk o f 
bleeding with any antithrombotic agent. Therefore, participants will be closely monitored for 
bleeding wit h oversight of the study  by [CONTACT_23275] ( DMC ).
More detailed informat ion about the known and expected benefit sand ri sks, as well as reasonably 
anticipated adverse events (AEs) of BMS -986177, is provided in the Invest igator‚Äôs Brochure.[ADDRESS_1230541] ives and endpo ints for CV010031 can be found in Table 4-1.Definit ion and details rel ated 
to study  endpo ints can be found in the Study  Events Assessment Manual .
Table 4-1: Objectives and Endpoints for CV010031
Objective Endpoint s
Primary
To estimate thedose-response relationship of 
BMS -986177 in participants with ischemic stroke or 
TIA treated with aspi[INVESTIGATOR_880475] (FLAIR +DWI) 
detected by [CONTACT_194704] 90 (MRI assessed by [CONTACT_880551] )
Secondary
To assess the rate of major bleeding after treatment 
with BMS -986177 relative to placeboEvent rate based on bleeding according to Bleeding 
Academic Research Consortium (BARC) Type 3 and 5
To assess the rate of all bleeding after treatment with 
BMS -986177 relative to placeboEvent rate based on BARC, ISTH and PLATO -defined 
criteria
To compare the rate of the composite of new ischemic 
stroke and new covert brain infarction detected by 
[CONTACT_66577] 90 days on treatment with BMS -986177 
compared to placeboRate of the composite of new ischemic stroke during the 
treatment period and new covert brain infarction
(FLAIR +DWI) detected by [CONTACT_66577] [ADDRESS_1230542] of BMS -986177 on characte ristics 
of brain lesions on Day 90 MRILocation, number, and volume of new FLAIR +DWI 
lesions
To compare the rate of the composite of new ischemic
stroke, myocardial infarction (MI) and all -cause 
mortality  during treatment with BMS -986177 vs.
placeboEvent rates for new ischemic non-fatal stroke, non-fatal 
MI,and all -cause death during the treatment period
To assess stroke severity, neurological, and cognitive 
function following BMS -986177 treatment vs. 
placeboNational Institutes of Health Stroke Scale (NIHSS), 
Modified Rankin Scale (mRS), Montreal Cognitive 
Assessment (MoCA), and Digit Symbol Substitution 
Test (subtest of WAIS -IV) at baseline, on Days 21 and 
90, and at the time of a new stroke event.
To assess the safety and tolerability of BMS -986177 Adverse events, vital signs, physical exams, 
electrocardiogram (ECG), and clinical laboratory results
To assess the pharmacokinetics (PK) of BMS -986177 
and potential effects of covariates on exposureEstimated clearance (CL) and volume of distribution 
(Vd) and effect of body weight, age, gender, race, renal 
function, liver function, concomitant medications
Revised Protocol No.: 06
Date: 09-Oct-2020 52
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Table 4-1: Objectives and Endpoints for CV010031
Objective Endpoint s
To assess the dose -response of BMS -986177 on 
pharmacodynamic (PD) biomarkers% change from baseline in aPT T and Factor XI clotting 
activity  during treatment
Exploratory
To assess the effect of BMS -986177 on characteristics 
of cerebral microbleeds (CMBs) , hemo rrhagic 
transformation of ischemic stroke and asymptomatic 
intracranial bleeding on Day 90 MRIIncidence and characteristics of CMBs , hemorrhagic 
transformation of ischemic stroke and asymptomatic 
intracranial bleeding on Day 90 MRI
To explore the exposure -response (E-R) relatio nship 
of BMS-986177 on efficacy endpointsNew ischemic non-fatal stroke, non-fatal MI, and all -
cause death during the treatment period
To explore the E-R relationship of BMS -986177 on 
major bleedingBleeding according to BARC Type 3 and 5 definitions
To assess the PK of clopi[INVESTIGATOR_7745] (and metabolites) , 
aspi[INVESTIGATOR_880432] (and metabolites) , aspi[INVESTIGATOR_880476] E-R relationship of BMS -986177 on 
aPTT and Factor XI clotting activity% change from baseline in aPTT and Factor XI clotting 
activity  during treatment
To explore biomarkers related to FXI pathway, stroke, 
thrombosis/hemostasis, inflammation and 
cardiovascular diseases, and their relationship to 
BMS -986177 treatment and selected endpointsThese markers may include, but are not limited to: 
plasm a D-dimer, PT, F1.2, and Factor XI antigen.
[ADDRESS_1230543] acebo -controlled ,dose-ranging
trial. Eligible participants will be screened for potent ial inclusio n into the study as soon as possible 
after presentation and rando mized within 48 hours of the index event .
Following signing of informed consent, participants will receive aspi[INVESTIGATOR_248] 100 mg and a single 
loading dose of clopi[INVESTIGATOR_7745]  300 m g. Participants will then be rando mized to receive BMS -986177 
or placebo, plus open -label uncoated aspi[INVESTIGATOR_248] 100 mg in combinat ion with clopi[INVESTIGATOR_7745]  75 mg QD 
for the next 21 days.Parti cipants will continue treatm entfrom Day 22 through Day 
90 with 
BMS -986177 or placebo ,plus open -label 100mg uncoated aspi[INVESTIGATOR_880434].
An MRI of the brain will be perform ed on Day 90 ¬± 6 days (based on randomizat ion on Day 1). 
All part icipants should remain on study treatment unt il the Day [ADDRESS_1230544] approximately 36months.
Screening Period:
ÔÇ∑All study  assessments shoul doccur within the first 48 hours afterthe index event, following 
participant consent.
Revised Protocol No.: 06
Date: 09-Oct-2020 53
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
ÔÇ∑Abaseline MRI shoul d be acqui red within [ADDRESS_1230545] dose 
of study medicat ion shoul d still be taken immediately after randomizat ion within 48 hours 
from the onset of the index event.
ÔÇ∑Within [ADDRESS_1230546] er ultrasound, com puted tomography angiogram (CTA), magnet ic resonance angiogram 
(MRA) , or catheter angiography to assess for the presence of intracranial or cervical arteri al 
atherosclerotic plaque , ulcerat ion, or thrombusthat is proximal to the index lesion. Use of 
available vascular imaging showing a qualifying lesion prior to the stroke e vent is allowed for 
participants who cannot complete the vascular imaging within 48 hours of the index event.
ÔÇ∑At screening, the following will be obtained: physical  examinat ion, physical measurements,
local clinical laboratory  tests(including pregnancy test for WOCBP) ,vital signs, ECG, and 
medical history .
ÔÇ∑The following functional/disease severit y assessments are to be completed at screening for 
eligibilit y assessment : ABCD2, NIHSS, and mRS .
Double -blind Treatment Period:
ÔÇ∑The double -blind treatment period will be fro m Day 1 to Day  90.
ÔÇ∑During the init ial phase of the study, a minimum o f 800 participants will be rando mized to one 
of the following 4 doses of BMS -986177: 25 m g daily  (QD); 25 m g, 50 m g, or 100 m g twi ce 
daily (BID) ;or pl acebo. Twenty -five perce nt (25%) of  the parti cipants will be randomized to 
the placebo arm,and the rest of  the participants will be rando mized equally to the 4doses of 
BMS -986177.
ÔÇ∑All participant s will be treated with open -label uncoated aspi[INVESTIGATOR_248], 100 mg QD ,and clopi[INVESTIGATOR_7745], 
75 mg QD(after a single 300-mg clopi[INVESTIGATOR_880438] +aspi[INVESTIGATOR_248] 100 mg one day prior), 
for 21 days ,followed by [CONTACT_6149][INVESTIGATOR_880477] 22 to Day  90.
ÔÇ∑On Day  1, pri or to the init ial dose of study  medicatio n, the fo llowing will be obtained: central
clinical laboratory  tests f or saf ety, PDsamples, expl oratory  biomarker samples, and optional 
pharmacogeno mic samples .
ÔÇ∑Assessments of stroke severit y, disabilit y, impact of stroke on daily activities, and cogni tive 
funct ion will be collected at times specified in Table 2-1andTable 2-2.
ÔÇ∑A Day 60 visit is requi red for central  clinical safety  laboratory  sample within a ÔÇ±7-day visit 
window for approximately [ADDRESS_1230547] igator s
by [CONTACT_157242].
ÔÇ∑A telephone contact [CONTACT_880552] [ADDRESS_1230548] not been 
completed onsite.
Revised Protocol No.: 06
Date: 09-Oct-2020 54
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
ÔÇ∑Onsite visits will be requi red on Days 21 and 90 (end-of-treatm ent visit). At these visits, the 
following will be obtained: central  laboratory  tests for safet y, PK, PD,and exploratory 
biomarkers.
ÔÇ∑In the event participants are unable or not permitted to attend a n onsite visit due to the COVID -
19 pandemic , alternat ive measures can be considered to ob tain requi red visit assessments as 
local regulatory  requi rements permi t.
ÔÇ∑The randomiza tion of part icipant s to the [ADDRESS_1230549] been randomized . The d ecisio n to proceed wi th the 
200-mg BID dose group will depend on the evaluati on of  the popul ation, the DMC review o f 
efficacy and safety data
,and an assessment of whether it is safe to randomize participants to 
that dose group.
ÔÇ∑When approximately [ADDRESS_1230550] been rando mized, rando mization for the placebo  
group will be used to achieve a 2:1 ratio relat ive to each treatment arm by [CONTACT_2054] .
Once a decisio n to add the 200- mg BID dose group has been made, rando mizat ion will be 
revised to achieve a target 2:1:1:1:1:1 (placebo: 25 m g QD: 25 mg BID: 50 mg BID: 100 mg 
BID: 200 mg BID) by [CONTACT_880553] .
ÔÇ∑All participants will also have an MRI of the brain performed on Day 90 ¬± 6 (based on 
rando mizat ion on Day 1) to accommodate scheduling and scanner availabilit y. Sites are 
encouraged to schedule the Day [ADDRESS_1230551] been pre -approved by [CONTACT_880565]. In the event the 
Day 90 MRI cannot be performed wit hin the ¬± 6-day window, the MRI can be acquired outsi de 
the + 6-day window using the study  site oran external facilit y MRI scanner. For these 
participants, i t is understood that they  may not be taking study  medicat ion past Day  96.
ÔÇ∑Invest igators will determine the management of parti cipants who have a clinical  event during 
the study  and assess events , 
including those lacking an MRI .
ÔÇ∑A telephone contact [CONTACT_880554] y events will be requi red for all participants.  
For participants co mpleting treatment, this contact [INVESTIGATOR_1317] t imed wit hin [ADDRESS_1230552] scheduled 7 day s after the Day  90 
MRI; if for any reason a Day [ADDRESS_1230553] is tobe 
perform ed at Day  97¬± 2.
ÔÇ∑Any participant who discontinues study  drug treatm entfor any reason during the trial will 
requi re aDay 90MRI , followed by  [CONTACT_880566](Day  97¬± 2).
ÔÇ∑Parti cipants who permanent ly discontinue study  treatment early shoul d complete the end-of-
treatm ent assessments, except MRI, at time of study drug discontinuat ion. For these 
participants, the Day [ADDRESS_1230554] between
discontinuat ion and Day  90 MRI is encouraged for participants who permanent ly discont inue 
study  treatm ent early.
Revised Protocol No.: 06
Date: 09-Oct-2020 55
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
ÔÇ∑For participants who withdraw consent for follow-up, there shoul d be docum entati on of the 
reason for withdrawal. Study  staff should explici tly seek informat ion about the possible 
contribution of AEs to the participant ‚Äôs desire to withdraw and docum ent any AEs that are 
ident ified in the AEsection of the CRF.
ÔÇ∑Early permanent discont inuat ion ofstudy  medicat ion shoul d be distinguished fro m withdrawal 
of consent for follow-up visits, telephone contacts, or medical records checks. Parti cipants 
requesting withdrawal from the follow-up shoul d be informed that withdrawal of consent for 
follow-up will resul t in loss of important information about the benefits and risks of 
BMS -986177.
Follow -
up Period:
ÔÇ∑To be di scharged from  the study, atelephone contact [CONTACT_880555]. For participants compl eting treatment, this contact [CONTACT_880556] [ADDRESS_1230555] is to be performed at Day  97¬± 2.
The study  design schem atic is presented in Figure 5.1-1.
Figure 5.1-1: Study D esign Schematic
Physical examinat ions, vital sign measurements, 12-lead electrocardi ograms (ECG), and clinical 
laboratory  evaluat ions will be perform ed at selected times throughout the dosing interval. 
Parti cipants will be closely  monitored for AEs throughout the study. Blood samples will be 
collected for PK analysis for up to 24hours after study  drug administration. Approximately 
200mL of blood will be drawn from each participant during the study.
Revised Protocol No.: 06
Date: 09-Oct-2020 56
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Rationale for Imaging Endpoints
Brain infarction detected by  [CONTACT_880567]. The difference between clinically  diagnosed stroke and 
‚Äúcovert /silent ‚Äù brain infarct ionsdetected by  [CONTACT_880568], but rather si ze and locati on 
(sparing motor and speech areas of the brain) of the lesio n. Covert ,MRI -detected brain infarct ions
can have clinically meaningful neurological consequences. Covert brain infarct ions,by [CONTACT_154020],
do not produce symptoms of TIA or stroke but they can be associ ated with neurologic dysfunct ion
such as cogni tive impairment and gait abnormalit y.46,47,48Furtherm ore,covert brain infarct ions
areassociated wit
h an up to 5-fold increase in the risk of future stroke, even after adjust ment for 
other risk factors, and with an increased risk of dementia (HR =6.12, 95% CI:1.82 to20.54) 
independent ly of vascular risk factors and interim stroke.48,49,50Clinicians consider covert brain 
infarctions clinically relevant, and this is now reflected in the recent Am erican Heart Associ ation 
Scientific Statem ent on prevent ing stroke in patients with apparent ly ‚Äúsilent‚Äù cerebrovascular 
disease, offering guidance for clinical evaluation and management of these participants .[ADDRESS_1230556] ions
(~12% at Day 90) is at least 2 -to 3-fold times higher than the cumulat ive rate of acute stroke (~ 5%
with aspi[INVESTIGATOR_880478] 90daysin the POINT tria
l13). Therefore ,the rate (~15%)of the 
composite endpo int of covert ,MRI -detected brain infarct ionand stroke should be sufficient to 
detect a treatment e ffect across doses in this dose -ranging study with a manageable sample size.
5.1.1 Data Monitoring and Other External Committees
Data Monitoring Committee (DMC )
An independent DMC , whose activi ties will  be described in a charter, will monitor the study  and 
be comprised of experienced clinicians, trialists, and statistical experts . The DMC will review
efficacy andsafet y data at designated times during the trial with the purpose of each review defined 
in the DMC charter. After approximately [ADDRESS_1230557] been 
rando mized, and assess whether it is safe to randomize participants to the 200-mg BID dose arm.
The DMC will use their clinical and statistical judgm ent to evaluate pertinent trial data and may 
recommend early terminat ion of an individual study  arm or the entire trialfor important safet y 
Revised Protocol No.: 06
Date: 09-Oct-2020 57
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
concerns that are feltto outwei gh potenti al benefits . Details of the DMC activit ies will be described 
in a DMC charter.
Steering Committee (SC)
The SC will consist of the Lead Invest igator, who will serve as SC Chair. Other members will 
include: nat ional leaders fro m other coun tries, other experts ,and Sponsor representatives. The SC 
will be responsible for sci entific aspects of the study  and will  ensure that the study  execut ion and 
management are of the highest qualit y. The SC will convene regul arly to discuss and report on 
ongoing supervisio n of the study .
5.2 Participants
Approximately  and up to 2350 participant s from approximately  30countri es andapproximately
380 clinical research siteswill be randomized using a competitive enrollment approach (see 
Secti on 10.1).
5.[ADDRESS_1230558] ed to be ,collected, if this 
is not the same as the end-of-study definit ion.The approximate durati on of the study  for each 
participant will be 99days, which includ es a maximum 48-hour screening period, a 90-day 
treatm ent peri od and 7 -day heal th follow
-upperiod.
5.4 Justification for Dose s
5.4.1 Identification of Effective Doses of BMS -986177
Ident ification of effective doses of BMS-986177 was based on inhibit ion of thrombus formatio n 
in a rabbit model of electri cally -induced thrombus in the caroti d artery  of rabbi ts (ECAT). The 
rabbit ECAT model has been calibrated against clinical resul ts in venous thromboembo lism 
prevent ion (VTEp) based on api[INVESTIGATOR_3822]. In this model, targeting the concentrati on that led to 50%
reducti on inthrombus weight was correlated with the steady-state trough concentration of the 
clinical dose of api[INVESTIGATOR_3822]. In therabbit ECAT model, BMS -986177 caused a dose-dependent  
decrease in both cl ot wei ght (Figure 5.4.1 -1) and preservat ion of blood flow wit hout a si gnificant 
increase in bleeding time
.  Th edose of BMS -[ADDRESS_1230559] human vsrabbi t factor XIa were 
used to estimate the human equivalent dose.
Revised Protocol No.: 06
Date: 09-Oct-2020 58
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Figure 5.4.1 -1: Exposure -dependent Reduction in Thrombus Weight and Human 
Equivalent Concentration Targets Based on B MS-[ADDRESS_1230560] total knee replacement provides t he only published data
on the clinical safet y and efficacy of reducing Factor XI activit y. Pat ients were treated for 36 days 
prior to surgery  with an antisense oligonucleotide (ASO) to reduce the level of Factor XI. The 
study  showed a dose-dependent reduction in the risk of VTE events compared to enoxaparin . 
Doses that did not reduce FXI levels to 20% or less of normal did not reduce the risk of VTE
events compared to enoxaparin .14
Figure 5.4.1 -2shows the dose-dependent decrease in FXI levels and clot wei ght observed in the 
rabbit ECAT model with ASO -induced inhibit ion of FXI. Based on the dose -dependent redu ction 
of FXI concentrations observed in the ASO VTEp study, a trough con centrati on of  approximately 
150ng/mL of BMS-[ADDRESS_1230561] equal to the 80% 
reducti on in FXI level in the rabbit ECAT model.Rabbit Plasma [ BMS -986177 ] nM10 100 1000 10000Thrombus Reduction (%) 020406080100
Revised Protocol No.: 06
Date: 09-Oct-2020 59
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Figure 5.4.1 -2: Reduction in FXI Concentration Based on Factor XI Antisense 
Oligonucleotide (FXI ASO) Compound Used in Phase [ADDRESS_1230562]  via inhibit ion 
of Factor XIa and therefore testing high doses of Factor XIa inhibit ion is warranted for 
investigat ion of a maximize ddose-response .
5.4.2 BMS -986177 with Aspi[INVESTIGATOR_248] + Clopi[INVESTIGATOR_880479] a combinati on of  aspi[INVESTIGATOR_880480] l on efficacy or safet y 
outcom es in any patient popul ation. Results fro m a drug interacti on study  in healt hy participants 
indicated that BMS -986177 and aspi[INVESTIGATOR_880481] y concerns. 
Similarly, a drug interacti on study  of dual antiplatelet therapy  (aspi[INVESTIGATOR_248] + clopi[INVESTIGATOR_7745] ) and 
Revised Protocol No.: 06
Date: 09-Oct-2020 60
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
BMS -986177 demonstrated that BMS -986177 may be administered with each antiplatelet agent 
separately  and in combinat ion withlow risk of  serious bl eeding.
The resul ts of the COMPASS trial24showed that,when combined with aspi[INVESTIGATOR_248], a dose of 
rivaroxaban only 25% of that used for stroke prevent ion in participants with nonval vular atrial 
fibrillat ion (NVAF) reduced the risk of ischemic stroke by 51% compared to aspi[INVESTIGATOR_264086]. The 
doses of rivaroxaban used in combinat ion with aspi[INVESTIGATOR_880482]. Assuming a similar synergist ic effect as observed with rivaroxaban 
and aspi[INVESTIGATOR_248] ,BMS -
[ADDRESS_1230563] favorable dose and dosing 
regimen for a secondary stroke prevent ion population for two reasons: (1) to evaluate the efficacy 
of BMS -986177 combined with aspi[INVESTIGATOR_880483] (2) to establish a n accurate and precise
dose-respon se relationship for BMS -986177.
Dose strengths selected for capsule development of BMS -[ADDRESS_1230564] be met at randomization .
6.1 Inclusion Criteria
1)Signed WrittenInformed Consent
a)Parti cipants ‚â•40 years of age(or legally acceptabl e representatives, as per country 
guidelines) from whom a signed and dated written consent for participat ion has been
obtained.
2)Type of Parti cipant and Target Disease Characteristics
a)Ischemic stroke: a neurological deficit attributable to a non -lacunar acute brain infarct ion 
detected by [CONTACT_95425] (CT or MRI )and relevant to the clinical symptoms .
AND
National Inst itutes of Healt h Stroke Score (NIHSS ) ‚â§7at time of rando mizat ion.
AND
Evidence of relevant intracranial or cervical arterial  atheroscl erotic plaque, ulceration or 
thrombus in a feeding artery  docum ented by [CONTACT_9661] (either Doppl er ultrasound orCTA 
orMRA or catheter angiography) .
Note :Atherosclerotic plaque does not need to be severe or stenotic, but must be visible .
Parti cipants wi th com plete occl usion of  a cervical caroti d orintracranial artery that 
is proximal to the index lesio nshoul d be excluded.
Revised Protocol No.: 06
Date: 09-Oct-2020 61
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
AND
Modified Rankin Score (mRS) ÔÇ£3 before the index event (pre-morbid) .
b)TIA: acute onset neurol ogical defici t attributable to focal  ischemia of the brain by [CONTACT_880569], with complete resol ution of the deficit and no brain infarction on
neuro imaging (CT or MRI) .
AND
ABCD2Score ‚â•63or presence of motor symptom s.
AND
Evidence of relevant intracranial or cervical arterial  atheroscl erotic plaque, ulceration or 
thrombus in a feeding artery  docum ented by [CONTACT_9661] (either Doppl er ultrasound or CTA 
or MRA or catheter angiography) .
Note :Atheroscl erotic plaque does not need to be severe or stenotic, but must be visible .
Parti cipants with complete occlusion of a cervical caroti dor intracranial arterythat is 
proximal t o the index lesio nshoul d be excluded.
AND
Modified Rankin Score (mRS) ÔÇ£3 before the index event (pre-morbid) .
3)Two MRI scans arerequi red for participat ion in this study  (see Section 9.2.12 ). Therefore ,
participants must have a body  habitus suitable for MRI and cannot have any contraindications 
to the performance of the MRI (seeSecti on7.7.2.1 ).
4)No contraindicat ion to clopi[INVESTIGATOR_880422] [ADDRESS_1230565] 90 days .
5)Age and Reproductive Status
a)Women of childbearing potential  (WOCBP) must have a negat ive serum  or urine 
pregnancy test (minimum sensit ivity 25 IU/L or equivalent units of HCG) within 24 hours 
prior to the start of study  treatm ent.
b)Women of childbearing potenti al (WOCBP) must agree to follow instructi ons for 
method(s) of contraception for the durati on of treatment with BMS -986177 plus 5 half-
lives of study treatment plus 30 days (durati on of ovulatory  cycle) for a total of 34days 
post-treatm ent com pletion.
c)Males who are sexually active with WOCBP must agree to follow instructi ons for 
method(s) of contraception (Appendix 4) for the duration of tre atment with study treatment  
BMS -986177, plus 5 half-lives of the study  treatment , plus 90 days (durat ion of sperm 
turnover) for a total of [ADDRESS_1230566] be willing to refrain fro m sperm  donat ion during this time. 
d)Azoospermic males are exempt from contraceptive requi rements. WOCBP who are 
continuously not heterosexually act ive,or are not of childbearing potent ial, are also exempt 
from contraceptive requirements, and still must undergo pregnancy  testing as described in 
this secti on.
Revised Protocol No.: 06
Date: 09-Oct-2020 62
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
e)Invest igators shall counsel  WOCBP, and male participants who are sexually active with 
WOCBP, on the importance of pregnancy prevent ion and the imp lications of an unexpected 
pregnancy. Invest igators shall advise on the use of highly  effective methods of
contraception, ( see Appendix 4 ). Highly effective methods of contraception have a failure 
rate of <1% when used consistent ly and correctly .
6)Enrollment of subjects who have received  thrombolyt ic therapy or mechanical thrombectomy
(without stenting) for the treatm ent of the index event is permi tted if all of the following 
condi tions are m et:
ÔÇ∑At least [ADDRESS_1230567] elapsed betw een end of IV thro mbolyt ic use/ thrombectomy and 
first dose of study  medicat ion.
ÔÇ∑Neuroimaging (either clinical imaging or study  MRI) after IV thrombo lytic therapy/ 
post-thrombectomy  excludes any  hemorrhagic transform ation.
ÔÇ∑NIHSS ‚â§ 7 at time of rando mizat ion.
ÔÇ∑Post-thrombo lytic therapy /post-thrombectomy  INR ‚â§ 1.5, aPTT ‚â§1.4 prior to study 
treatm ent administration.
ÔÇ∑No con traindicat ions have been ident ified that in the opi[INVESTIGATOR_3078] n of the invest igator would 
precl ude start of study medicat ion (e.g. large infarct volume, procedure -related 
bleeding).
ÔÇ∑All other study  criteria are m et.
In addi tion, we recommend following local practi ce and considering fibrinogen > 150 mg/dL 
before init iation of study  treatm ent.
6.2 Exclusion Criteria
1)Medical Condit ions
a)Predi cted inabilit y to swall ow study  medicat ion.
b)Women who are pregnant or breastfeeding .
c)Any condit ion that, in the opi[INVESTIGATOR_3078] n of the investigator, contraindicates ant icoagulant therapy 
or would have an unacceptable risk of bleeding such as a large infarct volume (per 
investi gator di scret ion) or uncontrolled hypertension .
d)Hem orrhage, tum or, arteri tis, large vessel dissect ion, arteri ovenous malformat ion (AVM) 
or other pathology that could account for index symptoms must be excluded by [CONTACT_880550] l ocally.
e)Symptom atic caroti d steno sisor intracranial artery stenosis for which endarterectomy or 
angioplasty is planned wi thin 90 days .
f)Not applicable per global protocol amendment 06.
g)Any condi tion forwhich chronic anticoagulati on is indicated and expected to be initiated 
(eg,NVAF, DVT, PE) .
h)Requi rement for continued use of d ual anti-platel et therapy  (DAPT) for more than 21 days 
or non
-aspi[INVESTIGATOR_880423] 
(eg,prophylaxis for venous thromboembo lism).
Note : Treatment wi th clopi[INVESTIGATOR_278458], aspi [INVESTIGATOR_248], dipy ridamole or another P2Y12 inhibi tor pri or 
to enrollment is allowed. Treatment with aspi[INVESTIGATOR_9601] a different dose before 
enrollment is also allowed. All participants must transit ion to the protocol -defined 
Revised Protocol No.: 06
Date: 09-Oct-2020 63
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230568] receive the clopi[INVESTIGATOR_880484]-clopi[INVESTIGATOR_7745]  P2Y12 inhibitor or dipyridam ole/dipy ridamole-
containing treatment.
i)History  of hemorrhage into the brain, subarachnoid hemorrhage, subdural hematom a or 
spi[INVESTIGATOR_880485] (CMB) and minor hemorrhagic 
transformation o f prior infarct manifest ing as scattered petechiae ( Hem orrhagic Infarcti on 
Type 1 [ HI1]according to Heidelberg classificat ion).54
Note : CMBs are defined as rounded foci of <[ADDRESS_1230569] from vascular flow voids, leptomeningeal hemosiderosi s, or non-
hemorrhagic subcortical mineralizat ion on T2* weighted MRI.55
j)History  of clinically meaningful hepat ic disease and/ or clinically significant abnormal liver 
funct ion.
k)Intracranial tumor (except meningio ma,which is permitted) or aneurysm >5mm(except 
treated aneurysm wit hout history  of intracranial bleed, which is permitted) or AVM .
l)History  of end-stage renal disease (ESRD) with eGFR <15mL/min /1.73 m2, or requi ring 
dialysis .
2)Prior/Concomi tant Therapy
a)Any invest igational drug or placebo exposure within 4 weeks of study drug administration.
b)Any pri or exposure to BMS -986177.
c)Planned use of anticoagul ants including warfarin or other vitamin K antagonis ts, oral 
thrombin and Factor Xa inhibitors, bivalirudin, hirudin, argatroban, unfract ionated and 
low-molecul ar-weight heparins, with the excepti on of heparin or low-molecular -weight 
heparin (LMWH) used to maintain patency  o f indwelling catheters .
Note : Parti cipants who received UFH or LMWH for DVT prophylaxis prior to enrollment  
can be randomized . The use of anticoagulants for post-stroke DVT prophylaxis after 
rando mizat ion is prohibited. For post-stroke DVT prophylaxis, non-pharmaco logical 
prophylaxis (ie, intermittent pneumat ic co mpression) is reco mmended.
d)Planned conco mitant use of omeprazo le or esomeprazo le after randomization for the 
durati on of  clopi[INVESTIGATOR_880430](eg, H2 bl ockers [except cimet idine]and other PPIs are 
allowed).
e)Anticipated concomitant chronic (>14 days) use of systemic nonsteroidal anti-
inflammatory  drugs (NSAIDs). NSAID (including COX -2inhibitors) use prior to 
rando mizat ion isallowed.
f)Use of combined P-gp and strong CYP3A4 inhibitors or combined P-gp and strong 
CYP3A4 inducers in the [ADDRESS_1230570] of
Revised Protocol No.: 06
Date: 09-Oct-2020 64
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230571] of
combined P-gp and strong CYP3A4 inducers is attached as Appendix 12. 
g)Inabilit y to com ply wi th restri ctions and prohibited treatments as listed in Sect ion 7.7.1 .
3)Physical and Laboratory  Test Findings
a)Any o f the fo llowing laboratory results outside of the ranges specified below prior to study
treatment administration, confirmed by [CONTACT_7850]:
-Hemoglobin <9g/dL
-Platelet count <100,000 mm3
-aPTT >1.4x upper limit of normal ( ULN )
-INR ÔÄæ1.[ADDRESS_1230572] or ALT >3x ULN
b)History  of or any of the following findings on 12-lead ECG pri or to study drug 
administration.
-Atrial fibrillat ion or atrial flutter
-Complete heart block or Mobitz second -degree heart block
c)Known positive blood screen for hepat itis C a ntibody , hepati tis B surface antigen, or HIV-1 
and HIV-2 ant ibody .
Note : Participants with a treated and completely resolved hepat itis C infect ion without any
sequelae are permitted .
4)Allergies and Adverse Drug Reaction s
a)History  of allergy  to BMS
-986177 , clopi[INVESTIGATOR_7745] , aspi [INVESTIGATOR_248], or aspi[INVESTIGATOR_248] -containing compounds.
b)History  of any significant drug allergy (such as anaphylaxis ).
c)History  of drug -induced hematologic o r hepat ic abnormalit ies.
5)Other Exclusio n Cri teria
a)Prisoners or participants who are invo luntarily incarcerated. 
Note : Under certain specific circumstances a person who has been imprisoned may be included 
or permitted to conti nue as a participant. Strict condi tions apply and Bristol -Myers 
Squibb approval is required.
b)Parti cipants who are compulsorily detained for treatment of either a psychiatric or physica l 
(eg, infect ious disease) illness .
c)Parti cipants in who m MRI procedures cannot be performed. Section [IP_ADDRESS] provides a list  
of some commo n condi tions that may preclude the participants from having MRI. 
However, this shoul d not be used as a subst itute for local clinical standards of care. The 
ultimate decisio n to perform MRI in an individual participant rests with the site radio logist, 
the invest igator and the standard set by [CONTACT_880570].
6)Known SARS -CoV -[ADDRESS_1230573] ion within 4 weeks prior to screening.
Note :To be considered for enrollment, symptoms must have completely resolved and based 
on invest igator assessment in consul tation with th e Medical Moni tor/Clinical  Trial 
Physician, there are no sequelae that would place the participant at a higher risk of 
receiving invest igational treatment.
Revised Protocol No.: 06
Date: 09-Oct-2020 65
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230574] fully  meet all  eligibili ty criteria.
6.3 Lifestyle Re strictions
Not applicable.
6.4 Screen Failures
Screen failures are defined as parti cipants who consent to parti cipate in the clinical study  but are 
not subsequently rando mized in the study. A minimal set of screen failure information is required 
to ensure transparent reporting of screen failure participants, to meet the Consolidated Standards 
of Reporting Trials (CONSORT) publishing requi rements, and to respond to queries from 
regul atory  authori ties. Minimal informat ion includes date of consent, dem ography , screen failure 
details, eligibilit y criteria, and any  serious AEs.
6.5 Retesting During Screening or Lead -In Period
This study  does not permi t the re-enrollment of a parti cipant who has discont inued the study  as a 
pre-treatm ent failure.
Retesting of laboratory  parameters and/or other assessment s during the screening period will not 
be permitted except for parameters that require a confirmatory  resul t.
The most recent result prior to randomizat ion is the value by [CONTACT_53962] n will be 
assessed, as it repres ents the participant‚Äôs most recent clinical state.
7 TREATMENT
Study  treatm ent (aka study drug) is defined as any investigational treatment(s), marketed 
product(s), placebo or medical device intended to be administered to a study participant according 
to the study  randomizat ion or treatment allocat ion.
Study  treatment includes both Invest igational [Medicinal] Product (IP/IMP) and 
Non-invest igational [Medicinal] Product (Non -IP/Non -IMP) and can consist of the fo llowing:
An invest igationalproduct, also known as invest igational medicinal product in some regions, is 
defined a pharmaceut ical form of an active substance or placebo being tested or used as a reference 
in a clinical study , including products already with a market ing authorization but used or 
assembled (formulated or packaged) different ly than the authori zed form, or used for an 
unauthori zed indicat ion, or when used to gain further informat ion about the authorized form. The 
investigat ional product should be stored in a secure area according to local regulat ions. The
investi gator is responsible for ensur ingthat investigat ional product is only dispensed tostudy 
participants . The invest igational product must be dispensed only from official study  sites by
[CONTACT_880571] g to l ocal regulat ions.
7.[ADDRESS_1230575] of care for a given diagnosi s, may be considered as non-
investigat ional products.
Revised Protocol No.: 06
Date: 09-Oct-2020 66
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
In this protocol ,all Sponsor -supplied treatm ents (Table 7.1-1)are considered invest igational 
product. The Sponsor will be providing uncoated 100-mg aspi[INVESTIGATOR_880486] 75-mg 
tablets.
Table 7.1-
1: Study Treatments for CV010 [ADDRESS_1230576] Description/
Class and Dosage FormPotency IP/Non -I
PBlinded or 
Open LabelPackaging /
AppearanceStorage 
Conditions
(per label)
BMS -986177 Capsule 25 mg
IP Blinded BlisterRefer to the 
label on 
container BMS -986177 Capsule 100 mg
Placebo For 
BMS -986177 CapsuleNA IP Blinded BlisterRefer to the 
label on 
container
Clopi[INVESTIGATOR_880446] 75 mg IP Open -LabelBottle : North America 
& South America 
Blister :Rest of WorldRefer to the 
label on 
container
Uncoated Aspi[INVESTIGATOR_880447] 100 mg IP Open -Label BlisterRefer to the 
label on 
container
7.2 Method of Treatment Assignment
This study will be using an Interactive Response Technol ogy (IRT) to centrally enroll  and 
rando mize all participants . Before the study  is initiated, each user will  receive log in informat ion 
and directions on how to access the IRT.
During the screening visit, the invest igative site will obtain the partici pant‚Äôs unique 5-di git 
participant number from the IRT system . Enrolled participants, inc luding those not dosed, will be 
assigned sequential  participant numbers starti ng with [ZIP_CODE], (eg,[ZIP_CODE], [ZIP_CODE], [ZIP_CODE]... [ZIP_CODE]). 
The participant ident ificat ion number (PID) will ultimately  be comprised of the site number and 
participant number. For example, the first participant screened (ie , enro lled) at Site Number 1, will 
have a PID of  [ADDRESS_1230577] igative site will obtain the participant‚Äôs unique 5-di git 
participant number fro m the IRT system.
Study  treatment will be dispensed at the study visits as listed in the Schedule of Activit ies (see 
Secti on 2).
This study  initially started wit
h placebo and 6 dose-schedule combinat ion (3 doses x once daily 
[QD] and twi ce daily  [BID] schedules), wi th 25% of  the parti cipants randomized to placebo. The 
rando mizat ion of participants t o the [ADDRESS_1230578] been rando mized. The DMC will review efficacy and 
safet y data and assess whether i t is safe to randomize parti cipants to the 200-mg BID dose group .
The target randomizat ion ratio by [CONTACT_880553], assuming addition of 200 m gBID, will be 
2:1:1:1:1:1 (placebo: 25 mg QD: 25 mg BID: 
50 mg BID: 100 mg BID: 200 mg BID). All 
participants will receive open -label aspi[INVESTIGATOR_248] 100 mg+open -label clopi[INVESTIGATOR_7745]  300- mg single 
Revised Protocol No.: 06
Date: 09-Oct-2020 67
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
loading dose followed by [CONTACT_8311][INVESTIGATOR_7745]  75 m g once daily (QD) and aspi[INVESTIGATOR_248] 100 mg for 21 day s then
continue to receive open -label aspi[INVESTIGATOR_248] 100 m g for the duration of the study .
At all study  visits when study  drug is dispensed, each participant will be assigned a container
number by [CONTACT_6606]. Container numbers will be assigned non-sequent ially and will correspond to 
the numbers printed on the packages and bottles containing study  drug, and will be recorded on 
the appropriate electronic Case Report Form ( eCRF ). The IRT will be available [ADDRESS_1230579] the participant wit h their 
daily  dosing.
Following signing of informed consent, participants will be rando mized to receive BMS -986177 
or placebo, plus open -label uncoated aspi[INVESTIGATOR_248] 100 mg in combinat ion with clopi[INVESTIGATOR_7745]  (a loading 
dose followed by [CONTACT_65119]) for the next 21 days. Participants will continue treatment 
fromDay 22 through Day 90 with BMS-986177 or placebo, plus open -label 100 mg uncoated 
aspi[INVESTIGATOR_880434]. 
Aspi[INVESTIGATOR_880487] -label as a background therapy  according to the 
following scena rios:
1)Prior to si gning informed consent:
ÔÇ∑Parti cipants who have received a single open -label  clopi[INVESTIGATOR_880488] 
300mg a nd [ADDRESS_1230580] -of-care prior to obtaining informed consent can be enrolled 
in the study . No addit ional loading dose of clopi[INVESTIGATOR_880489]. 
ÔÇ∑Following a standard -of-care clopi[INVESTIGATOR_880438], the standard -of-care clopi[INVESTIGATOR_880439] 75 m g will be taken the next day , and i t can be taken pri or to randomizat ion. 
ÔÇ∑Participants who report taking chronic clopi[INVESTIGATOR_880426] a 300-mg clopi[INVESTIGATOR_880440] i nvest igator can verify that the participant has taken the daily dose 
for at least the preceding 3 days. 
2)Prior to randomizat ion and after signing i nformed consent:
ÔÇ∑Following si gning of informed cons ent, a 300 -mg loading dose of clopi[INVESTIGATOR_123943] 100 mg 
aspi[INVESTIGATOR_880442] (IRT) , if considered 
clinically appropriate. Daily 75 mg clopi[INVESTIGATOR_123943] 100 mg daily aspi[INVESTIGATOR_880443] .
3)After rando mizat ion:
ÔÇ∑A clopi[INVESTIGATOR_880444] [ADDRESS_1230581] not received any clopi[INVESTIGATOR_880490]. 
Revised Protocol No.: 06
Date: 09-Oct-2020 68
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
ÔÇ∑For participants who have received at least [ADDRESS_1230582] dose of double -blind study medicat ion (BMS -986177 or placebo) should be taken as soon 
as possible after the baseline MRI assessment, preferably within [ADDRESS_1230583] dose of study medicati on shoul d still be taken immediately after 
rando mizat ion and within 48 hours from the onset of the index event.
BMS-986177 or placebo will be taken twice daily (BID), once in the morning (between 
6AM -9AM) and again in the evening (between 6PM -9PM).
Open -label aspi[INVESTIGATOR_880491] d be taken QD in the morning (between 6AM - 9AM)  
with thedose of double -blind study  medicat ion.
Following the firs t dose of study  medicati on, the interval between Dose 1 and Dose 2 on Day  1is 
flexible to ensure a consistent AM-PM dosing schedul eafter Day 1
 dosing . The second dose of 
study  medicat ion (if outside the window o f 6AM -9AM or 6PM ‚Äì9PM ) can be administ ered at a 
minimum of [ADDRESS_1230584] dose. Three examples are 
provi ded below:
ÔÇ∑Parti cipant enters the study  and is administered study  medicat ion at 2:30AM . The next dose 
of study medicati on would be administered between 8:30AM and9AM (a 6-to6.5-hour 
window) on the same day. The participant would then receive the next dose between 6 PMand
9PM .
ÔÇ∑Parti cipant enters the study  and is administered study  medicat ion at 4AM. The next dose of 
study  medicat ion woul d be administered between 6PM and7PM(a 14-to15-hour window). 
Since the interval between 4AM and 9 AM is <
[ADDRESS_1230585] wait for the 
evening dose to be taken no more than 15 hours after Dose 1.
ÔÇ∑Parti cipant enters the study  and is administered study  medicat ion at 5PM. The next dose of 
study  medicat ion would be administered between 6AM and 8AM (a 13 -to 15 -hour window) .
Since the interval  between 5PM and 9PM is <[ADDRESS_1230586] ethical dosing of 
BMS -986177 to ensure the integrity of the study  while provi ding appropri ate exposure coverage 
during a high -risk peri od for a strok e.
Blinded study  medicat ion (BMS -986177 or placebo) will be provided by [CONTACT_1034] .Open -label 
aspi[INVESTIGATOR_880492] . Participants will take onetablet each day  in the AM wit h 
their morning dose of blinded study  medicat ion.Open -label clopi[INVESTIGATOR_880493] . Parti cipants will take onetablet each day in the AM wi th their morning dose of blinded 
study  medicat ionon Days 1 through Day  21.
Revised Protocol No.: 06
Date: 09-Oct-2020 69
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Study  medicat ion (doubl e-blinded medication and aspi[INVESTIGATOR_248] +clopi[INVESTIGATOR_7745] ) will  be provi ded as a [ADDRESS_1230587] 90¬± [ADDRESS_1230588] Day  96 (see Secti on 9.2.12 ).
Study  medicat ion shoul d be taken at approximately the same time each dayonce a consistent 
AM/-PM dosing schedule is achieved .If a  participant misses a dose of study medicat ion, the 
missed dose should be taken as soon as possible and no later than [ADDRESS_1230589] is critical to the participant's management, the blind for that participant 
may be broken by [CONTACT_093]. The participant‚Äôs safet y takes priority over any other 
considerations in determining if a treatment assignment should be unblinded.
Before breaking the blind of an individual participant's treatm ent, the invest igator should 
determine that the unblinded informat ion is necessary, i.e., that it will alter the participant's 
immediate m anagement. In many  cases, parti cularly  when the emergency  is clearly not rel ated to 
the investigational product, the problem may be properly managed by [CONTACT_53964]. It is highly desirable that the decision to unblind treatment assignment 
be discussed wi th the Medical Moni tor, but the investigator al ways has ul timate authori ty for the 
decisio n to unblind. The principal invest igator shoul d only call in for emergency  unblinding 
AFTER the decisionto discont inue the participant 's study  medicat ionhas been made.
For this study , the method of unblinding for emergency purposes is through the IRT system. I
n 
case of an emergency , the invest igator has unrestricted access to randomizat ion inform ation via 
IRT and can break the blind through the IRT system  without prior approval from the Spon sor. 
After the unblinding, the invest igator shall notify the Medi cal Monitoror Clinical Scientist . The 
method of unblinding for emergency purposes is described in the IRT Manual. Parti cipant and 
unblinded treatment informat ion and the reason for the blind being broken must be recorded on 
the appropriate study  status pa ge of the eCRF.
In cases of accidental  unblinding, contact [CONTACT_53966]. Any request to unblind a participant for non -emergency purposes shoul d be 
discussed wi th the Medical Monitor.
Revised Protocol No.: 06
Date: 09-Oct-2020 70
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230590] 
of this study , will perform an administrative interim analysis (see Secti on 10.3.7 ), in order to 
facilitate subsequent program development.
Designated staff of Bristol-Myers Squibb Research & Devel opment , not involved in the study , 
may be unblinded (obtain the randomizat ioncodes) prior to database lock to facilitate the 
bioanalyt ical analysi s of pharmacokinet ic samples . A bioanalyt ical scient ist in the Bioanaly tical 
Sciences depart ment of Bristol -Myers Squibb Research & Devel opment (or a designee in the 
external central  bioanaly tical laboratory ) will be unblinded to (may obtain) the randomized 
treatm ent assignments in order to minimize unnecessary bioanalyt ical analysis o f samples , as well 
as provi de assist ance for analyses needed for DMC in scope of the DMC charter.
The Da ta Monitoring Committee (DMC; see Sect ion 5.1.1) will assess safet y on an ongoing basis, 
and will have access to unblinded treatm ent codes for individu al participants . An analysis team , 
including a reporting statistician and programming support, who are not invo lved with the conduct  
of the study , will  provide analyses to the DMC.
Except as noted above, other members of Sponsor Research and Devel opment personnel, as well 
as all vendors responsible for the conduct of the trial (protocol team) will remain blinded.
7.5 Preparation/Handling/Storage/Accountability
The invest igationalproduct should be stored in a secure area according to local regulat ions. The 
i
nvesti gator is responsible for ensuring that investigat ional product is only dispensed to study 
participants. The invest igational product must be dispensed only from official study  sites by 
[CONTACT_880572] l
.
The product storage manager shoul d ensure tha t the study  treatm ent is stored in accordance with 
the environmental  condi tions (tem perature, light, and humidit y) as determined by [CONTACT_20444] . Ref er to 
Table 7.1-1for storage requirements for study medicat ion.If concerns regarding the qualit y or 
appearance of the study  treatment arise, the study  treatment shoul d not be dispensed and contact 
[CONTACT_20445].
Invest igationalproduct documentation (whether supplied by [CONTACT_880573]) that includes all 
processes requi red to ensure drug is accurately administered must be maintained . This includes 
docum entati on of  drug storage, administration and, storage temperatures .
7.6 Treatment Compliance
Study  treatm entcompliance will be periodically  monitored by [CONTACT_53973] y. Drug 
accountabilit y shoul d be reviewed by [CONTACT_880574]. Sites shoul d discuss discrepancies with the participant ateach on-treatm ent study 
visit.
Each time study  medicati on (BMS -986177, placebo , clopi[INVESTIGATOR_7745] , oraspi[INVESTIGATOR_248] ) is dispensed, 
compliance will be reinforced. When study  medicati on is returned, compliance will be assessed 
based upon the participant ‚Äôs interview and a count of the tablets or capsules returned. Compliance 
shoul d be between ‚â•80 and ‚â§120%.
Revised Protocol No.: 06
Date: 09-Oct-2020 71
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230591] igator (or designee) will record the amounts of study medicat ion dispensed and returned 
at each visit, as well as document reasons for non -compliance in the source document.
The dates ofall study  medicat ion dosing, including interruptions, missed doses or overdose, must
be recorded on the eCRF. Non-compliant participants shoul d be re-educated regarding treatm ent 
compliance.
Inform ation on overdose is provided in Sect ion 9.2.8 .
7.7 Concomitant Therapy
7.7.1 Prohibited and/or Restricted Treatments
The treatments outlined in the exclusio n criteria are prohibited as described below: 
ÔÇ∑Anticoagulants including warfarin or other vitamin K antagonists, oral thrombin and Factor 
Xa inhibitors, bivalirudin, hirudin, argatroban, unfractionated and low-mole cular-weight 
heparins, with the exception of heparin or low-molecular -weight heparin (LMWH) used to 
maintain patency  of indwelling catheters. 
ÔÇ∑Omeprazo le or esomeprazo le after randomizat ion for the duration of clopi[INVESTIGATOR_87237] (eg , 
H2 blockers [except ci metidine]and other PPIs are allowed).
ÔÇ∑Chronic (>14 days) use of systemic nonsteroidal anti-inflammatory  drugs (NSAIDs).
Combined P-gp and strong CYP3A4 inhibitors or combined P-gp and strong CYP3A4 
inducers. A list of  combined P- gp and strong CYP3A4 inhib itors is attached as Appendix 11. 
A list of combined P -gp and strong CYP3A4 inducers is attached as Appendix [ADDRESS_1230592] be recorded on the CRF.
Nonew concomitant medicat ions (prescript ion, over -the-counter or herbal) are to be administered 
during study  unless they are prescribed for treatment of specific clinical events. Any concomitant 
therapi [INVESTIGATOR_576865].
7.7.2 Other Restrictions and Precautions
Participants arenotpermitted toconsume anyfood or beverages containing grapefruit juice forthe 
durati on of  the study.
[IP_ADDRESS] Imaging Restriction and Precautions
Study  parti cipat ion does notrequire x-ray imaging (e g,computed tomography). Study MRIs may 
be performed with or without contrast administration as per invest igator discret ion and local 
clinical practice.
Imaging contraindicat ionsshoul d be considered in this assessment. Participants with tattoos, 
metallic i mplants, pacemakers, etc. ,may be excluded fro m MRI .
MRI contraindicat ionsinclude, but are not limited to:
1)
Historyof claustrophobi a
2) P hysical limitat ion related to fitting in the bore of the magnet (i.e., weight greater than that 
allowable by [CONTACT_880575])
Revised Protocol No.: 06
Date: 09-Oct-2020 72
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
3)MRI -incompat ible implantable cardiac device , epi[INVESTIGATOR_122343], MRI -incompatible 
cardi ac valve prostheses, and MRI -incompatible vascular clips less than two months old, or 
MRI -incompatible aneurysm clips of any  age
4)MRI -incompat ible cochlear implants
5)Spi[INVESTIGATOR_880494]
6)Infusio n pum pthat cannot be discont inued temporarily for the scan
7) Tattoos or perm anent m akeup near the ey e
8) M etallic fragments in the eyes/orbits or in the vicinit y of the brain or majo r neuro vascular 
structures of the bod y
9) E mplo yment history , which involves exposure to welding; unless absence of metallic 
fragments is documented by X -ray examinat ion as per institutional practice.
10)Shrapnel at any place in the body
The ultimate decision to pe rform MRI in an individual participant in this study  rests with the site 
radiologist, the i nvest igator and the standard set by [CONTACT_61857].
7.8 Treatment After the End -of-Study
At the end ofthe study , the Sponsor will not continue to provide study treatm ent to 
participants/i nvestigators unless the Sponsor chooses to extend the study . The i nvest igator should 
ensure that the participant r eceives appropriate treatment forthe condi tion under study .
[ADDRESS_1230593] igator considers a 
temporary  interrupti on or permanent discont inuation of study drug necessary. For treatm ent 
interrupti ons ‚â•[ADDRESS_1230594] the event . An adverse event ( AE)should 
be reported , if applicable.
Guidance on dose interrupti ons or permanent discontinuat ions for selected events are described 
below. For an individual participant , dose interrupti ons may be more or less conservat ive than 
indicated below based on the clinica l judgment of the i nvest igator.
All part icipants who discont inue study treatm ent should comply wit h protocol specified fo llow-up 
procedures as outlined in Sect ion 2. The only  excepti on to this requi rement is when a parti cipant 
withdraws consent for all study  procedures including post -treatm ent study  follow
-up or l oses the 
abilit y to consent freely  (ie, is imprisoned or invo luntarily incarcerated for the treatment of either 
a psy chiatri c or phy sical illness).
If study  treatm ent is di scontinued prior to the participant‚Äôs co mpletion of the study , the reason for 
the discont inuat ion must be docum ented in the participant‚Äôs medical records and entered on the 
appropriate case report form (CRF) page.
Revised Protocol No.: 06
Date: 09-Oct-2020 73
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230595] be discont inued immediately in participants with a majo r bleeding event 
(BARC Types 3 and 5).  Please refer to the Study Events Asses sment Manual  for definit ions/details 
related to BARC bleeding criteria.
Parti cipants with other than major bleeding or suspected bleeding shoul d be assessed for an 
underlying cause wit h appropriate laboratory testing (e.g., hematology, ultrasound, CT, MRI) . The 
date and time of onset of the bleeding event should be recorded on the CRF. Refer to Section 9.2.1
for measures to consider for management of a bleeding event.
8.2 Elevated Liver Function Tests
All participants will discont inue treatment with blinded study treatment immediately if criteria for 
drug-induced liver injury (DILI) are met (see Section 9.2.11 for details).
In addition, s top treatm ent wi th blinded study  treatment if:
ÔÇ∑ALT and/or AST >5x ULN for ‚â•7 consecutive days ,confirmed by [CONTACT_7850] .
ÔÇ∑ALT and/or AST ‚â•10x ULN , confirmed by [CONTACT_7850] .
Interrupt treatment with blinded study  treatm ent if:
ÔÇ∑ALT and/or AST >3x ULN ,confirmed by [CONTACT_7850].
Parti cipants wi th abnorm al liver funct ion tests shoul d be followed until  ALT/AST returns to <2x 
ULN or to baseline prior to considering re -start of treatment with blinded study  treatm ent, but not 
later than [ADDRESS_1230596] igator determines that hemostasis is secure andresuming treatm ent is safe, but no 
earlier tha n 24 hours after the procedure/surgery .
The interruption of aspi[INVESTIGATOR_880495].
8.[ADDRESS_1230597] of BMS-986177 dissipates in 48 - 72 hours.
Refer to Section 9.2.1 for measures to consider for management of a bleeding event .
For participant with a new stroke during the study  period, the use of thrombo lytic therapy , 
mechanical thrombectomy (without stenting) ,or other standard -of-care therapy ,is to be 
implemented at the discretion of the i nvest igator , to include possibilit y of unblinding (see Secti on 
Revised Protocol No.: 06
Date: 09-Oct-2020 74
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
7.4). If thrombo lytic therapy and/or mechanical thrombectomy is used, study  treatment with BMS -
[ADDRESS_1230598] be interrupted and restart of BMS-986177 is only permi tted if all of thefollowing 
condi tionsare m et: 
ÔÇ∑At least [ADDRESS_1230599] elapsed between end of IV thro mbolyt ic use/thrombectomy and first 
dose of study  medicat ion.
ÔÇ∑Clinical imaging has been performed to exclude any hemorrhagic transform ation of the 
new infarct.
ÔÇ∑Post-thrombo lytic therapy /post -thrombectomy  INR ‚â§ 1.5, aPTT ‚â§ 1.4 at the time of 
BMS -986177 restart.
ÔÇ∑No contraindications have been ident ified that in the opi[INVESTIGATOR_3078] n of the invest igator would 
precl ude start of study  medicat ion (eg, large infarct volume, procedure -related bl eeding).
ÔÇ∑All other study  criteria are m et.
In addition, we recommend following local practice and considering fibrinogen > 150 mg/dL 
before init iation of study  treatm ent.
8.[ADDRESS_1230600] di scont inue BMS -
986177 for any  of the f ollowing reasons:
ÔÇ∑Parti cipant‚Äôs request to stop study treatm ent. Participants who request to discontinue study 
treatm ent will remain in the study  and shoul d be encouraged to be followed for protocol -
specified follow-up procedures. The only except ion to thi s is when a participant specifically 
withdraws consent for any further contact [CONTACT_35859]/her or persons previously authori zed by 
[CONTACT_880576].
ÔÇ∑Any clinical  AE, laboratory  abnorm ality or intercurrent illnes s which, in the opi[INVESTIGATOR_3078] n of the 
investi gator, indicates that continued participat ion in the study  is not in the best interest of the 
participant .
ÔÇ∑Terminat ion of the study  or program  by [CONTACT_414] -Myers Squ ibb (BMS) .
ÔÇ∑Loss of ability to freely  provide consent through imprisonment or involuntarily incarceration 
for treatm ent of ei ther a psychiatric or physical (e.g. , infect ious di sease) illness. 
Note : Under specific circumstances, a participant who has been i mprisoned may be permitted
to con tinue as a parti cipant. Strict condi tions apply and Sponsor approval is required.
ÔÇ∑Severe non-compliance to protocol, as judged by  [CONTACT_941] i nvest igator and/or Sponsor .
ÔÇ∑Incorrect enrollment (i.e., the participant does not meet the required inclusion/exclusio n 
criteria) for the study , as determined after consultation with the Sponsor .
ÔÇ∑Pregnancy: the i nvest igator must immediately, within 24 hours of awareness of the pregnancy , 
notify the BMS M edical Monitor/designee of this event. See Section 9.2.7 .
Discontinuati on of  open -label clopi[INVESTIGATOR_880441]/or aspi [INVESTIGATOR_880496] i nvest igator.
In the case of pregnancy, the invest igator must immediately notify the BMS Medical 
Moni tor/desi gnee of this event. In the event a female participant becomes pregnant during a 
clinical trial, the study treatment must be discont inued immediately. Pleas e call the BMS Medical 
Moni tor wi thin 24 hours of  awar eness of the pregnancy. If the investigator determines a possible 
Revised Protocol No.: 06
Date: 09-Oct-2020 75
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
favorable benefit/risk ratio that warrants continuation of study treatment, a discussio n between the 
investigator and the BMS Medical Mo nitor/desi gnee m ust occur.
All participants who discont inue study  treatm ent shoul d comply with protocol -specified follow-
upprocedures as outlined in Section 2. The only excepti on to this requirement is when a participant  
withdraws consent for all study  procedures including post -treatm ent study  follow
-up or l oses the
abilit y to consent freely  (ie, is imprisoned or invo luntarily incarcerated for the treatment of either 
a psy chiatri c or phy sical illness).
If study  treatm ent is di scontinued prior to the participant‚Äôs co mpletion of the study , the reason for 
the discont inuat ion must be docum ented in the participant‚Äôs medical records and entered on the 
appropriate case report form (CRF) page.
8.[ADDRESS_1230601] be conducted:
ÔÇ∑End-of-treatm ent assessments, except MRI, at the time of study  drug discont inuat ion.
ÔÇ∑MRI at Day  90 ( ¬±6 days) .In the event that parti cipants are unable or not permi tted to attend 
the Day [ADDRESS_1230602] been pre-
approved by [CONTACT_880565]. In the event the Day 90 MRI cannot be performed 
within the ¬± 6-day window, the MRI can be acquired at any  time after Day  [ADDRESS_1230603] Day  96.
ÔÇ∑Aphone call visit Day  97 ¬± 2 (7 day s after Day  90 MRI)
In addit ion, a fo llow-up telephone contact [CONTACT_880577] [ADDRESS_1230604] with him/her or persons 
previously authorized by [CONTACT_880578].
For participants who withdraw consent for fo llow-up, there should be document ation of the reason 
for withdrawal. Study  staff shoul d explici tly seek inform ation about the possible contribut ion of 
AEs to th e participant ‚Äôs desire to withdraw and docum ent any AEs that are ident ified in the AE
section of the CRF.
Withdrawal of consent for treatm ent with study medicat ion shoul d be distinguished from 
withdrawal  of consent for follow-up visits, telephone contacts, or medical records checks. 
Parti cipants requesting withdrawal from follow-up shoul d be informed that withdrawal o f consent 
for follow-up will resul t in loss of important inform ation about the benefits and risks of 
BMS -986177.
Revised Protocol No.: 06
Date: 09-Oct-2020 76
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
ÔÇ∑Parti cipants shoul d notify  the investi gator of the decisio n to withdraw consent from future 
follow-up in writing, whenever possible .
ÔÇ∑The withdrawal  of consent should be explained in detail in the medical records by [CONTACT_298956], as to whether the wi thdrawal is from  further treatm ent wi th study  treatm ent only 
or also from study procedures and/or post-treatment study  follow-up, and entered on the 
appropriate CRF page.
ÔÇ∑In the event that vital status (whether the participant is alive or dead) is being collected , 
publicly  available informat ion shoul d be used to determine vital status only as appropri ately 
directed in accordance with loc al law.
ÔÇ∑If the partici pant withdraws consent for disclos ure of future informat ion, the Sponsor may 
retain and cont inue to use any data collected before such a withdrawal o f consent.
8.[ADDRESS_1230605]-treatm ent fo llow-up is required to ass ess partici pant safety  and to preserve the integrit y of the 
study . Efficacy outcomes will also be collected during the foll ow-up peri od.If study  treatm ent is 
discontinued early, the participant is expected to complete the end -of-treatm ent assessments at the 
time of di scont inuat ion (Table 2-2) except MRI . For these parti cipants, a Day [ADDRESS_1230606] been pre-approved by [CONTACT_880565]. In the event the Day 90 MRI cannot be 
perform ed wi thin the ¬± 6-day window, the Day [ADDRESS_1230607] to follow-up is defined by [CONTACT_53981] y to reach the participant after a minimum of three
docum ented phone calls, faxes, or emails as well as lack of response by [CONTACT_102448]. All attempts should be documented in the participant‚Äôs medical records.
If at the participant has died, the site willuse permissible local methods to obtain date and cause 
of death.
If investi gator‚Äôs use of third -party  representative to assist in the fo llow-up porti on of the study has 
been included in the participan t‚Äôs informed consent, then the invest igator may use a Sponsor 
retained third-party  representative to assist site staff with obtaining participant‚Äôs contact 
[CONTACT_251604]-up porti on of the 
study .
The site staff and representative will consult publicly  available sources, such as public health 
registries and databases, to obtain updated contact [CONTACT_4203].
Revised Protocol No.: 06
Date: 09-Oct-2020 77
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230608] igator should be reported and docum ented in the participant‚Äôs medical 
records.
9 STUDY ASSESSMENTS AND PROCEDURES
Study  procedures and timing are summarized in the Schedule of Activities (see Sect ion 2). Protocol 
waivers or exempt ions are not allowed. All immediate safet y concerns must be discussed with the 
Sponsor immediately upon occurrence or awareness to determine if the participant should continue 
or discontinue tr eatment.
Adherence to the study  design requirements, including those specified in the Schedule of 
Activities, is essent ial and required for study  conduct. All screening evaluat ions must be completed 
and reviewed to confirm that potenti al partici pants meet all eligibilit y criteria before 
rando mizat ion. The investigator will maintain a screening log to record details of all partici pants 
screened and to confirm eligibilit y or record reasons for screening failure, as applicable.
Procedures conducted as part of the parti cipant‚Äôs routine clinical  management ( e.g., blood c ount) 
and obtained before signing of inform ed consent may be utilized for screening or 
pre-treatment  
baseline purposes provi ded the procedure meets the protocol -defined criteria and has been 
perfo rmed wi thin the tim eframe defined in the Schedule of Act ivities.
9.[ADDRESS_1230609] a study  MRI scan at baseline (Day  1) and Day 90,as described in Table 
2-1andTable 2-2.The baseline MRI shoul d be acqui red within 48 hours of the index event and 
prior to randomizat ion on Day  1. If the baseline MRI cannot be performed within 48 hours of the 
index event and before rando mizat ion, it can be acqui red after randomization but mustbe 
perform ed wit hin 72 hours of the index event and up to 24 hours after randomizat ion.If the study -
specific MRI cannot be acqui red atbaseline, a clinical (standard -of-care) MRI scan can be used 
provi ded that the clinical MRI protocol  and scanner have b een pre-approved by [CONTACT_11382].
The first dose of study  medicat ion (BMS -[ADDRESS_1230610] acebo) shoul d be taken as soon as possible 
after the baseline MRI assessment, preferably wit hin [ADDRESS_1230611] dose of 
study  medicat ion shoul d still be taken immediately after randomizat ionwithin 48 hours from the 
onset of the index event.
The baseline MRI and the Day 90 MRI will be submitted to a central imaging vendor for analysis.
Details regarding MRI acquisit ion, including required sequences, slice thickness, and qualifying 
phantom  image( s)are presented in the CV010 -[ADDRESS_1230612] ion(FLAIR +DWI) detected by [CONTACT_880579] 90.
Revised Protocol No.: 06
Date: 09-Oct-2020 78
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Please refer to the Study  Events Assessment Manual for definit ions/details concerning 
stroke/covert brain infarct ion endpo ints.
9.1.2 Secondary Efficacy Assessments
The fo llowing are secondary  efficacy  assessments :
ÔÇ∑Com posite ofnew ischemic non-fatal stroke, non-fatal myocardi al infarc tion, or all-cause
death
ÔÇ∑Locati on, number, and vo lume of new FLAIR +DWI l esions
ÔÇ∑National Insti tutes of  Heal th Stroke Scal e(NIHSS), Modified Rankin Scale (m RS), Montreal 
Cogni tive Assessment (MoCA), and Digit Symbol Subst itution Test (subtest of WAIS -IV) will 
be co llected at baseline (at randomizat ion for NIHSS) , on Days [ADDRESS_1230613] (subset of WAIS -IV) will be read by a third -party central 
laboratory  blinded to treatm ent.
9.2 Safety Assessments
9.2.1 Bleeding
The main safety endpo int assessment is majo r bleeding (based onBARC Types 3 and 5
definit ions). Participants with bleeding or suspected bleeding will be assessed and treated 
according to usual  clinical  practice at each site. Severit y of bleeding will be classified according 
to BARC, ISTH and PLATO ( Refer to the Study  Events Assessment Manual for definitions and 
details for the bl eeding endpoints ).
Approach to a Participant with a Bleeding Event
If a participant has a bleeding event requiring intervent ion dur ing the study, the following measures 
shoul d be considered:
ÔÇ∑Discontinue the study  drug (refer to Secti on 8.1, Discontinuat ion of Study Drug).
ÔÇ∑Usual treatment measures for bleeding events, including local pressure , fluid replacement and 
hemodynamic support, and blood transfusio n,if indicated
ÔÇ∑Other causes besides antithrombotic medication can contribute to the seriousness of the 
bleeding event (e.g., rule out thrombocy topenia, disseminated intravascular coagul ation, and 
other coagulopathies, kidney and liver dysfunct ion, concomitant medicat ions, etc. ) and should 
be assessed and treated accordingly
ÔÇ∑Consult ation with a coagulati on/hematol ogyexpert
ÔÇ∑Possibilit y of unblindin g at the di screti on of  the i nvestigator (see S ection 7.4)
Current ly, there is no specific reversal  agent f or BMS -986177. Before considering the use of any 
pro-hemostatic agent, the benefit and risk for each individual participant shoul d be assessed, and 
consultation with a  hematologist shoul d be considered. Replacement therapy  with Factor XI 
concentrates is not recommended because the participan ts are not Factor XI deficient. 
BMS -[ADDRESS_1230614] on BMS -986177 
pharmaco logy. In vitro studi es in human plasma demonstrated that addit ion of 4-factor activated 
Revised Protocol No.: 06
Date: 09-Oct-2020 79
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
prothrombin concentrate complex (FEIBA ÔÉí, aPCC) or recombinant Factor VIIa (NovoSeven ÔÉí) 
reduced the BMS -986177- induced prolongati on of the aPTT. In FXI-deficient participants , 
recombinant Factor VIIa has been used successfully  to prevent surgi cal bleeding without 
complicat ion. Therefore, if severe bleeding occurs that cannot be controlled by [CONTACT_401145], or emergent surgery /invasive procedure is required, pro-hemostatic agents may be 
considered according to their package insert. 
At therapeutic doses, the anticoagulant effects of BMS-
986177 will not bereflected by 
[CONTACT_880580] (INR) values but may be reflected by [CONTACT_880581]. The 
anticoagulant effect of BMS -[ADDRESS_1230615] label.
9.2.2 Adverse Events
The definit ionsof an AE or seri ous adverse event (SAE) can be found in Appendix 3.
AEs will be reported to the investigator by [CONTACT_2299] (or, when appropri ate, by a caregiver, 
surrogate, or the participant's lega lly authorized representative).
The invest igator and any designees are responsible for detecting, docum enting, and reporting 
events that meet the definit ion of an AE or SAE and remain responsible for following up AEs that 
are serious, considered related to the study treatment or the study, or that caused the participant to 
discontin ue before com pleting the study.
Conta cts for SAE reporting are specified in Appendix 3.
9.2.[ADDRESS_1230616] ion of non-serious AE (NSAE) information shoul d begin at randomizat ionuntil the 
time points specified in the Schedule of Activities (Secti on2). NSAE informat ion shoul d also be 
collected from the start of a  placebo lead-in period or other observat ional period intended to 
establish a baseline status for the participants.
Secti on [ADDRESS_1230617] igator ‚ÄôsBrochure26(IB) represent sthe Reference Safety  Information (RSI) 
to determine expectedness of SAEs for expedi ted reporting. Following the partici pant‚Äôs written 
consent to participate in the study , all SAEs, whether related or not related to study  drug, m ust be 
collected, including those thought to be a ssoci ated wi th protocol -specified procedures.
All SAEs that occur during the screening perio d through the fo llow-up peri odmust be collected.
The investigator must report any SAE that occurs af ter these time periods and that is believed to 
be related to study drug or protocol -specified procedure:
ÔÇ∑Medical occurrences that begin before the start of study treatment but after obtaining informed 
consent will be recorded on the appropriate sectio n of the eCRF section.Labs perform ed 
locally for assessment of SAEs shoul d have reports faxed or scanned and emailed to  
.
Revised Protocol No.: 06
Date: 09-Oct-2020 80
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
ÔÇ∑All SAEswill be recorded and reported to Sponsor or designee within 24 hours, as indicated 
in Appendix 3 .
ÔÇ∑The invest igator will submit any updated SAE data to the sponsor within [ADDRESS_1230618] igator learns of any SAE, including a death, at any time after a participant 
has been discharged fro m the study, and he/she considers the event reasonably related to the study 
treatm ent or study  parti cipat ion, the i nvest igator must prompt ly notify the Sponsor.
The method of evaluat ing, and assessing causali ty of NSAEs and SAEs and the procedures for 
completing and repor ting/transmitt ing SAE reports are provided in Appendix 3.
9.2.[ADDRESS_1230619] ing NSAE and/or SAEs. Inquiry about specific AEs should be guided by [CONTACT_880582], when appropri ate for the program or protocol.
9.2.5 Follow -up of AEs and SAEs
ÔÇ∑Non-serious AEs should be fo llowed to resol ution or stabilizat ion, or reported as SAEs if they 
beco me serious (see Appendix 3).
ÔÇ∑Follow-up is also required for NSAEs that cause interrupti on or discont inuat ion of study 
treatm ent and for those present at the end of study  treatm ent as appropri ate.
ÔÇ∑All ident ified non -serious AEs m ust be recorded and described on the NSAE page of the CRF 
(paper or electronic). Com pletion of supplemental CRFs may be requested for AEs and/or 
laboratory  abnorm alities that are reported/ident ified during the course of the study .
ÔÇ∑Invest igators should collect a Medical Release Form fro m all study participants to allow access 
to SAE information occurring at off -site medical  facili ties.
All SAEs will be followed until resolution, until the condi tion stabilizes, until the event is 
otherwi se explained, or until the participant is lost to fo llow-up (as defined in Sect ion8.8).
Further informat ion on fo llow-up procedures i s given in Appendix 3.
9.2.6 Regulatory Reporting Requirements for SAEs
ÔÇ∑Prom pt notificat ion by [CONTACT_880583] y of participants and the safet y of a 
produc t under clinical investigation.
ÔÇ∑An invest igator who receives an invest igator safety report describing SAEs or other specific 
safet y informat ion (e.g., summary  or listing of  SAEs) f rom the Sponsor will  file it along wi th 
the Invest igator‚Äôs Brochure and will notify  the IRB/IEC, if appropri ate according to local 
requi rements .
Revised Protocol No.: 06
Date: 09-Oct-2020 81
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Sponsor or designee will be reporting AEs to regul atory  authori ties and ethics committees 
according to local applicable laws including European Directive 2001/20/EC and FDA Code of 
Federal Regulat ions 21 CFR Parts 312 and 320. A S[LOCATION_003]R (Suspected, Unexpected Serious 
Adverse React ion) is a su bset of SAEs and will be reported to the appropriate regul atory  authori ties 
and invest igators following local and glo bal guidelines and requirements.
9.2.[ADDRESS_1230620] 5 
half-lives (4 days) after product administration, the invest igator must immediately notify the 
Sponsor Medical Moni tor/desi gnee of this event and complete and forward a Pregnancy 
Surveillance Form  to Sponsor Designee within [ADDRESS_1230621] igator determines a possible favorable benefit/risk rati o that warrants con tinuat ion of 
study  treatment, or re -initiation of study treatment, a discussio n between the invest igator and the 
BMS Medical Moni tor/desi gnee must occur. If, for whatever reason, pregnancy has ended, 
confirmed by [CONTACT_648688], treatment ma y be resumed (at l east 3 weeks and not 
greater than 6 weeks after the pregnancy has ended), following approvals of 
participant/Sponsor /IRB/EC, as applicable.
Follow-up informat ion regarding the course of the pregnancy, including perinatal  and neonatal 
outcome and, where applicable, offspring informat ion must be reported on the Pregnancy 
Surveillance Form.
Any pregnancy that occurs in a female partner of a male study  participant should be reported to 
Sponsor or designee. In order for Sponsor or designee tocollect any pregnancy surveillance 
inform ation from the female partner, the female partner must sign an informed consent form for 
disclosure of this informat ion. Inform ation on this pregnancy will be collected on the Pregnancy 
Surveillance Form.
9.2.[ADDRESS_1230622] igator will be considered an 
overdose and should be reported as a SAE (medically important event).
The sponsor does not recommend specific interventio n for an overdose. There is no known antidote 
for overdose with BMS -[ADDRESS_1230623] been performed to assess methods of reversing 
BMS -986177 absorption effects; however, in theory, act ivated c harcoal  may reduce the absorption 
of BMS -[ADDRESS_1230624] 
label for management of aspi[INVESTIGATOR_880497].
Revised Protocol No.: 06
Date: 09-Oct-2020 82
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230625] the Medi cal 
Moni tor immediately and:
ÔÇ∑Obtain a plasma sample for PK analysis as soon as possible afterthe last dose of study 
treatm ent,if requested ,by [CONTACT_1689] (determined on a case -by-case basis) .
ÔÇ∑Docum ent the quantit y of the excess dose as well as the duration of the overdosing o n the CRF.
Decisio nsregarding dose interruptions or modificat ions will be made by [CONTACT_880584] h the Medical Monitor based on the clinical evaluat ion of the participant.
Planned time points for all safet y assessme nts are listed in the Schedule of Activities (see 
Secti on2).
9.2.[ADDRESS_1230626] resul t abnormalit ies shoul d be captured on the non -serious AE CRF 
page or SAE Report Form  electronic, as appropri ate. Paper f orms are only intended as a back-up 
option when the el ectronic system is not functioning.
ÔÇ∑Any laboratory  test resul t that is clinically si gnificant or m eets the definit ion of an SAE 
ÔÇ∑Any abnorm al laboratory  test resul t that required the participant to have study  treatment 
discontinued or interrupted
ÔÇ∑Any abnorm al laboratory  test resul t that requi red the parti cipant to receive specific correct ive 
therapy
The clinical rather than laboratory  term(e.g., anemia vs.low hemoglobin value) shoul dbe used 
wherever possible by [CONTACT_342015] i nvest igator.
9.2.10 Other Safety Considerations
Any significant worsening noted during interim or final physical examinat ions, ECG, X-ray 
filming, any  other potenti al safety  assessment required or not requi red by  [CONTACT_880585] d also be 
recorded as a NSAE or SAE, as appropriate, and reported accordingly .
9.2.11 Potential Drug Induced Liver Injury (DILI)
Parti cipants meet ing the criteria for DILI must have blinded study  treatm ent discont inued 
immediately .
Wherever possible, timely confi rmation of initial liver-related laboratory  abnormalit ies shoul d 
occur prior to the reporting of a potential DILI event. All occurrences of potential DILIs, meet ing 
the defined criteria, must be reported as SAEs (See Appendix 3 for reporting details).
Potenti al drug -induced liver injury is defined as:
ALT or AST elevat ion >3x ULN
AND
Total  bilirubin >2x ULN, without initial findings of cholestasis (elevated serum alkaline 
phosphatase)
Revised Protocol No.: 06
Date: 09-Oct-2020 83
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
AND
No other immediately apparent possible causes of transaminase elevat ion and 
hyperbilirubinemia , including, but not limi ted to: viral hepat itis, pre-exist ing chronic or acute 
liver di sease, or the administration of other drug(s) known to be hepatotoxic.
9.2.[ADDRESS_1230627] be performed within 72 hours of 
the index event and up to 24 hours after randomizat ion.If the study -specific MRI cannot be 
acqui red at baseline, a clinical (standard -of-care) MRI scan can be used provided that the clinical 
MRI protocol  and scanner have been pre -approved by  [CONTACT_880565].
A second MRI of the brain will be perform ed on Day 90 ¬± 6 days (based on randomization on 
Day 1) to accommodate scheduling and scanner availabilit y. Sites are encouraged to schedule the 
Day [ADDRESS_1230628] been pre -approved by [CONTACT_880565]. In the 
event the Day 90 MRI cannot be perform ed within the ¬± 6-day window, the Day 90MRI can be 
acqui red outside of the + 6-day window after Day [ADDRESS_1230629] of the study  withpreference to perform baseline and Day 90 scans on 
the sam e scanner or of the same manufacturer, or minimally wit h the same magnetstrength as the 
baseline scan.
AnImaging Manual and Quick Reference Guide (QRG) will be provi ded detailing site 
qualificat ion process , requi red MRI sequences, andparticipant scanning.
9.2.13 Physical Examinations
A co mplete physical examinat ion should include general appearance, head, eyes, ears, nose, throat, 
neck, cardi ovascular, lungs, abdo men, lymph nodes, extremit ies, neurological, skin, and 
musculoskeletal .Full physical exams will be conducted at screening and on Day  90.
Revised Protocol No.: 06
Date: 09-Oct-2020 84
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
A brief physical  assessment (including organ system s pertinent to the participant ‚Äôs signs, 
symptoms, or adverse events, e.g., assessment of signs o f thromboembo lism and bleeding) will be 
conducted on the Day  21visit.
Physical measurement of height and weight will also be collected at screening and weight will be 
collected again on Day  90.
The individual performing the physical examinat ions must be licensed by [CONTACT_880586] -specific assessment after randomizat ion.
9.2.14 Vital Signs
Vital signs (bl ood pressure and heart rat e) will be recorded during the s creening visi t and at each 
study  visit during the treatment period. Vital signs scheduled at the same visit as blood samples or 
ECG shoul d be co mpleted before blood is drawn.
9.2.15 Electrocardiograms
A 12-lead ECG will be recorded at screening , on Day 21,and at the end-of-treatm ent visit
(Day 90)
.
9.2.16 Clinical Safety Laboratory Assessments
All screening laboratory tests will be performed locally to assess eligibilit y per inclusio n/exclusio n 
criteria. Laboratory  samples collected as standard -of-care prior to signing informed consent can 
be used to assess eligibilit y if meet ing protocol -specified requi rements. Invest igators must  
docum ent thei r review of each laboratory  safet y report.
The central laboratory  will perf orm the study -specific analyses and w ill provi de ref erence ranges 
for these tests. A centra l laboratory sample will be collected on Day [ADDRESS_1230630] dose of 
blinded study  medicat ion, and atDay 21, Day 60, and Day 90visits.In the event that the Day 1 
lab results are not available, l ocal screening labs will be used for analysis.
Table 9.2.16 -1: Clinical Laboratory Assessments
Hematology:
Hemoglobin
Hematocrit
Red blood cell count (RBC)
Total leukocyte count, including differential
Absolute platelet count
Chemistry:
Aspartate aminotransferase (AST)
Alanine aminotransferase (ALT)
Total bilirubin (TB)
Direct bilirubin (done as reflex if TB is > 2xULN)
Alkaline phosphatase
Bicarbonate
Lactate dehydrogenase (LDH)Total Protein
Albumin
Sodium
Potassium
Chloride
Calcium
Revised Protocol No.: 06
Date: 09-Oct-2020 85
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Table 9.2.16 -1: Clinical Laboratory Assessments
Hematology:
Creatinine
eGFR
Blood Urea Nitrogen (BUN)
Uric acidPhospho rus
Magnesium
WOCBP Only:
Pregnancy test ( at screening and ever y 30 day s).
Follicle stimulating hormone (FSH) (screening only for women only) use as applicable
Note: PT and aPTT are collected as PD markers and will be sent to the central laboratory for analysis (See Section 9.3).
9.3 PK, PD, Biomarkers and PK/PD Assessments
Table [IP_ADDRESS] -1and Table [IP_ADDRESS] -1show collect ion times for PK and PD in participants who are 
being treated .Samples for BMS -986177 PK are considered mandatory and the planned times allow 
a window to accommodate site staff and scheduling.  PK and PD data will be used for exploratory 
exposure -response (E-R) analyses for efficacy, safety , and PD endpoints. These samples will be 
analyzed atcentral laborator ies: PT aPTT and FXI clotting activity assay ,and the resul ts will be 
blinded to i nvest igator, study staff and Sponsor .
9.3.1 PK Assessments
Pharmacokinet ics of BMS -
986177, clopi[INVESTIGATOR_7745] (and metabolites), aspi[INVESTIGATOR_248] (acetylsalicylic acid) 
andits major metabo lite (salicylic acid)will be assessed . A population PKmodel (PPK) will be 
developed to understand the PKof BMS -
986177 (See Secti on10.3.4 ).
[IP_ADDRESS] PKSample Analyses
The plasma samples will be analyzed for BMS -986177 by a val idated liquid chrom atography -mass 
spectrometry /mass spectrometry (LC-MS/MS) assay. The plasma samples for acetylsalicylic acid , 
salicylic acid, clopi[INVESTIGATOR_7745] , and clopi[INVESTIGATOR_880498]-
perform ance liquid chrom atography  mass spectrom etry/mass spectrom etry assays. (HPLC -
MS/MS) .PKsamples collected from  a parti cipant who received pl acebo will  not be analyzed for 
BMS -986177, but may be analyzed for clopi[INVESTIGATOR_7745]  (and metabo lites), aspi[INVESTIGATOR_880499]. 
Detailed instructi ons for the PK bl ood collecti on, labeling, processing, storage, and shippi[INVESTIGATOR_880500] e site in the central  laboratory procedure m anual .
In addition, after the scheduled PKanalyses are completed, residual plasma may be used for 
metabo lite profiling or assessment of other metabolites, if t he need ar ises and to the extent possible. 
If these analyses are conducted, they  will be reported separately from the CSR. Further details of 
sample collect ion and processing will be provi ded to the site in thecentral laboratory  procedure 
manual.
Table [IP_ADDRESS] -1lists the sampling schedule to be followed for the assessment of PKin treated 
participants . Further details of blood collect ion and processing will be provi ded to the site in the 
central  laboratory  procedure manual. In addition to th e times listed in the table below, a sample 
Revised Protocol No.: 06
Date: 09-Oct-2020 86
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
for measurement of BMS-986177 plasma concentrati on, PT, aPTT and FXI clotting activity shoul d 
be co llected as cl ose aspossible to the time of major bleeding or a new stroke.
Table [IP_ADDRESS] -1: Pharmacokinetic Sampling Schedule
Study Day of Sample 
CollectionTime of Sample 
Collection Relative to 
BMS -986177 Dose 
(Hour:Min)aBMS -986177 
Blood Sample 
for PlasmaClopi[INVESTIGATOR_7745],
Acetylsalicylic Acid 
andSalicylic Acid Blood    Sam
ple for Plasma
Day 1-Day 4(Relative to 1st
or 2nd dose)b00:30 -6:00 X
6:00 -12:00 X
12:00 -72:00cX
Day [ADDRESS_1230631] one PK sample prior to discharge.  
dSample for acetylsalicylic acid and salicylic acid PK only .
9.3.2 PDand Biomarker Assessments
Effects of BMS-986177 on PD markers including aPTT, FXI clotting activit y,and PT will be 
assessed . Blood sam ples for these PD markers will be co llected and sent to central labo rator iesfor 
analysis. A dose -response assessment will be performed for aPTT and FXI clotting activit y as PD 
biomarker sfor BMS -986177 accordi ng to th e sample collection schedule detailed inTable 
[IP_ADDRESS] -1.
[IP_ADDRESS] Exploratory Biomarker Assessments
Blood will be drawn at the times indicated in Table [IP_ADDRESS] -1for exploratory biomarker 
assessments. The goal of these assessment is to explore the effect of BMS-[ADDRESS_1230632] s, markers of stroke, 
thrombosis, cardi ovascular disease and related pathophy siological condi tions (such as 
inflammat ion, endothelial funct ion, metabo lic, neurological , and extracell ular matrix turnover ).
The assessmen tsmay include, but are not limited to, those listed below and in Table [IP_ADDRESS] -1and
Table 2-2.
ÔÇ∑Thrombosis, 
hemostasis, and cardi ovascular disease s related exploratory  biomarker ssuch as 
PT, FXI antigen, D-dimer, and F1.2 .
ÔÇ∑Exploratory  serum  and plasma bio markers associated with FXI pathway or pathways impacted 
by [CONTACT_232798], stroke, cardiovascular disease, metabolic and neurol ogical disorder, brain injury , 
Revised Protocol No.: 06
Date: 09-Oct-2020 87
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230633] ion, inflammat ion, and severe acute respi[INVESTIGATOR_19960] 2 
(SARS -CoV -2) infect ion status or related pathophysio logical pathways . Biomarkers may 
include but are not limited to kallikrein, bradykinin, IL-6, NT -proBNP, fibrinogen, chemerin,
soluble von Willebrand factor (vWF )and or related multi-biomarker panels. Exploratory
serum  andplasma samples to develop new or improved assays for pathway markers associated 
with either BMS -986177, FXI , stroke , or cardiovascular diseases.
ÔÇ∑A PK/PDsample shoul d be drawn at the time of stroke or major bleed.
ÔÇ∑Ablood samplefor future genotypi[INVESTIGATOR_620366] , but not be limited to specifically FXI, 
genes related to FXI pathway , stroke, cardiovascular disease, and disposit ion of BMS -986177
and other co-medication(drug absorption, distribut ion, metabolism, and excret ion related 
genes such as CYP3A4/ CYP3A5, 2C9/2C19, P-gp, MDR1 ,BCRP, OATP1B1, CES1 and 
CES2 )as well as Who le Genome Sequencing. These samples will be collected only in 
participants in count riesand siteswhere genet ic testing is allowed and who opt in to geneti c 
testing as captured on an I nform ed Consent Form (ICF) .
ÔÇ∑Further details of sample collection and processing will be provi ded to th e site in thecentral
laboratory procedure manual. Results of exploratory  biomarkers maybe reported separately 
from the CSR.
Table [IP_ADDRESS] -
1: Biomarker Sampling Schedule
Study Day of Sample 
Collection Time of Sample 
Collection 
Relative to BMS -
986177 Dose 
(Hour:Min)aPT,aPTT
andFXI C
lotting
Activityb  FXI Antigen Exploratory
Plasma and
Serum 
BiomarkersF1.2
and
DDimer
Day 1-Day 4(Relative 
to 1stor 2nd dose)c00:00 (pre-dose)dX X X X
00:30 -6:00 X
6:00 -12:00 X
12:00 -72:00eX X X
Day 21 Any time X X X
Day 90 Any time X X X
Outcome Event
(Up to 48 hours after 
stroke event or major 
bleeding event)X X
a It is critical to record ingestio n time of each dose prior to each PD sample and sample collection time. Ensure that 
there is at least a one-hour gap between samples collected, as windows are continuous. 
bPDsamples (PT, aPTT and FXI clotting activity) must be collected at same time as the matched PK time points , 
where applicable, and at the time of a new major bleeding or stroke event.
cAll PD samples on Day [ADDRESS_1230634] one PD sample prior to discharge.  
Revised Protocol No.: 06
Date: 09-Oct-2020 88
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
9.3.3 Additional Research Collection
This protocol will include residual sample storage for additional research (AR). All samples, 
including all residual samp les,may be stored and the research with these samples as described in 
the protocol may co ntinue for [ADDRESS_1230635] end -of-study . The scope of work invo lves using serum, 
plasma, DNA from who le blo od to assess markers of stroke, cardiovascular andassoci ated diseases 
and pathways (such as inflammat ion, endothelial funct ion, metabolic, neuro logical, brain injury , 
and extracellular matrix turnover ). Work may also include studi es on the FXI pathway and 
mechanism of act ion as well as any  pathways impacted by  [CONTACT_20444]-986177, as well  as development 
of newor improved assays for pathway  and markers associ ated with either BMS -986177, FXI, 
stroke, or cardiovascular diseases. The goal is to better understand stroke, cardiovascular and
associ ated di seases/syndrom es and any  effects of the drug, BMS -986177.
Sites in the [LOCATION_002]
Consent to addit ionalresearch is requi red for all study  participants, except where prohibited by 
[CONTACT_1744]/ECs or academic/inst itutional requi rements. Where one or more of these exceptions occurs, 
participat ion in the addit ional research should be encouraged but will not be a condit ion of overall 
study  participati on.
ÔÇ∑If the IRB/ECs and site agree to the mandatory addit ional research retent ion and/or collection, 
then the study participant must agree to the mandatory addit ional research as a requirement for 
inclusio n in the study
ÔÇ∑If optional participation is permitted and approved, then the study  participants may opt in or 
opt out of the additional research retent ion and/or collect ion
For non -US Si tes
Addit ional research is opti onal for all study  parti cipants, except where retention and/or collect ion 
of such samples is prohibited by [CONTACT_880587], ECs, or institutional requirements. 
Parti cipants (or legally authori zed representatives, as applicable) will be requi red to provide 
separate informed consent to participate. Participants must also provide separate informed consent 
to participate in collection of additional blood samples for future genotypi[INVESTIGATOR_007], including, but not 
limited to FXI. Sampl es for genotypi[INVESTIGATOR_880501].
Sample Collect ion and Storage
All s erum , plasma , and blood DNA samples from PK, PD and expl oratory  biomarker collect ions 
(as defined inTable [IP_ADDRESS] -1, Table [IP_ADDRESS] -1andTable 2-2) may be retained for addit ional 
research purposes as described above. Samples kept for future research will be stored at the 
Sponsor biorepository  or an independent, Sponsor -approved storage v endor.
Themanager of  these samples will  ensure they  are properly  used throughout thei r usable life and 
will destroy  the samples at the end of  the scheduled storage peri od, no l onger than 15 years af ter 
the end of the study  or the maximum allowed by [CONTACT_880588].: 06
Date: 09-Oct-2020 89
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230636] parties will be participant to the recipi[INVESTIGATOR_841]‚Äôs agreement to 
establish similar storage procedures
All requests for access to sam ples or data f or addi tional research will  be vetted by  [CONTACT_880589] e research supports appropriate research activit ies.
Samples will be stored in a coded fashion, and no researcher will have access to the key . The key 
is securely  held by  [CONTACT_54005], so there is no direct abilit y for a researcher
to connect a sample to a specific individual.
Further details of sample co llection, processing, submissio n and storage are provided in the Study 
Laboratory  Manual.
9.4 Other Assessments
9.4.1 Assessment of Index Stroke and New Strokes
The National Institutes of Health Stroke Sc ore(NIHSS) will be used to assess the index stroke as 
a qualifying criteria (must be ÔÇ£ÔÄ∑)atrandomizat ion on Day 1. The NIHSS will also be evaluated
onDays
21and 90 ,and at the time of a new stroke (see Appendix 5).
9.4.2 Assessment of Risk for Subsequ ent Stroke Associated with Index TIA
The ABCD2Score3or presence of motor sym ptoms will be used as one of  the qualifying cri teria 
for TIA (m ust be ÔÇ≥6)(see Appendix 6).
9.4.[ADDRESS_1230637] had a prior stroke, the Modified Rankin Scale (mRS) will be used to 
assess theclinical severit y of the prior stroke or TIA at 
screening as a qualifying criteria (must be 
ÔÇ£3) to be randomized .mRS will also be assessed onDays 21 and 90, and at the time of a new 
stroke (see Appendix 7).
9.4.[ADDRESS_1230638]-party  laboratory blinded to study 
treatment:
ÔÇ∑The Mo ntreal Cognit ive Assessment (Mo CA) (see Appendix 8)
ÔÇ∑The Di git Symbo l Subst itution Test ( DSST; subtest of WAIS -IV) (see 
Appendix 9)
9.4.5 Assessment of Bleeding Severity
Severi ty of bleeding will be based ondefinit ions contained in the Study  Events Assessment  
Manual for
:
ÔÇ∑Bleeding Academic Research Consortium (BARC)
ÔÇ∑International Society of Thrombosis and Hemostasis (ISTH)
ÔÇ∑Platelet Inhibit ionand Pat ient Outcomes (PLATO)
Revised Protocol No.: 06
Date: 09-Oct-2020 90
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
10 STATISTICAL CONSIDERATIONS
10.1 Sample Size Determination 
The primary endpo int for this study  is the incidence of events within a co mposite of new ischemic 
stroke during the treatm ent period and new covert brain infarction (FLAIR + DWI) detected by 
[CONTACT_66577] [ADDRESS_1230639] with 
the MCP -MOD methodol ogy using simulat ions with the Dose -Finding package in Rstatistical 
analysis software . Simulati ons of 2500 clinical trials were performed, assuming a true incidence 
for placebo of 15%, aplateau shaped dose response relationship with maximum  relative risk 
reducti on of 32% for BMS -986177 100 or 200 mg BID relative to placebo and reductions o f 10%, 
17.5%, and 27% for the 25-mg QD, 25 - mg BID, and 50-mg BID doses, respectively. Candidate 
models included an E maxmodel, a logisti c model, and an exponenti al model.
Using these assumpt ions, a total o f 2100 participants allocated in a 2:1:1:1:1:1 ratio to placebo and 
BMS -986177, 25 m g QD, 25 m g BID, 50 mg BID, 100 m g BID, and 200 mg BID groups would
provi de approximately 80% power to demonstrate a dose-response relationship, with a
 1-sided 
type I error of 0.049 (See Secti on 10.3.7 ).Without the 200- mg group, a total of 1800 part icipants 
allocated in a 2:1:1:1:1 ratio to placebo and BMS -986177, 25
-mg QD, 25-mg BID, 50-mg BID, 
and 100 -mg BID groups would provide approximately 79% power to demonstrate a dose -response 
relationship with similar pattern, but risk reducti on of 32% forBMS -986177 50 or 100 mg BID 
relative to placebo and reductio ns of 17.5%, and 27% for the 25-mg QD and 25-mg BID doses, 
respectively . Allowing up to 10% of participants who do not have a clinical event and also d o not 
have a Day 90 imaging assessment, approximately and up to 2350 participants may be randomized. 
The frequency and reasons for missing data will be evaluated in blinded fashio n during the course 
of the study .
10.2 Populations for Analyses
The analyses will use several populations as defined below:
1)All Enrolled Participants : Incl udes all partici pants who si gned informed consent.
2)All Rando mized Parti cipants /Intent -to-Treat (ITT) Populat ion: Includes all participants who 
were randomized to a treatment, regardless of whether they  received study  drug or not.  This 
popul ation will be analyzed according to the treatment assigned at randomization.
3)All Evaluable Participants : Includes All Randomized Participants ,as above, excluding those 
participants‚Äô visits where relevant protocol deviat ions occurred. The relevant protocol 
deviat ions will be pre -specified in the SAP prior to database lock.
4)All Treated Participants : Includes all participants who received at least one dose of study 
medicat ion.  Thi s will  be the primary populat ion used in safety  analyses and will  be analyzed 
according to the treatment assigned at randomizat ion, except in the following cases:
ÔÄ≠If a participant received the same incorrect treatment throughout the study (unt il either Da y 
90 or discon tinuation of the study drug), then the participant will be analyzed based on the 
treatm ent received.
Revised Protocol No.: 06
Date: 09-Oct-2020 91
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
ÔÄ≠If a participant received study  drug from more than one treatm ent group, and none of the 
administrations were consistent with the assigned randomized treatment group, then the 
participant will be analyzed based on the first treatment received.
5)Pharmacodynamics (PD) Populat ion: A subset of the ITT Populat ion that includes participants 
with at least one PD endpoint assessed fo llowing the first dose of BMS -986177.
6)Pharmacokinet ic (PK) Population for BMS -986177 ,clopi[INVESTIGATOR_7745] , and aspi[INVESTIGATOR_248]: Includes all 
participants treated with BMS -986177, clopi[INVESTIGATOR_7745] , and aspi[INVESTIGATOR_248], respectively, who also have 
at 
least one post -dose PK sample.
The primary  efficacy  data set will be the ITT populat ion.For the primary efficacy  endpo int 
analysis, the popul ationwill include all  Randomized Participants who:
ÔÇ∑have a primary endpoint event (a new ischemic stroke during the study period or a new covert 
brain infarct iondetected by  [CONTACT_880579] 90)
OR
ÔÇ∑have an evaluable MRI image onDay 
90.
For the primary endpoint, analys is will be performed using the Evaluable Participant data set as 
well as the Primary  Efficacy d ata set.
10.3 Statistical Analyses
The StatisticalAnalysis P lan (SAP) will be develo ped and finalized before the final database l ock 
and will describe the select ion of participants to be included in the analyses, and procedures for 
accounting for missing, unused, and spuri ous data. Below is a summary of planned statistical 
analyses o f the primary  and secondary  endpoints.
Except as otherwise noted, descript ive summaries will use data from all rando mized groups, while 
dose-response analyses of primary and secondary  endpo ints will use data from participants 
rando mized to placebo, 25 mg QD and 25 m g, 50 mg, 100 mg, and 200 mg BID groups.
A descri ptionof the participant popul ation will be included in the statistical output reported, 
including subgroups of age, gender ,and race.
10.3.1 Demographics and Baseline Characteristics
Frequency distributi on and summary statistics for demograph ic and baseline variables will be 
presented by [CONTACT_880590]. Key demographic and baseline 
variables to be summarized include geographic region, age, gender, race, height, weight, body 
mass index, vital signs (systolic blood pressure, diastolic blood pressure, and heart rate) and 
medical history (hypertensio n, diabetes, heart failure) .
10.3.2 Efficacy Analyses
Clinical defini tions and details related to the study endpo ints can be found in the Study  Events 
Assessment Manual.   Table 10.3.2 -1provides details about efficacy endpo ints and analysis 
methods to be used.
Revised Protocol No.: 06
Date: 09-Oct-2020 92
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Table 10.3.2 -1: Efficacy Endpoints and Analysis Methods
Endpoint Statistical Analysis Methods
Primary
ÔÇ∑Estimation of dose-response using 
composite of new ischemic stroke 
during the treatment period and new 
covert brain infarction 
(FLAIR +DWI) detected by [CONTACT_304608] 90 day susing central reviewDose -response relationship will be analyzed based on a generalized 
Multiple Comparisons and Modeling (gMCP -Mod) analysis56,57for the 
BMS -[ADDRESS_1230640] dose added to the ordered BID dose regimens . If a dose -
response relationship exists, then fitted estimates for the incidence of 
the primary endpoint will be calculated in each of the treatment groups 
using the selected dose -response models. An Emaxmodel ,a logistic 
model , and an exponentia l model will be used as the candidate models 
for the gMCP -Mod analysis. 
Secondary
ÔÇ∑Comparison of rates of the 
composite of new ischemic stroke 
during the treatment period and 
new covert brain infarction 
(FLAIR +DWI) detected by [CONTACT_304608] 90 day s
ÔÇ∑Event rates for new ischemic non -
fatal stroke, non -fatal MI, and all -
cause death during the treatment 
period
ÔÇ∑Location, number, and volume of 
new FLAIR +DWI lesions
ÔÇ∑Natio nal Institutes of Health Stroke 
Scale (NIHSS), Modified Rankin 
Scale (mRS), Montreal Cognitive 
Assessment (MoCA), and Digit 
Symbol Substitutio n Test (subtest 
of WAIS -IV) at baseline, on Days 
21 and 90, and at the time of a new 
stroke event.Point estimates with 95% confidence intervals for the following event 
rates will be summarized by [CONTACT_17673].
ÔÇ∑Composite of new ischemic stroke during the treatment period and 
new covert brain infarction detected by [CONTACT_66577] 90 days
ÔÇ∑New covert brain infarction detected by [CONTACT_194704] 90
ÔÇ∑Composite of new ischemic non -fatal stroke, non -fatal MI and all -
cause death d uring the treatment period
ÔÇ∑New ischemic stroke during the treatment period
ÔÇ∑Non-fatal myocardial infarction (MI)
ÔÇ∑All-cause death
Dose -response analysis for new ischemic non -fatal stroke and the 
composite of new non -fatal stroke, non -fatal MI, and all -cause death 
will be assessed similar to the primary endpoint analysis.
Location, number, and volume of new FLAIR +DWI lesions will be 
summarized descriptively by [CONTACT_1570].
Functional/disability status assessed by [CONTACT_880591] (NIHSS), modified Rankin Scale (mRS), Montreal 
Cognitive Assessment (MoCA) and Digit Symbol Substitution Test 
(subtest of WAIS -IV) will be summarized by [CONTACT_1570]. 
10.3.3 Safety Analysis
Table 10.3.3 -1provides details about safet y endpoints and analysis methods to be used.
Table 10.3.3 -1: Safety Endpoints and Analysis Methods
Endpoint Statistical Analysis Methods
ÔÇ∑Major bleeding event rate based on 
bleeding according to Bleeding 
Academic Research Consortium 
(BARC) Type 3 and 5The event rates of major bleeding (based on BARC Types 3 and 5 
definitions) will be summarized by [CONTACT_880592] 95% confidence intervals will be presented for each 
treatment group.
If a sufficient number of major bleeding events occurs, then dose -
response for the BMS -986177 will be assessed.  
Revised Protocol No.: 06
Date: 09-Oct-2020 93
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Table 10.3.3 -1: Safety Endpoints and Analysis Methods
Endpoint Statistical Analysis Methods
ÔÇ∑Event rate for all bleeding events, 
based on BARC, ISTH and 
PLATO -defined criteriaThe event rates for all bleeding will be summarized by [CONTACT_6490], including point estimates with 95% confidence intervals within 
group. Additionally, bleeding events will be summarized by [CONTACT_880558], ISTH (major an d CRNM bleeding) , and PLATO criteria 
(major, including life -threatening and other; minor, and minimal).
ÔÇ∑Incidence and characteristics of 
CMBs, hemorrhagic transformation 
of ischemic stroke and 
asymptomatic intracranial bleeding 
on Day  90 MRIIncidence and characteristics of CMBs, hemorrhagic transformation of 
ischemic stroke and asymptomatic intracranial bleeding on Day 90 
MRI will be summarized by [CONTACT_1570]
ÔÇ∑Adverse events, vital signs, 
physical exams ,electrocardiogram 
(ECG), and clinical laboratory 
resultsÔÇ∑Incidence of adverse events, related adverse events, serious adverse 
events, adverse events leading to discontinuation, and deaths will 
be summarized by [CONTACT_880593], changes from ba seline in vital signs, ECG and clinical 
laborato ry results will be summarized by [CONTACT_1570].
10.3.4 Pharmacokinetic Analysis
The PK of BMS-986177, clopi[INVESTIGATOR_7745] (and metabo lites), aspi[INVESTIGATOR_248] (acet ylsalicylic acid) and its major 
metabo lite, salicylic acid, will be assessed. A popul ation PK model (PPK) will be devel oped to 
understand the PK (CL and Vd) of BMS -[ADDRESS_1230641] of covariates (e.g., body 
weight, age, gender, race, renal function, liver funct ion, concomitant medicine) on the PK of 
BMS -986177. These results will be reported separately.
10.3.5 Pharmacodynamic and Biomarker Analysis
Percent ( %) c hange from baseline foraPTT , PT and Factor XI cl otting activi ty, as well D-dimer, 
PT, F1.2, and Factor XI antigen maybe summarized by [CONTACT_1570].   In addition, exploratory 
analyses may be conducted to explore the relat ionship of BMS -986177 to:
ÔÇ∑Percent (%) change from baseline in aPTT and Factor XI clotting activityvia exposure -
response
ÔÇ∑Biomarkers related to FXI pathway, stroke, thrombosis/hemo stasis, inflammat ion and 
cardi ovascular diseases, include, but are not limited to: plasma D -dimer, PT, F1.2, and Factor 
XI antigen.
ÔÇ∑PD and bio marker resul ts and analysis may be repor ted separately .
10.3.6 Exposure -Response Analyses
Exposure -response analyses will be conducted to explore the relationship of BMS-986177 
exposure to the following using data collected from all randomized participants:
ÔÇ∑Com posite of new ischemic stroke during the t reatment period and new covert brain infarctio n
detected by  [CONTACT_66577] 90 day s
ÔÇ∑New ischemic stroke non-fatal MI, and all -cause death during the treatment period
Revised Protocol No.: 06
Date: 09-Oct-2020 94
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
ÔÇ∑Major bleeding according to BARC Ty pe 3 and 5 definit ions
ÔÇ∑Percent ( %)change fro m baseline in aPTT and Factor XI clotting activity
ÔÇ∑Biomarkers related to FXI pathway, stroke, thrombosis/hemo stasis, inflammat ion and 
cardi ovascular diseases, including, but not limited to: include, but are notlimited to: plasma 
D-dimer, PT, F1.2, and Factor XI antigen.
10.3.7 Interim Analyses
In order to f acilit ate subsequent program  devel opment, an administrative interim analysis will  be 
conducted after approximately 70% of participants have had a [ADDRESS_1230642] the analysis, and unblind data will not 
be shared outside th e analysis group. A Data Monitoring Committee will assess safety throughout 
the course of this trial (see Secti on 5.1).
Revised Protocol No.: 06
Date: 09-Oct-2020 95
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
11 REFERENCES
1Feigin VL, Forouzanfar MH, Krishnamurthi R, et al on behalf of t he Global Burden of Diseases 
Stroke Experts Group. Lancet 2014: 383: 245 -55.
2Kernan WN, Ovbiagele B, Black HR, et al . Gui delines for the prevent ion of stroke in pat ients 
with stroke and transient ischemic attack. Stroke 2014; 45(7):2160 -23.
3Amarenco P, Lavallee PC, Labreuche J et al. for the TIAregistry .org Investigators. One-year 
Risk of Stroke After Transient Ischemic Attack or Minor Stroke. N Engl J M ed 2016; 374: 
1533-42.
4Wu CM, McLaughlin K, Lorenzetti  DL, Hill MD, Manns BJ, Ghali WA. Early risk of stroke 
after transi ent ischemic attack: A system atic review and meta -analysis. Archives of internal 
medicine. 2007;167:[ADDRESS_1230643] igators. Ti cagrel or versus aspi[INVESTIGATOR_880502]. N Engl  J 
Med 2016; 375(14):1395.
6Giles MF, Rothwe ll PM. Risk of stroke early after transient ischaemic attack: a system atic 
review and meta -analysis. Lancet Neurol 2007; 6: 1063 -72.
7Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, et.al. Definit ion and evaluat ion 
of transient ischemic attack: A scientific statement for healt hcare professio nals from the 
American Heart Associat ion/American Stroke Associ ation Stroke Council; Council on 
Cardi ovascular Surgery  and Anesthesia; Council on Cardi ovascular Radiology and 
Intervention; Council on Cardi ovascular Nursing; and the Interdi sciplinary Council on 
Peripheral  Vascular Disease. Stroke. 2009;40:2276-2293.
8Coull AJ, Lovett JK, Rothwell PM. Popul ation based study  of early risk of stroke after transi ent 
ischaemic attack or minor stroke: Implicati ons for public educat ion and organisat ion of 
services. BMJ. 2004;328:326.
9Lin HJ, Yeh PS, Tsai  TC, Cheng TJ, Ke D, Lin KC, Ho JG, Chang CY. Different ial risks of 
subsequent vascular events for transient ischaemic attack and minor ischaemic stroke. J Clin 
Neurosci . 2007;14:17-21.
10Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, Ringelstein EB. Dual 
Antiplatelet Therapy  With Clopi[INVESTIGATOR_880503] d Stenosis 
Evaluated Using Doppl er Embo lic Signal Detecti on The Clopi[INVESTIGATOR_880504] d Stenosis (CARESS) Trial. Circulat ion. 
2005;111:2233-2240.
11Wong KS, Chen C, Fu J, Chang HM, Suwanwela NC, Huang YN, Han Z, Tan KS, Ratanakorn 
D, Chollate P, Zhao Y, Koh A, Hao Q, Markus HS;. Clopi[INVESTIGATOR_880505]
h acute symptom atic cerebral or caroti d artery 
stenosi s (CLAIR study ): a rando mised, open -label, blinded -endpo int trial. Lancet Neurol . 2010 
May;9(5):489-97.
Revised Protocol No.: 06
Date: 09-Oct-2020 96
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230644] igators. Clopi[INVESTIGATOR_880506]. N Engl J Med 2013; 369:11 -
19.
13Johnston SC, Easton JD, Farrant M, Barsan W, Conwi tRA, Elm JJ, Kim AS, Lindblad AS, 
Palesch YY for the Clinical Research Collaboratio n, Neurol ogical Emergencies Treatment 
Trials Network, and the POINT Investigators. Clopi[INVESTIGATOR_880507] -Risk TIA. NEJM 2018; doi: 10.1056/NEJMoa1800410:1 -11.
14Buller HR, Bethune C, Bhanot S, et al. Factor XI Ant isense Oligonucleotide for Prevent ion of 
Venous Thrombosis. NEJM 2015;372:232 -240.
15Yang DT, Flanders MM, Kim H, et al. Elevated factor XI activit y levels are associ ated with 
an increased odds ratio for cerebr ovascular events. Am J Clin Pathol. 2006 Sep;126(3):411 -5.
16Suri MF, Yam agishi  K, Aleksic N, et al. Novel hemostati c factor levels and risk of ischemic 
stroke: the Atherosclerosis Risk in Communit ies (ARIC) Study . Cerebrovasc Dis 
2010;29:497 ‚Äì502.
17Siegerink B, Govers -Riemslag JW, Rosendaal FR, et al. Intrinsic coagul ation activation and 
the risk of arteri al thrombosis in young wom en: resul ts from the Risk of  Arterial Thrombosis 
in relat ion to Oral contraceptives (RATIO) case ‚Äìcontrol  study. Circulat ion 2010;122:1854 ‚Äì61.
18Gom ez K, Bol ton-Maggs P. Factor XI deficiency. Haemophilia 2008;14(6):1183-1189.
19Preis M, Hirsch J, Kotler A, Zoabi A, Stein N, Rennert G, Saliba W. Factor XI deficiency is 
associ ated with lower risk for cardi ovascular and venous thromboembo lism events. Blood. 
2017;129(9):[ADDRESS_1230645] 2011;105:[ADDRESS_1230646] 2009;[ADDRESS_1230647]:[ADDRESS_1230648] Treated with Chronic Hem odialysis. Bristol 
Myers Squibb Company, 2018. Document Control No. 930125554 .
23Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Hill MD, Jonasson J, 
Kasner SE, Ladenvall P, Minematsu K , MolinaCA, Wang Y, WongKSL, and Claiborne 
Johnston Sfor the SOCRAT ES Steering Commi ttee and Investi gators. Efficacy  and safety  of 
ticagrel or versus aspi[INVESTIGATOR_880508]: 
a subgroup analysis of SOCRATES, a randomised, double -blind, controlled trial. Lancet 2017;
16(4): 301‚Äì310.
24Eikelboom  JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovsaka O, et al. on 
behalf of the COMPASS invest igators. Rivaroxaban with and without aspi[INVESTIGATOR_880509]. N Engl  J Med 2017; 377: 1319 -
30.
Revised Protocol No.: 06
Date: 09-Oct-2020 97
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230649] LB7: The effect of rivaroxaban wit h 
aspi[INVESTIGATOR_880510] (COMPASS) trial. 2018.
26BMS -[ADDRESS_1230650] of Co-administration of Multiple Doses of BMS -986177 on Aspi[INVESTIGATOR_880511] . Bristol-Myers Squibb Com pany, 2017. Document Control  No. 
930119159.
28Final SafetyReport Synopsis for Study  CV010034. A Randomized, Cross -Over Study  to 
Evaluate the Safet y, Tolerabilit y, Pharmacokinet ics, and Pharmacod ynamics oBm s
-986177 
(An Oral Antithrombotic) With Single and Dual  Antiplatelet Therapy  (Aspi[INVESTIGATOR_880512] ) In Healthy Parti cipant s. Bristol  Myers Squibb Company. 2019. Document  
Control  No. 930139416.
29The Stroke Prevention  In Reversible Ischemia Trial (SPI[INVESTIGATOR_61192]) Study  Group. A randomized 
trial of anticoagulants versus aspi[INVESTIGATOR_880513]. The 
Stroke Prevent ion in Reversible Ischemia Trial (SPI[INVESTIGATOR_61192]) Study  Group. Ann Neurol . 1997 
Dec;42(6):857-65.
30Mohr JP, Thom pson JLP, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, et. al. A 
Com parison of Warfarin and Aspi[INVESTIGATOR_880514]. N Engl 
J Med 2001;345:1444 -51.
31Chimowitz MI, Lynn NJ, Howlett -Smit h H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, 
et. al. Com parison of Warfarin and Aspi[INVESTIGATOR_880515] 
(WASID). N Engl J Med 2005;352:1305-16.
32The ESPRIT Study  Group. Aspi[INVESTIGATOR_880516] (ESPRIT): randomised controlled trial. Lancet 2006; 367:1665‚Äì
73.
33Clinical Study  Report for CV185030 (ARISTOTLE): A Phase 3, Active (War farin) Controlled, 
Randomized, Double -Blind, Parallel- Arm Study  to Eval uate Efficacy and Safet y of Api[INVESTIGATOR_880517]. 
Bristol-Myers Squibb Company , 2011. Docum ent Control  No. 930050122.
34Conno lly SJ, Ezekowi tz MD, Yusuf S, Eikelboom J, Oldgren J, et. al. Dabigatran versus 
Warfarin in Pat ients with Atrial Fibrillat ion. N Engl J Med 2009; 361:1139 -1151.
35Patel  MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et. al. Rivaroxaban versus 
Warfarin in Nonvalvular Atrial Fibrillat ion. N Engl J Med 2011;365:[ADDRESS_1230651], James S, Kilaru R, He Y, et.al. Api[INVESTIGATOR_880518] e. N Engl  J Med 2011; 365:699-708.
37Mega JL. Braunwald E, Wiviott SD, Bassand J-P, Bhatt DL, et. al.. Rivaroxaban in Patients 
with a Recent Acut e Coronary  Syndrom e. N Engl  J Med 2012; 366:9 -19.
Revised Protocol No.: 06
Date: 09-Oct-2020 98
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230652] of Different 
Antithrombotic Strategi es in Very  Elderly Patients With Atrial Fibrillat ion: A Sub-Analysis 
From  the PREFER in AF (PREvent ion oF Thromboembo lic Events ‚ÄìEuropean Registry in 
Atrial Fibrillat ion). J Am Heart Assoc. 2017;6:e005657.
39Gage BF, Yan Y, Milligan PE, et al. Clinical classificat ion schemes for predict ing hemorrhage: 
resul ts from the National Registry  of Atrial Fibrillation (NRAF). Am Heart J 2006;151:713 ‚Äì
9.
40Fang MC, Go AS, Chang Y, et al. A
 new risk scheme to predict warfarin -associ ated 
hemorrhage: the ATRIA (Anticoagulat ion and Risk Factors in Atrial Fibrillat ion) study . J Am 
Coll Cardio l 2011;58:395 ‚Äì401.
41Pi[INVESTIGATOR_9698] R, Lane DA, Nieuwlaat R, et al. A novel user -friendly  score (HAS -BLED) to assess 1 -
year risk of major bleeding in patients with atrial fibrillat ion: the Euro Heart Survey. Chest 
2010;138:1093
‚Äì100.
42Kirchhof P, Benussi S,Kotecha D,Ahlsson A, At ar D, Casadei B, et. al. 2016 ESC Guidelines 
for the Management of Atrial Fibrillat ion Developed in C ollaborati on with EACTS . European 
Heart Journal (2016) 37, 2893‚Äì2962.
43Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowi tzMD, Camm
AJ, et al. Compar ison of the efficacy and safet y of new oral anticoagul ants with warfarin in 
patients with atrial fibrillat ion: a meta -analysis of rando mised trials. The Lancet. 
2014;383(9921):955 - 962.
44Hicks KA, Mahaffey KW, Mehran R, Nissen SE. Consens us Report: 2017 Cardiovascular and 
Stroke Endpoi nt Definit ions for Clinical Trials. Circulat ion. 2018;137:961‚Äì972.
45Kasner SE.Clinical Interpretation and Use of Stroke S cales. Lancet Neurol. 200 6 Jul;5(7):[ADDRESS_1230653], Provenzale JM, Petrella JR, Alberts MJ. Diffusio n MRI Imaging and Transient 
Ischemic Attacks. Stroke; A
Journal  of Cerebral Circulation. 1999;30:2762-2763.
47Hicks KA, Tcheng JE, Bozkurt B, Chait man BR, Cutlip DE, Farb A, Fonarow GC, Jacobs J P,
et al. 2014 ACC/AHA Key Data Elements and Definit ions for Cardiovascular Endpoint Events 
in Clinical Trials: A Report of the Amer ican College of Cardio logy/American Heart 
Associ ation Task Force on Clinical Data Standards. J Am Co ll Cardio l. 2015 Jul 28; 66(4):403 -
69.
48Smith, EE. Prevent ion of Stroke in Pat ients With Silent Cerebrovascular Disease A Scient ific 
Statem ent for Healthcare Professio nals From  the Amer ican Heart Associat ion/American 
Stroke Associat ion. Stroke. 2017;48:e44- e71.
49Verm eer SE, Pr ins ND, den Heijer T et al. Silent Brain Infarcts and the Risk of Dement ia and 
Cogni tive Decline. N Engl J Med 2003; 348: 1215 -22.
50Verm eer SE, Longstreth  WT , Koudstaal PJ. Silent Brain Infarcts: A Systematic Review. 
Lancet Neurol 2007; 6: 611 ‚Äì19.
Revised Protocol No.: 06
Date: 09-Oct-2020 99
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
51DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, et al. Controlled 
Trial of Transfusio ns for Silent Cerebral Infarcts in Sickle Cell Anemia.  N Eng J Med 
2014;371(8):[ADDRESS_1230654] L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen -Kudsk JE, et al. 
Patent F oram en Ovale Clo sure or Ant iplatelet Therapy  for Cry ptogenic Stroke. N Eng J Med. 
2017;377(11):1033 -42.
53Hill MD, Martin RH, Mikulis D, Wong JH, S ilver FL, Terbrugge KG, et al. Safet y and Efficac y 
of NA-1 in Patients w ith Iatrogenic Stroke After Endovascular Aneurysm Repair (ENACT): a 
Phase 2, Rando mised, Double- blind, Placebo -controlled Trial. Lancet neuro logy. 
2012;11(11):942 -50.
54von Kummer R, Broderi ck JP, Campbell BCV ,Dem chuk A, Goyal M, Hill MD, et.al. The 
Heidelberg Bleeding Classificat ion:Classificat ion of Bleeding Events After Ischemic Stroke 
and Reperfusio n Therapy. Stroke. 2015; 46:2981 -2986.
55Greenberg SM, Vernooij MW, Cordonnier C, Viswanathan A, Al -Shahi Salman R, Warach S, 
Launer LJ, Van Buc hem MA, Bretel er MM .Cerebral Microbleeds: A Guide to Detection and 
Interpretation . 2009, Lancet Neurol; 8(2):165‚Äì174.
56Bretz F, Pi[INVESTIGATOR_144676], Branson M. Combining multiple com parisons and modeling techniques 
in dose -response studies. Bio metrics 2005; 61: 738‚Äì748.
57Pi[INVESTIGATOR_17872] J, Bornkamp B, Glimm E, Bretz F. Model-based dose finding under model uncertaint y 
using general parametric models. Statist ics in Medicine 2014; 33:1646-1661.
Revised Protocol No.: 06
Date: 09-Oct-2020 100
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
12 APPENDICES
Revised Protocol No.: 06
Date: 09-Oct-2020 101
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
APPENDIX 1 ABBREVIATIONS AND TR ADEMARKS
Term Definition
ABCD2 neuro logical assessment scores (age, blood pressure, clinical features, 
d  i bACC American College of Cardio logy
ADRC adaptive design review committee
AE adverse event
AF atrial fibrillat ion
AHA American Heart Associat ion
ALT alanine aminotransferase
Am, AM morning
aPTT activated partial thro mboplast in time
ASA acetylsalicylic acid
ASO anti-sense oligonucleotide
AST aspartate aminotransferase
ALT amino transaminases
AUC area under the concentration -time curve
AUC(0 -24) area under the concentration -time curve (time zero to [ADDRESS_1230655] dose)
AVM arteri ovenous malformat ion
BARC Bleeding Academic Research Consortium
BID twice-a-day
BMI body  mass index
BMS [COMPANY_016]
BMS -986177 BMS Factor XIa (FXIa) inhibitor invest igational ant icoagulant com pound
BP blood pressure
BT bleeding time
BUN blood urea nitrogen
C Celsius
CFR Code of Federal Regulat ions
CI confidence interval
CK creatine kinase
CL estimated clearance
Revised Protocol No.: 06
Date: 09-Oct-2020 102
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230656] e Using Anticoagul ation Strategies
cm centimeter
Cmax, CMAX maximum observed concentration
CONSORT Conso lidated Standards of Reporting Trials
COX -2 cyclooxygenase -2, enzyme responsible for inflammat ion and pain
CRF case report form (paper or electronic)
CRNM clinically relevant non -majo r
CSR clinical study  report
CT computeri zed tom ography
CTA computed tom ography  angi ography
CAT computeri zed tom ography angi ography
CV cardi ovascular
CYP cytochrom e P450
CYP3A4 member of the cy tochrom e P450 family of oxidizing enzymes
DDI drug-drug interaction
D-Dimer protein fragment present in the blood after a clot is degraded by  [CONTACT_880594]-induced liver injury
dL deciliter
DNA deoxy ribonucleic acid
DOAC direct oral anticoagul ants
DSMB data safet y monitoring board
DSST Digital Symbo l Substi tution Test
DWI diffusio n-weighted imaging MRI
ECAT electroni cally induced thrombus in the carotid artery
EC ethics commi ttee
EC20 20% of maximal effect is observed
EC50 half maximal effective concentration
EC80 80% of maximal effect is observed
ECG electrocardi ogram
eCRF electroni c case report form
Revised Protocol No.: 06
Date: 09-Oct-2020 103
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230657] ive dose in 90% of patients
Emax asymptotic maximum change from placebo effect
EOT end of treatment
ESC European Societ y of Cardi ology
ESRD end stage renal disease
F1.2 F1.2 fragment of prothrombin
FXa Factor Xa, one of the enzymes in the coagulation cascade.
FXI (FXI) Factor XI, one of the enzymes of the coagulat ion cascade
Factor XIa Activated plasma Factor XI
FDA Food and Drug Administration
FIH first in human
FLAIR fluid-attenuated inversio n recovery
FSH follicle stimulat ing horm one
g, gm gram
GCP good clinical pract ice
GPI[INVESTIGATOR_97086]/IIIa glycoprotein IIb/IIIa
GRE gradi ent echo sequences
h hour
Hb hemoglo bin
HBsAg hepat itis B surface antigen
HBV, HepB hepat itis B virus
HCG human chorionic gonadotropin
HepC hepat itis C virus
HepB hepat itis B virus
HepA hepat itis A virus
HI hemorrhagic infarction
HIV human immunodeficiency virus
hr, hrs hour, hours
HPLC -MS/MS high-performance liquid chromatography -mass spectrom etry/mass 
 
Revised Protocol No.: 06
Date: 09-Oct-2020 104
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230658] ive web/vo ice response system
K slope of  the terminal phase of the log concentration -time curve
K3EDTA potassi um ethylenediaminetetraacetic acid
kg kilogram
ÔÅ¨z terminal disposit ion rate constant
L liter
LC-MS/MS liquid chro matography -mass spectrom etry/mass spectrom etry
LDH lactate dehy drogenase
LFT liver funct ion test
LMWH low-molecular -weightheparin
Lp-PLA(2) lipoprotein -associ ated phospho lipase A2
Revised Protocol No.: 06
Date: 09-Oct-2020 105
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230659] ion
min minute
mL milliliter
mmHg millimeters of mercury
MoCA Montreal Cognit ive Assessment
MRA magnet ic resonance angiography
mRNA messenger ribonucleic acid
MRI magnet ic resonance imaging (or image)
mRS modified Rankin Score
ÔÅ≠g microgram
ÔÅ≠L microliter
N number of participants or observations
N/A not applicable
ng nanogram
NIHSS National Inst itutes of Healt h Stroke Score/Scale
nm nano molar
NOAEL no observed adverse effect l evel
Non-IMP Non-Invest igational Medicinal P roduct
NSAE non-serious adverse event
NSAID nonsteroidal ant i-inflammatory drug
NT-proBNP n-terminal prohormone of brain natriuretic pept ide
NVAF non-valvular atrial fibrillat ion
NYHA [LOCATION_001] Heart Associat ion
PCR polymerase chain react ion
Revised Protocol No.: 06
Date: 09-Oct-2020 106
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Term Definition
PD pharmacodynamics
PID patient identificat ion
PK pharmacokinet ics
PLATO Platelet Inhibit ion and Pat ient Outcomes
pm, PM evening
PO by [CONTACT_880595] [INVESTIGATOR_880519](pharmacokinet ics)
PT prothrombin t ime
PTT partial thromboplast in time
P2Y12 group of g protein -coupl ed (gpcr) purinergic receptors
OATP1B1 organi c-anion-transporting polypept ide
QC qualit y control
QD, qd once daily
RAR response adaptive rRando mization
R2 coefficient of determinat ion
RBC red bl ood cell
RNA ribonucleic acid
RRR relative risk reduct ion
RSI reference safet y informat ion
SAD single ascending dose
SAE serious adverse event
SARS -CoV -[ADDRESS_1230660] ion
SWI suscept ibilit y weighted imaging
TB total bilirubin
Revised Protocol No.: 06
Date: 09-Oct-2020 107
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230661] upper limit of normal
Vd volume of distribut ion
VTE venous thromboembolism
VTEp venous thromboembolism prevent ion
WOCBP wom en of childbearing potential
wt weight
Revised Protocol No.: 06
Date: 09-Oct-2020 108
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
APPENDIX 2 STUDY GOVERN ANCE CONSIDERATIONS
The term  ‚ÄòParti cipant‚Äô i s used in the protocol to refer to a person who has consented to participate 
in the clinical research study. The term ‚ÄòSubject‚Äô used in the eCRF is intended to refer to a person 
(Parti cipant) who has consented to participate in the clinical research study .
REGULATORY AND ETHIC AL CONSIDERATIONS
GOOD CLINICAL PRACTI CE
This study  will be conducted in accordance wit h:
ÔÇ∑Consensus ethical principles derived from internatio nal guidelines including the Declarat ion 
of Helsinki and Council for Internat ional Organizat ions of Medical Sciences (CIOMS) 
International Ethical Guidelines Good Clinical Practice (GCP), 
ÔÇ∑as defined by  [CONTACT_880596](ICH)
ÔÇ∑in accordance wit h the ethical principles underlying European Unio n Directive 2001/20/EC
ÔÇ∑[LOCATION_002] Code of Federal Regulations, Tit le 21, Part 50 (21CFR50) 
ÔÇ∑Applicable l ocal requirements.
The study  will be conducted in com pliance wi th the protocol . The protocol  and any amendments 
and the participant informed consent will receive approval/favorable opi[INVESTIGATOR_3078] n by [CONTACT_54016]/Independent Ethics Committee (IRB/IEC), and regulatory  authori ties according to 
applicable local regulat ions pri or to init iation of the study .
All potenti al serious breache s must be reported to Sponsor or designee immediately. A serious 
breach is a breach of the conditions and principles of GCP in connect ion with the study  or the 
protocol , which is likely to affect, to a significant degree, the safet y or physical or mental i ntegrity 
of the subjects of the study  or the sci entific value of the study.
Personnel involved in conducting this study  will be qualified by [CONTACT_54017], training, and 
experience to perform their respective tasks.
This study  will not use the services of study personnel where sancti ons have been invoked or where 
there has been scient ific misconduct or fraud (eg, loss of medical licensure, debarment). 
INSTITUTIONAL REVIEW BOARD/INDEPENDENT E THICS COMMITTEE
Before study  initiation, the invest igator must have written and dated approval/favorable opi[INVESTIGATOR_3078] n 
from the IRB/IEC for the protocol , consent form, participant recruitment materials 
(eg,advertisements), and any other written information to be provided to subjects. The investigator 
or BMS shoul d also provi de the IRB/IEC with a copy of the Invest igator Brochure or product 
labeling informat ion to be provided to subjects and any updates. 
The invest igator, Sponsor or designee should provide the IRB/IEC with reports, updates and other 
inform ation (eg,expedited safety reports, amendments, and administrative letters) according to 
regul atory  requi rements or i nstitution procedures.
Revised Protocol No.: 06
Date: 09-Oct-2020 109
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230662] igator should not implement any deviati on or change to the protocol  without prior 
review and docum ented approval /favorabl e opi[INVESTIGATOR_53910]/IEC (and if 
applicable, also by [CONTACT_54018]) except where necessary to eliminate an immediate 
hazard(s) to study  subjects. 
If a deviat ion or change to a protocol is implemented to eliminate an immediate hazard(s) prior to 
obtaining relevant approval/favorable opi[INVESTIGATOR_3078] n(s) the deviat ion or change will be submitted, as soon 
as possible to:
ÔÇ∑IRB/IEC
ÔÇ∑Regulatory  Authori ty(ies), if applicable by  [CONTACT_54019] (per nat ional requirements)
Docum entati on of approval /favorabl e opi[INVESTIGATOR_3078] n signed by [CONTACT_54020](s)/IEC(s) and if applicable, also by [CONTACT_54021] h authorit y must be sent to BMS.
If an amendment substant ially alters the study  design or increa ses the potential risk to the 
participant: (1) the consent form must be revised and submi tted to th e IRB(s)/IEC(s) for review 
and approval/favorable opi[INVESTIGATOR_3078] n; (2) the revised form must be used to obtain consent from subjects 
currently enrolled in the study  if they are affected by [CONTACT_29991]; and (3) the new form must 
be used to obtain consent from new subjects prior to enrollment.
If the revisio n is done via an administrative letter, investigators must inform their IRB(s)/IEC(s).
FINANCIAL DISCLOSURE
Invest igators and sub-Invest igators will provi de the Sponsor with sufficient, accurate financia l 
inform ation in accordance with local regulati ons to allow the Sponsor to submit complete and 
accurate financial certification or disclosure statem ents to the appropriate healt h authori ties. 
Invest igators are responsible for provi ding information on financial interests during the course of 
the study  and f or [ADDRESS_1230663] ensure that subjects are clearly and fully informed about the purpose, potential 
risks, and other crit ical issues regarding clinical studies in which they  volunteer to participate. 
In situat ions where consent cannot be given to subjects, their legally acceptable representatives ( as 
per country guidelines) are clearly and fully informed about the purpose, potential risks, and other 
critical issues regarding clinical studies in which the participant volunteers to participate. 
Sponsor or designee will provide the invest igator with a n appropriate ( ie,Global or Local) sample 
inform ed consent form which will include all elem ents requi red by [CONTACT_12212], GCP and applicable 
regul atory  requirements. The sample inform ed consent form will adhere to the ethical principles 
that have their origin in t he Declaration o f Helsinki.
Revised Protocol No.: 06
Date: 09-Oct-2020 110
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230664]:
ÔÇ∑Provi de a copy  of the consent form and written information about the study in the language in 
which the part icipant is most proficient prior to clinical study part icipation. The language must 
be non-technical and easily  understood. 
ÔÇ∑Allow time necessary for participant or participant's legally acceptable representative to 
inquire about the details o f the study .
ÔÇ∑Obtain an informed consent signed and personally dated by  [CONTACT_54022]'s 
legal ly acceptable representative and by [CONTACT_54023] n. 
ÔÇ∑Obtain the IRB/IEC‚Äôs written approval/favorable opi[INVESTIGATOR_3078] n of the written informed consent form 
and any other informat ion to be provided to the subjects, prior to t he beginning of the study , 
and after any revisio ns are com pleted for new info rmation.
If inform ed consent is initially given by a partici pant‚Äôs legally acceptable representative or legal 
guardi an, and the participant subsequent ly beco mes capable of making and communicat ing his or 
her informed consent during the study, consent must additionally be obtained from the participant.
Revise the informed consent whenever important new informat ion beco mes available that is 
relevant to the participant's consent. Theinvest igator, or a person designated by [CONTACT_3170], 
shoul d fully inform  the participant or the participant's legally acceptable representative or legal 
guardi an, of all pertinent aspects of the study  and of any new information relevant to the 
participant's willingness to conti nue participat ion in the study . This communication shoul d be 
docum ented. 
The confidentialit y of records that could ident ify subjects must be protected, respecting the privacy 
and confident iality rules applicable to regulatory  requirements, the subjects' signed ICF and, in the 
US, the subjects‚Äô signed HIPAA Authorizat ion.
The consent form must also include a statem ent that BMS and regul atory  authori ties have direct 
access to participant records. 
Subjects unable to give their wri tten consent ( eg,stroke or subjects with or severe dement ia) may 
only be enro lled in t he study with the consent of a legally acceptable representative. The partici pant 
must also be informed about the nature of the study  to the extent compatible with his or her 
understanding, and shoul d this partici pant become capable, he or she shoul d personally  sign and 
date the consent form as soon as possible. The explicit wish of a participant who is unable to give 
his or her wri tten consent, but who is capable of form ing an opi[INVESTIGATOR_3078] n and assessing information to 
refuse participat ion in, or to be withdrawn fro m, the clinical study at any time should be considered 
by [CONTACT_093].
The ri ghts, safet y, and well -being of the study  subjects are the m ost important considera tions and 
shoul d prevail  over interests of science and societ y.
Revised Protocol No.: 06
Date: 09-Oct-2020 111
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
SOURCE DOCUMENTS
The Investi gator is responsible for ensuring that the source data are accurate, legible, 
contemporaneous, ori ginal  and attributable, whether the data are hand -written on paper or entered 
electroni cally. If source data are created (first entered), modified, maintained, archived, retrieved, 
or transmitted electroni cally via computerized systems (and/or any other kind of electronic 
devices) as part of regulated clinical trial activities, such system s must be compliant with all 
applicable laws and regulati ons governing use of electronic records and/or electronic signatures. 
Such systems may include, but are not limited to, electronic medical/healt h records (EMRs/EHRs), 
adverse event tracking/reporting, protocol  required assessments, and/or drug accountabilit y 
records).
When paper records from such systems are used in place of electronic format to perform regulated 
activit ies, such paper records should be certified copi[INVESTIGATOR_014]. A certified copy  consists of a copy of 
original  informat ion that has been verified, as indicated by a dated signature, as an exact copy 
having all o f the sam e attri butes and informat ion as the original. 
STUDY TREATMENT RECO RDS
Records for study treatments (whether s upplied by [CONTACT_20444], its vendors, or the site) must substant iate 
study  treatment integrity and traceabilit y from  receipt, preparation, administration, and through 
destruction or return. Records must be m ade available for revi ew at the request of BMS/desi gnee 
ora Health Authorit y.
Revised Protocol No.: 06
Date: 09-Oct-2020 112
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
If Then
Supplied by [CONTACT_20444] (or its vendors): Records or logs must comply with applicable 
regul ations and guidelines and should include:
ÔÇ∑amount received and placed in storage 
area
ÔÇ∑amount currently  in storage area
ÔÇ∑label ident ificat ion number or batch 
number
ÔÇ∑amount dispensed to and returned by  [CONTACT_37117], including unique participant 
ident ifiers
ÔÇ∑amount transferred to another area/site for 
dispensing or storage
ÔÇ∑non-study  disposi tion (e.g., l ost, wasted) 
ÔÇ∑amount destroy ed at study  site, if 
applicable
ÔÇ∑amount returned to BMS
ÔÇ∑retain samples for 
bioavailabilit y/bioequivalence, if 
applicable 
ÔÇ∑dates and init ials of person responsible for 
Invest igational Product 
dispensing/accountabilit y, as per the 
Delegati on of  Authori ty Form.
Sourced by [CONTACT_3725], and not supplied by [CONTACT_82769] (examples include IP sourced from 
the sites stock or commercial supply, or a 
specialt y pharmacy)The invest igator or designee accepts 
responsibilit y for document ing traceabilit y and 
study  treatment integrity in accordance with 
requi rements applicable under law and the 
SOPs/standards of the sourcing pharmacy.
BMS or desi gnee will  provide forms to facilitate inventory  control  if the invest igational site does 
not have an established system that meets these require ments.
CASE REPORT FORMS
An investigator is required to prepare and maintain adequate and accurate case histories designed 
to record all observat ions and other data pertinent to the invest igation on each individual treated 
or entered as a control in the investigation. Data that are derived from source documents and 
reported on the CRF must be consistent with the source documents or the discrepancies must be 
explained. Addit ional clinical informat ion may be collected and analyzed in an effort to enhance 
Revised Protocol No.: 06
Date: 09-Oct-2020 113
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230665] safet y. CRFs may  be requested for AEs and/or laboratory  abnorm alities 
that are reported or ident ified during the course of the study .
For sites using the Sponsor or designee electronic data capture tool, electroni c CRFs will be 
prepare d for all data collect ion fields except for fields specific to SAEs and pregnancy, which will 
be reported on the electroni c SAE form and Pregnancy Surveillance form, respect ively. If 
electroni c SAE form is not available, a paper SAE form can be used. Space s may be left blank 
only in those circumstances permitted by [CONTACT_3449] -specific CRF completion guidelines provi ded by 
[CONTACT_35886]. 
The confidentialit y of records that could ident ify subjects must be protected, respecting the privacy 
and confidentialit y rules in accordance wi th the applicable regulatory  requi rement(s).
The invest igator will maintain a signature [CONTACT_54048] m ake entri es and/or corrections on CRFs. 
The co mpleted CRF, SAE/pregnanc y CRFs, must be pro mptly reviewed, signed, and dated by [CONTACT_54025] a subinvesti gator and who is delegated thi s task on the 
Delegati on of  Authori ty Form. Subinvest igators in Japan may not be delegated the CRF approval 
task. Electroni c CRF review and approval /signature [CONTACT_880606] c data capture tool . The invest igator m ust retain a copy  of the CRFs including records of 
the changes and corrections.
Each individual electronically signing electroni c CRFs must meet Sponsor or designee training 
requi rements and must only access the BMS electronic data capture tool using the unique user 
account provided by [CONTACT_35886]. User accounts are not to be shared or reassigned to other 
individual s
MONITORING
Sponsor or designee representatives will review data centrally to ident ify potenti al issues to 
determine a schedule of on -site visi ts for targeted review o f study  records. 
Representatives of BMS must be allowed to visit all study  site locati ons peri odically to assess the 
data qualit y and study integrit y. On site orthrough other means of remote monitoring approved by 
[CONTACT_880597], they will review study  records and 
directly compare them with source documents, discuss the conduct of the study with the 
investigator, and verify  that the facilit ies remain acceptable. Certain CRF pages and/or el ectroni c 
files may  serve as the source documents:
In addi tion, the study  may be evaluated by  [CONTACT_54026], source documents, other study  files, and study 
facilit ies. BMS audit reports will be kept confidential.
The investigator must notify BMS prom ptly of any inspect ions scheduled by [CONTACT_3118], 
and prompt ly forward copi [INVESTIGATOR_53911]. 
Revised Protocol No.: 06
Date: 09-Oct-2020 114
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230666] igator (or head of the study  site in Japan) must retain all study records and source 
docum ents for the maximum period requi red by [CONTACT_35888], or 
institution procedures, or for the period specified by [CONTACT_54029], whichever is longer. The 
investigator (or head of the study site in Japan) must contact [CONTACT_186767] .
BMS or desi gnee will notify the invest igator (or head of the study  site in Japan) when the study 
records are no longer needed.
If the invest
igator withdraws from the study  (e.g., relocation, retirement), the records shall be 
transferred to a mutually agreed upon designee (e .
g., another investigator, study site, IRB). Notice 
of such transfer will be given in writ ing to BMS or designee. 
RETURN OF STUDY TREA TMENT
For this study , study  treatm ents (those supplied by  [CONTACT_20444], a vendor or sourced by  [CONTACT_154715]) 
such as partially  used study  treatm ent containers, vials and syringes may  be destroy ed on si te. 
If Then
Study  treatments supplied by [CONTACT_20444] (including 
its vendorsAny unused study treatments supplied by [CONTACT_880598] i nspected and 
reconciled by [CONTACT_880599] y, 
or to meet local regulat ions (eg, cytotoxi cs or 
biologics).
If study  treatm ents will  be returned, the return 
will be arranged by [CONTACT_54032].
Study  treatm ents sourced by [CONTACT_3725], not supplied 
by [CONTACT_20444] (or its vendors) (examples include 
study  treatm ents sourced from the sites stock 
or commercial supply , or a specialt y 
pharmacy)It is the investigator‚Äô s or designee‚Äôs 
responsibilit y to dispose of all containers 
according to the institutional guidelines and 
procedures.
It is the Invest igator‚Äôs or designee‚Äôs responsibili ty to arrange for disposal , provided that procedures 
for proper disposal have been established according to applicable federal, state, local, and 
institutional guidelines and procedures, and provided that appropriate records of disposal are kept. 
The fo llowing minimal standards must be met:
ÔÇ∑On-site disposal  pract ices must not expose humans to risks fro m the drug.
Revised Protocol No.: 06
Date: 09-Oct-2020 115
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
ÔÇ∑On-site disposal pract ices and procedures are in agreement with applicable laws and 
regul ations, including any special requirements for controlled or hazardous substances.
ÔÇ∑Written procedures for on-site disposal  are available and followed. The procedures must be 
filed with the site‚Äôs SOPs and a copy  provi ded to BMS upon request.
ÔÇ∑Records are maintained that allow for traceabilit y of each container, including the date 
disposed of, quanti ty disposed, and ident ification of the person disposing the containers. The 
method of disposal, ie, incinerator, licensed sanitary landfill, or licensed waste disposal vendor 
must be documented.
ÔÇ∑Accountabilit y and disposal  records are complete, up- to-date, and available for the Monitor to 
review through out the clinical trial period.
It is the i nvest igator‚Äôs or designee‚Äôs responsibilit y to arrange for di sposal  of all empt y containers.
If condit ions for destruction cannot be met the responsible Study Monitor will make arrangements 
for return of study treatm ents provided by [CONTACT_20444] (or its vendors). Destruction of non-study 
treatm ents sourced by [CONTACT_779], not supplied by [CONTACT_20444], is so lely the responsibilit y of the Invest igator 
or desi gnee.
CLINICAL STUDY REPOR T AND PUBLICATIONS
A Signatory  Invest igator must b e selected to sign the clinical study  report. 
For this protocol, the Signatory Invest igator will be selected as appropriate based on the fo llowing 
criteria:
ÔÇ∑National Coordinating Invest igator 
ÔÇ∑Study  Steering Committee C hair 
ÔÇ∑Parti cipant recrui tment (e .
g.,among the top quartile of enro llers)
ÔÇ∑Involvement in trial design
ÔÇ∑Regional representati on (e.
g., among top quartile of enrollers from a specified region or 
country )
ÔÇ∑Other criteria (as determined by  [CONTACT_2362] )
The data collected during thi s study  are confident ial and propri etary  to Sponsor or desi gnee. Any 
publicat ions or abstracts arising from this study  must adhere to the publicat ion requi rements set 
forth in the clinical trial agreement (CTAg) governing [Study  site or Invest igator] participat ion in 
the study . These requi rements include, but are not limited to, submitting proposed publicat ions to 
Sponsor or designee at the earliest practicable time prior to submissio n or presentation and 
otherwi se wi thin the time period set forth in the CTAg.
Revised Protocol No.: 06
Date: 09-Oct-2020 116
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
APPENDIX 3 ADVERSE EVENTS AND S ERIOUS ADV ERSE EVENTS: 
DEFINITIONS AND PROC EDURES FOR RECORDING , 
EVALUATING, FOLLOW U P AND REPORTING
ADVERSE EVENTS
Adverse Event Definition:
An Adverse Event (AE) i s defined as any  new untoward m edical  occurrence or worsening of a 
preexist ing medical condit ion in a c linical invest igation partici pant administered study  treatm ent 
and that does not necessarily  have a causal  relati onship wi th this treatm ent. 
An AE can therefore be any unfavorable and unintended sign (such as an abnorm al laboratory 
finding), symptom, or disease temporally associated with the use o f study treatment, whether or 
not consi dered rel ated to the study  treatment.
Events Meeting the AE Definition
ÔÇ∑Any abnorm al laboratory  test results (hematol ogy, clinical chemistry , or urinalysis) or 
resul ts from other safet y assessments (eg, ECG, radio logical scans, vital signs 
measurements), including those that worsen from baseline, cons idered clinically significant 
in the medical and scientific judgment of the investigator. Note that abnormal lab tests or 
other safet y assessments shoul d only be reported as AEs if the final diagnosis is not 
available. Once the final diagnosis is known, t he reported term  should be updated to be the 
diagnosis .
ÔÇ∑Exacerbat ion of a chronic or intermittent pre -existing condit ion including eit her an increase 
in frequency and/or intensit y of the condit ion.
ÔÇ∑New condit ions detected or diagnosed after study intervent ion administration even though it 
may have been present before the start of the study.
ÔÇ∑Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
ÔÇ∑Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  intervention 
or a concomitant medicat ion.
Events NOT Meeting the AE Definition
ÔÇ∑Medical or surgical procedure (eg, endoscopy , appendectomy): the condi tion that leads to 
the procedure is the AE.
ÔÇ∑Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admissio n to a hospi[INVESTIGATOR_307]).
Revised Protocol No.: 06
Date: 09-Oct-2020 117
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
DEFINITION OF SAE
If an event i s not an AE per definit ion above, then it cannot be an SAE even if serious condi tions 
are met.
SERIOUS ADVERSE EVEN TS
Serious Adverse Event (SAE) is defined as any untowa rd medical occurrence that, at any 
dose:
Results in death
Is life-threatening (defined as an event in which the parti cipant was at ri sk of  death at the time 
of the event; it does not refer to an event which hypothetically might have caused death if it we re 
more severe)
Requi res inpat ient hospi[INVESTIGATOR_53912] (see NOTE 
below)
NOTE: 
The fo llowing hospi [INVESTIGATOR_53913]: 
ÔÇ∑a visit to the emergency room or other hospi[INVESTIGATOR_20347] < 24 hours, that does not result in 
admissio n (unless considered an important medical or life -threatening event)
ÔÇ∑elective surgery, planned prior to signing consent
ÔÇ∑admissio ns as per protocol for a planned medical/surgical proce dure
ÔÇ∑routi ne health assessment requiring admissio n for baseline/trending of health status 
(eg,routine co lonoscopy )
ÔÇ∑medical/surgical admissio n other than to remedy ill healt h and planned prior to entry into 
the study . Appropri ate docum entati on is requi red in these cases
ÔÇ∑admissio n encountered for another life circumstance that carries no bearing on healt h status 
and requi res no medical/surgical interventi on (e.g., lack of housing, economic inadequacy, 
caregiver respi[INVESTIGATOR_040], family circumstances, administrative r eason)
ÔÇ∑admissio n for administration of anticancer therapy in the absence of any other SAEs (applies 
to oncology  protocol s)
Results in persistent or significant disabilit y/incapacit y
Is a congenital ano maly/birth defect
Revised Protocol No.: 06
Date: 09-Oct-2020 118
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Is an important m edical event (defined as a medical event(s) that m ay not be immediately life-
threatening or resul t in death or hospi [INVESTIGATOR_3092], based upon appropriate medical and 
scientific judgment, may jeopardi ze the participant or may require intervention [e.g., medical, 
surgi cal] to prevent one of the other seri ous outcomes listed in the definit ion above.) Examples 
of such events include, but are not limited to, intensive treatm ent in an emergency  room or at 
home for allergic bronchospasm; blood dyscrasias or convulsio ns that do not resul t in 
hospi [INVESTIGATOR_28689].) Potenti al drug induced liver injury  (DILI) is also considered an important 
medical event. (See Section 9.2.11 for the definit ion of potenti al DILI.) 
Pregnancy and potenti al drug induced liv er injury (DILI) must follow the same transmissio n timing 
and processes to BMS as used for SAEs (see section 9.2. 7for reporting pregnancies).
Any co mponent of a study  endpoint that i s considered related to study  therapy  should be reported 
as SAE (e.g., death is an endpo int, if death occurred due to anaphylaxis, anaphylaxis must be 
reported).
EVALUATING AES AND S AES
Assessment of Causality
ÔÇ∑The invest igator i s obligated to assess the rel ationship between study  intervent ion and each 
occurrence of each AE/SAE.
ÔÇ∑A ‚Äúreasonable possibilit y‚Äù of a relationship conveys that there are facts, evidence, and/or 
argum ents to suggest a causal relationship, rather than a relat ionship cannot be rul ed out.
ÔÇ∑The invest igator will use clinical judgment to determine the rel ationship.
ÔÇ∑Alternat ive causes, such as underlying disease(s), concomitant therapy , and other risk 
factors, as well as the temporal relat ionship of the event to study intervent ion administratio n 
will be considered and invest igated.
ÔÇ∑The invest igator will also consult the Investigator‚Äôs Brochure (IB) and/or Product 
Inform ation, for marketed products, in his/her assessment.
ÔÇ∑For each AE/SAE, the invest igator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
ÔÇ∑There may be situations in which an SAE has occurred and the invest igator has minima l 
inform ation to include in the init ial report to Sponsor. However, it is very important that the 
investigator always make an assessment of causalit y for every event before the initial 
transmissio n of the SAE data to Sponsor.
ÔÇ∑The invest igator may change his/her opi[INVESTIGATOR_3078] n of causalit y in light of follow-up informat ion 
and send a SAE fo llow-up report wi th the updated causalit y assessment.
ÔÇ∑The causalit y assessment is one of the criteria used when determining regul atory  reporting 
requi rements.
Revised Protocol No.: 06
Date: 09-Oct-2020 119
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Follow -up of AEs and SAEs
If only limited informat ion is initially available, follow-up reports are requi red. (Note: Foll ow-
up SAE reports must include the same invest igator term(s) init ially reported.) 
If an ongoing SAE changes in its intensit y or relationship to study  treatm ent or if new 
inform ation beco mes available, the SAE report must be updated and submitted within 24 hours 
to BMS (or designee) using the same procedure used for transmitt ing the init ial SAE report.
All SAEs must be fo llowed to resol ution or stabilization.
REPORTING OF SAES TO S PONSOR OR DESIGNEE
ÔÇ∑SAEs, whether related or not related to study  treatment, and pregnancies must be reported 
to BMS (or designee) immediately wit hin 24 hours of awareness of the event.
ÔÇ∑SAEs m ust be recorded on the SAE Report Form.
ÔÄ≠The requi red m ethod for SAE data reporting is through the eCRF.
ÔÄ≠The paper SAE Report Form  is only intended as a back-up option when the electronic 
data capture (EDC) sy stem  is unavailable/not functi oning for transmissio n of the eCRF 
to BMS (or designee).
ÔÇ®In this case, the paper form is transmitted via email  or confirmed facsimile (fax) 
transmissio n
ÔÇ®When paper forms are used, the original paper forms are to remain on site
ÔÇ∑Pregnancies must be recorded on a paper Pregnancy Surveillance Form and transmitted via 
email or confirmed facsimile (fax) transmissio n 
SAE Email Address: Refer to Contact [CONTACT_20491].
SAE Facsimile Number: Refer to Contact [CONTACT_20491].
SAE Telephone Contact (required for SAE and pregnancy  reporti ng): Refer to Contact 
[CONTACT_186771].: 06
Date: 09-Oct-2020 120
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
APPENDIX 4 WOMEN OF CHILDBEARING POTE NTIAL DEFINITIONS AN D 
METHODS OF CONTRACEP TION
DEFINITIONS
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post-menopausal unless 
perm anent ly sterile. Perm anent sterilizat ion m ethods include hysterectomy, bilateral 
salpi[INVESTIGATOR_1656] , and bilateral  oophorectomy.
Women in the following categories are not considered WOCBP
ÔÇ∑Prem enarchal
ÔÇ∑Prem enopausal  female wi th 1 of the f ollowing:
ÔÄ≠Docum ented hysterectomy
ÔÄ≠Docum ented bilateral  salpi[INVESTIGATOR_42451]
ÔÄ≠Docum ented bilateral  oophorectomy
Note: Docum entati on can come from the site personnel‚Äôs review of the partici pant‚Äôs medica l 
records, medical examinat ion, or m edical history  interview.
ÔÇ∑Postmenopausal  female
ÔÄ≠A postm enopausal state is defined as [ADDRESS_1230667] a serum  follicle stimulat ing horm one, (FSH) level 
> 40 mIU/mL to confirm menopause.
Note: Females treated with horm one replacement therapy, (HRT) are likely to have artificially 
suppressed FSH levels and may require a washout period in order to obtain a physi ologic FSH 
level. The durati on of the washout period is a function of the type ofHRT used. The durati on of 
the washout period below are suggested guidelines and the invest igators should use their 
judgement in checking serum FSH levels. 
ÔÇ∑1 week minimum for vaginal hormonal products (rings, creams, gels)
ÔÇ∑4 week minimum for transdermal p roducts
ÔÇ∑8 week minimum for oral products
Other parenteral products may requi re washout periods as long as 6 months. If the serum  FSH 
level is >40 mIU/ml at any time during the washout period, the woman can be considered 
postm enopausal.
CONTRACEPTION GUIDA NCE FOR FEMALE PARTI CIPANTS OF CHILD BEA RING
POTENTIAL
Any one of the approved methods of contraceptio n (highly effect ive and/or less than highly
effect ive) listed below is requi red during study  duration plus 5 half-lives of study treatm ent
BMS -986177 (4 days) plus 30 days (durati on of ovulatory  cycle) for a total of 34days 
Revised Protocol No.: 06
Date: 09-Oct-2020 121
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230668]-treatm ent completion or after treatm ent has been discont inued. Local  laws and regulat ions 
may require use of alternat ive and/or additional contraception methods.
Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of <1% per year w hen used consistently and correctly.a
ÔÇ∑Combined (estrogen -and progestogen -containing) horm onal contracepti on associ ated with 
inhibit ion of ovulationb 
ÔÄ≠oral 
ÔÄ≠intravaginal 
ÔÄ≠transderm al 
ÔÇ∑Progestogen -only hormonal contraception associated with inhibition of ovulationb 
ÔÄ≠oral 
ÔÄ≠injectable 
Highly Effective Methods That Are User Independent 
ÔÇ∑Implantable progestogen -only hormonal contracepti on associ ated with inhibit ion of 
ovulation b
ÔÇ∑Intrauterine device (IUD)c
ÔÇ∑Intrauterine hormone -releasing system (IUS)c
ÔÇ∑Bilateral tubal occlusio n
ÔÇ∑Vasectomized partner 
A vasectomized partner is a highly effec tive contraception method provided that the partner 
is the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. 
If not, an additional highly effective method of contraception should be used. 
ÔÇ∑Sexual abstinence
Sexual abstine nce is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated w ith the study treatment. 
The reliability of sexual abstinence needs to be evaluated in relation to the dura tion of the 
study and the preferred and usual lifestyle of the participant.
ÔÇ∑It is not necessary to use any other method of contraception when complete abstinence is 
elected. 
ÔÇ∑WOCBP participants who choose complete abstinence must conti nue to have pregnancy 
tests, as specified in Section 2. 
ÔÇ∑Acceptable alternate methods of highly effective contraception must be discussed in the 
event that the WOCBP participants chooses to forego complete abst inence 
NOTES: 
aTypi[INVESTIGATOR_186722] . Use should be consistent 
with local regulations regarding the use of contraceptive methods for participants participating in clinical stu dies. 
Revised Protocol No.: 06
Date: 09-Oct-2020 122
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
bHormonal contraception may be susceptible to interaction with the study treatment, which may reduce the 
efficac y of the contraceptive method. Hormonal contraception is permissible only when there is sufficient 
evidence that the IMP and other study medicatio ns will not alter hormonal exposures such that contraception 
would be ineffective or result in increased exposures that c ould be potentially hazardous. In this case, alternative 
methods of contraception should be utilized. 
cIntrauterine devices and intrauterine hormone releasing systems are acceptable methods of contraception in the 
absence of definitive drug interaction studies when hormone exposures from intrauterine devices do not alter 
contraception effectiveness
Less Than Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of >1% per year w hen used consistently and correctly.
ÔÇ∑Male or female cond om with or without spermicide. Male and female condo ms cannot be 
used simultaneously
ÔÇ∑Diaphragm  with spermicide
ÔÇ∑Cervical cap wit h spermicide
ÔÇ∑Vaginal Sponge with spermicide
ÔÇ∑Progestogen -only oral hormonal contracepti on, where inhibit ion of ovulation is not the 
primary  mechanism o f action
Unacceptable Methods of Contraception
ÔÇ∑Periodic abst inence (cale ndar, symptothermal, post- ovulation methods)
ÔÇ∑Withdrawal(co itus interruptus).
ÔÇ∑Spermicide only
ÔÇ∑Lactati on amenorrhea m ethod (LAM)
CONTRACEPTION GUIDAN CE FOR MALE PARTICIP ANTS WITH PARTNER(S) OF 
CHILD BEARING POTENT IAL.
Male participants with female partners of childbearing potenti al are eligible to participate if they 
agree to the fo llowing during the treatment and until the end of relevant sy stemic exposure.
ÔÇ∑Inform  any and all partner(s) of their participation in a clinical drug study  and the need to 
complywith contracepti on instructi ons as di rected by  [CONTACT_17062].
ÔÇ∑Male participants are required to use a condom for study durat ion and until the end o f relevant 
systemic exposure defined as 4days after the end of treatment plus an addit ional 90 days for a 
total of 94days.
ÔÇ∑Female partners of males participat ing in the study  to consider use of effective methods of 
contraception until the end of relevant systemic exposure, defined as 4days after the end of 
treatm ent with BMS -986177 in the male participant plus an addit ional 90 days for a total of 9 4
days.
ÔÇ∑Male participants with a pregnant or breastfeeding partner must agree to remain abst inent fro m 
penile vaginal intercourse or use a male condo m during each epi[INVESTIGATOR_880520] 4days after the end of treatment with BMS-986177 plus an 
additional 90 days for a total  of 94days. 
Revised Protocol No.: 06
Date: 09-Oct-2020 123
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
ÔÇ∑Refrain from  donating sperm  for th e duration of the study  treatment and for 4days after the 
end of treatment with BMS -986177 pl us an addi tional 90 days for a total of 94 days.
COLLECTION OF PREGNA NCY INFORMATION
Guidance for collection of Pregnancy  Inform ation and outcom e of pregnancy on the Pregnancy 
Surveillance Form is provided in Section 9. 2.7and the  Appendix 3 for Adverse Events and Serio us 
Adverse Events Definit ions and Procedures for Evaluat ing, Fo llow-up and Reporti ng
Revised Protocol No.: 06
Date: 09-Oct-2020 124
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
APPENDIX 5 NATIONAL INSTITUTES OF HEALTH STROKE SCA LE (NIHSS )
Revised Protocol No.: 06
Date: 09-Oct-2020 125
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Revised Protocol No.: 06
Date: 09-Oct-2020 126
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Revised Protocol No.: 06
Date: 09-Oct-2020 127
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Revised Protocol No.: 06
Date: 09-Oct-2020 128
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
  
Revised Protocol No.: 06
Date: 09-Oct-2020 129
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Revised Protocol No.: 06
Date: 09-Oct-2020 130
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Revised Protocol No.: 06
Date: 09-Oct-2020 131
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
APPENDIX 6 ABCD2 SCORE ASSESSMENT T OOL
http://www.stroke.org/sites/default/files/resources/tia -abcd2 -tool.pdf
Revised Protocol No.: 06
Date: 09-Oct-2020 132
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
APPENDIX 7 MODIFIED RANKIN S CORE
http://www.strokec enter.org/wp -content/uploads/2011/08/modified_rankin.pdf
Revised Protocol No.: 06
Date: 09-Oct-2020 133
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
APPENDIX 8 MONTREAL COGNITIVE ASSESSMENT (MO CA)
Revised Protocol No.: 06
Date: 09-Oct-2020 134
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230669]
Revised Protocol No.: 06
Date: 09-Oct-2020 135
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Revised Protocol No.: 06
Date: 09-Oct-2020 136
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Revised Protocol No.: 06
Date: 09-Oct-2020 137
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Revised Protocol No.: 06
Date: 09-Oct-2020 138
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Revised Protocol No.: 06
Date: 09-Oct-2020 139
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Revised Protocol No.: 06
Date: 09-Oct-2020 140
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230670] ives, minimize the number of study participants being exposed to the new 
investigat ional drug, reduce the burden on participants and study  centers, and streamline study 
procedures. Specifically, rand omization to t he once -daily  (QD) arms of 50 -, 100 -and 200 -mg dose 
arms will be closed for the study  while maintaining the 25- mg QD a rm and twice- daily (BID) dose 
arms (25, 50, 100 ,and 200 mg). Assessment of dose response remains the primary  object ive. Th e 
methodol ogy to achieve this will result from analysis of  data from placebo, 25 mg QD arms, and 
BID dose arms (25, 50, 100 ,and 200 mg) using MCP -MOD to assess dose response, which allows 
assessment of mult iple different dose -response patterns. Wit h fewe r study  arms primarily focused 
on one schedule, the sel ected randomizat ion is more closely  oriented to assessment of the overall 
dose-response relat ionship with some improved power for detection of a dose -response (from ~77 -
78% to 80%). The modificat ion ofthe randomizatio n to a non response- adaptive rando mizat ion 
will be completed while the study  is still in the init ial ‚Äúburn -in‚Äù period, ie, prior to addit ion of the 
200-mg doses and prior to when the response -adaptive rando mization was to be initiated. 
Participants who have received 50-mg and 100-mg QD doses will continue treatm ent until they 
complete the study  period. Data acquired in these subjects will be used for descript ive analyses, 
popul ation PK/PD modeling, and exposure -response analysis.
Maintaini ng the 25-mg QD dose is of importance in this secondary  stroke prevent ion (SSP) tri al 
for several reasons: [ADDRESS_1230671] total daily dose included in the study and thus 
presents unique informat ion in the context of dose -response co mpared t o 50, 100 ,or 200 m g QD; 
also, PK/PD modeling with assumpt ions around combinat ion dual ant iplatelet therapy  and exist ing 
data from direct oral anticoagulants (DOAC s) suggests there is potenti al for this dose of 
BMS -986177 to be efficacious in secondary  stroke prevent ion with a potenti al for lower risk of 
bleeding. The dose change will not all ow a separate dose-response assessment for QD; however, 
it is possible a QD dose can st ill be an option for Phase III based on modeling and simulat ion. The 
25 m g QD dos e plus the four BID doses will still be utilized in the exposure -response assessment. 
Popul ation PK/PD analysis and exposure -response outcom e modeling will be perform ed using 
data from  all randomized parti cipants, including those who received [ADDRESS_1230672] ion changes listed below.
Revised Protocol No.: 06
Date: 09-Oct-2020 141
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Summary of Key C hanges for Revised Protocol 0 5
Section Number & 
TitleDescription of Change Brief Rationale
Title Page A Glo bal, Phase 2, Rando mized, 
Doubl e-Blind, Pl acebo -Controlled, 
Response -Adaptive Dose -Ranging 
Study of BMS -986177, an Oral Factor 
XIa Inhibitor, for the Prevention of 
New Ischemic Stroke or New Covert 
Brain Infarct ion in Patients Receiving 
Aspi[INVESTIGATOR_880521] (TIA)
Title Changed to:
A Glo bal, Phase 2, Rando mized, 
Doubl e-Blind, Pl acebo -Controlled, 
Dose -Ranging Study of BMS -986177, 
an Oral Factor XIa Inhibitor, for the 
Prevent ion of New Ische mic Stroke or 
New Covert Brain Infarct ion in Pat ients 
Receiving Aspi[INVESTIGATOR_880522] (TIA)The ti tle was changed to 
reflect changes in the 
rando mizat ion schema.
Secti on 2 (Schedule 
of Activities), Tabl e 
2-1 (Screen ing Peri od 
Procedural  Outline),
Secti on 
9.4.1(Assessment of 
Index Stroke and 
New Strokes)National Inst itute of Health Stroke 
Scale (NIHSS) score assessment is 
removed from  screening table and 
clarified in Section 9.4.1. 
Added text to Clinical Laboratory  Tests 
Row: ‚ÄúResults fro m the screening labs 
shoul d be f axed or scanned to  
.‚ÄùNeurol ogical impairment 
will be assessed prior to 
rando mizat ion but not at 
screening.
Clarificat ion for sites.
Revised Protocol No.: 06
Date: 09-Oct-2020 142
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Summary of Key C hanges for Revised Protocol 0 5
Section Number & 
TitleDescription of Change Brief Rationale
Secti on 3.2.1 (Phase 
1 and 2a Studi es wi th 
BMS -986177) Table 
3.2.1 -1 (Highlights of 
Clinical 
Pharmaco logy after 
Oral Administrati on 
of Single and 
Multiple Doses of 
BMS -986177 to 
Healthy Parti cipants 
and Subjects with 
Renal or Hepatic 
Impairment), Secti on 
5.4.2 (BMS -986177 
with Aspi [INVESTIGATOR_248] + 
Clopi[INVESTIGATOR_7745] )Added Hepat ic Impairment PK 
properties to the table.
Added study  resul ts for drug i nteracti on 
study  with BMS -986177 wi th and 
without cl opi[INVESTIGATOR_880523].Provi de new preliminary 
data from  recently 
completed studi es.
Secti on 4 (Object ives 
and Endpo ints), 
10.3.2 (Efficacy 
Analysis)Kept estimat ion of dose response but 
removed specific ment ion of MED and 
ED90 in the primary  object ive. Primary 
analysis will be based on an MCP -
MOD m ethod.  
Also cl arified MRI assessment of 
endpo int.MED and ED90 are specific 
parts of a dose- response 
relationship. Wit h scient ific 
interest in the overall dose -
response relat ionship, the 
objective was made more 
general. Primary analysis to 
be made consistent with 
study  design, including 
powering of study .
Revised Protocol No.: 06
Date: 09-Oct-2020 143
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Summary of Key C hanges for Revised Protocol 0 5
Section Number & 
TitleDescription of Change Brief Rationale
Secti on 5.1 (Overall 
Design), 5.4 
(Scientific Rat ionale 
for Adapt ive Study 
Design), 7.2 (Method 
of Treatm ent 
Assignment), 7.4 
(Blinding), 10.1 
(Sam ple Si ze), 10.2 
(Rando mizat ion), 
10.3 (Statist ical 
Analyses), 10.3.6 
(Exposure -Response 
Analyses),10.3.7 
(Interim RAR 
Analyses)Removed reference to response 
adaptive rando mizat ion (RAR), 
including interim analyses, including 
removal of Early  Stoppi[INVESTIGATOR_880524] 5.1 (Overall Design, Follow-up 
Period), rem oval of Sect ion 5.4 
(Scientific Rat ionale for Ada ptive 
Study  Design), removal of Section 10.2 
(Rando mizat ion). Updated the study  
schemat ic to reflect the new dose arms.
Removed ref erences to dose arms for 
50 m g QD, 100 m g QD, and 200 m g 
QD BMS -986177, except to note how 
participants randomized to these a rms 
are included in analyses.
Added administrative interim analysis.To simplify  the study  design 
while maintaining scientific 
rigor to attain trial 
objectives, minimizing the 
number of study  parti cipants 
being exposed to the new 
investigat ional drug, 
reducing the burden on 
participants and 
streamlining study  
procedures. 
Secti on 5.2 
(Parti cipants), 10.1 
(Sam ple Si ze)Sample size was adjusted to indicate 
2100 participants will b e needed for 
assessment of dose response, and 
allowing approximately and up to 2350 
participants to be randomized, with 
consideration of missing data.Power was raised fro m 
approximately  80% (77 %-
78%) to 80%.  Sample size 
also reflects changes in 
treatm ent arm s used for 
dose response (removal o f 
50-, [ADDRESS_1230673] dose in the 
dose-response assessment), 
aswell as modification to a 
non
-RAR desi gn using 
MCP -MOD analysis 
method.
Secti on 5.4.1 
(Identificat ion of 
Effect ive Doses of 
BMS -986177)Doses to achieve trough concentration 
targets were updated to [ADDRESS_1230674] dose in the dose -
response assessment.
Revised Protocol No.: 06
Date: 09-Oct-2020 144
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Summary of Key C hanges for Revised Protocol 0 5
Section Number & 
TitleDescription of Change Brief Rationale
Secti on 7.3 (Sel ection 
and Timing of Dose 
for Each Parti cipant)Added another example to demonstrate 
flexible interval to ensure consistent 
AM-PM dosing schedule.To ensure consistent AM-
PM dosing schedule if 
outsi de the specified 
window.
Secti on 9.2.8 
Overdose, Appendix 
3 Appendix 3 
Adverse Events and 
Serious Adverse 
Events: Definit ions 
and Procedures for 
Recording, 
Evaluat ing, Follow 
UP and ReportingText was revised for reporting o verdose 
as an AE to align wit h Janssen process .To provi de consistency 
across protocols wit h a 
more conservat ive approach 
to capturing AEs. To align 
with Janssen as they  hold 
the database for the study . 
Secti on [IP_ADDRESS] 
(Expl oratory  
Biomarker 
Assessments ),Table 
[IP_ADDRESS] -1 (Biomarker 
Sampling Schedule), 
Secti on 9.3.3 
(Addit ional Research 
Collect ion)Removed RNA and miRNA sample 
collect ion and testing.These markers are removed 
to reduce burdens for the 
participants and the study  
sites. T hey are exploratory
and are not crit ical data for 
the assessment of efficacy 
and safet y of BMS -
986177.
Revised Protocol No.: 06
Date: 09-Oct-2020 145
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Overall Rationale for Revised Protocol 0 4, 03 -May -2019
 
 The only change implemented in this revised protocol  is to exclude partici pants with 
arteri ovenous malformat ion (AVM).
No object ives or endpoints have been changed from the original  protocol . The table below 
highlights the changes made to the protocol .
Summary of Key C hanges for Revised Protocol 04
Section Number & Title Description of Change Brief Rationale
Secti on 2: Schedule of 
Activities,
Table 2-1Included AVM as 
exclusio nary pathol ogy that 
could account for index 
symptoms.To restri ct enrollment of 
patients wi th the incidental  
imaging finding of AVM  
Secti on 6.2: Excl usion 
Criteria 1d and 1k
and
Synopsis: Key Exclusio n 
Criteria 4 and 12
Revised Protocol No.: 06
Date: 09-Oct-2020 146
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Overall Rationale for Revised Protocol 03, 05- Apr-2019
The purpose of this amendment is to update the protocol  in consideration of feedback from the 
study  sites, Steering Committee, and regul atory  agencies. Key changes include: allowance of 
clopi[INVESTIGATOR_880525] 300 mg to 600 m g pri or to si gning of  informed consent; rem oval of 
aortic arch atheroma >4 mm in thickness fro m vascular imaging criteria; clarifying that MRI is not 
requi red to determine study  eligibilit y; clarifying Day 1, pre-dose assessments to be completed, 
adding instructions for missed doses; providing guidance for the management of bleeding events; 
modificati on of the PK and PD sample collect ion window for the 12-hour post -first dose time point 
and the requirement of a 12 -and 24 -hour PK/PD sample co llection for TIA subjects on Day 1; and 
change in the SAE collect ion duration after discont inuat ion of study medication. Addit ionally, new 
appendices were added for strong CYP3A inhibitors and inducers. An exploratory  objective was 
added to assess the incidence and characteri stics of cerebral microbleeds (CMBs), hemorrhagic 
transformation of ischemic stroke and asymptomatic intracranial bleeding on Day [ADDRESS_1230675] the integrity of the study , such as 
typographical errors or cl arificat ions and changes in termino logy.The changes made in the body 
of the protocol  were also implemented in the Synopsis, where applicable. The table below 
highlights the key  changes m ade to the body  of theprotocol starting at Secti on 2.
Summary of key changes for Revised Protocol 03
Section Number & 
TitleDescription of Change Brief Rationale
Secti on 2: Schedule 
of Activities,
Table 2-[ADDRESS_1230676] ices for 
clopi[INVESTIGATOR_880526]. 
Removed aorti c arch athero ma >4 
mm as vascular imaging criteriaTo simplify  the cri teria used for 
the required evidence of large 
vessel atherosclerosis on vascular 
imaging, as an iso lated aortic arch 
atherom a is a rare imaging finding 
and therefore not routinely 
assessed wit h CTA/MRA or other 
modalities after TIA/stroke
Added clarificat ion that pre -
morbid mRS shoul d be ÔÇ£3 prior 
to index eventTo align eligibilit y criteria for TIA 
and stroke pati ents
Revised Protocol No.: 06
Date: 09-Oct-2020 147
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Summary of key changes for Revised Protocol 03
Section Number & 
TitleDescription of Change Brief Rationale
Clarified timing of sample 
collect ion for clinical laboratory  
tests pri or to treatm entTo provi de clear instructions on 
the collect ion of pre -treatm ent 
safet y laboratory  blood sam ples 
for safet y monitoring
Removed T 1 and T 2 sequence s
from Study -specific MRI 
requi rementsTo cl arify that the T1 and T2 
sequence sare not part of the 
study -specific MRI protocol . 
Secti on 2: Schedule 
of Activities,
Table 2-2Changed the clopi[INVESTIGATOR_880527] [ADDRESS_1230677] be ÔÇ£[ADDRESS_1230678] 
study  drug di scont inuedTo provi de further gui dance to 
sites regarding requi red study  
related activit ies in the case o f 
early  treatm ent di scont inuat ion.
Changed Day  97 visi t descri ption 
from Study  Discharge to End -of 
Study  To align with text
Added window ( ÔÇ±6 days) to Day 
[ADDRESS_1230679] ion from 30days to 
7daysModified to coincide wit h 
BMS -986177 half -life
Secti on 3.2.1: Phase 
[ADDRESS_1230680] ics to 
provide results from renal 
impairment study
Secti on 4:
Table 4- 1: 
Objectives and 
Endpoints for 
CV010031Added new exploratory  object ive 
to assess effect of BMS -[ADDRESS_1230681] ics of cerebral 
microbleeds (CMBs), 
hemorrhagic transformation o f 
ischemic stroke and To increase understanding of 
BMS -986177 safet y profile 
Revised Protocol No.: 06
Date: 09-Oct-2020 148
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Summary of key changes for Revised Protocol 03
Section Number & 
TitleDescription of Change Brief Rationale
asymptomat ic intracranial  
bleeding on Day  90 MRI 
Secti on 5.1: Overall 
Design, Screening 
PeriodAdded assessments to be done at 
screeningAdded to align with Schedule of 
Activities (Table 2-1)
Secti on 5.1: Overall 
Design, Double -
Blind Treatment 
PeriodRemoved vi tal signs, ECG, PK 
sample collect ion and m edical  
history  from Day  1, pre -dose 
assessmentsRemoved to ali gn wi th Schedule 
of Activities (Table 2-2)
Clarified assessments for 
participants who permanent ly 
discontinue study  treatm ent earlyTo cl arify that this is to be for 
subjects who permanent ly 
discontinue study  treatm ent and 
not for dose interruptions
Added clarificat ion that early 
discontinuat ion of study  
medicat ion shoul dbe 
distinguished from wit hdrawal o f 
inform ed consent for follow -up To cl arify that parti cipants who 
discontinue study  treatm ent shoul d 
continue study  assessments unless 
they also wi thdraw inform ed 
consent
Secti on 5.1: Overall 
Design, Early  
Stoppi[INVESTIGATOR_880528] y 
(RRR> 0.20) from  <0.05 to <0.10 
for stoppi[INVESTIGATOR_880529] 5.2: 
Parti cipantsUpdated to reflect addit ional 
countri es and sitesUpdated to current operational 
status
Secti on 6.1: 
Inclusio n Cri teria
and 
SynopsisClarify  that MRI is not required 
to determine study  eligibilit yTo also allow subjects to be 
enrolled in the study  based on CT 
imaging (consistent with accepted 
alternate m odali ties to detect 
ischemic stroke) t o reduce the si te 
and subject burden within the 
rando mizat ion window. 
Clarified that NIHSS m ust be ÔÇ£5 
at tim e of rando mizat ionTo ensure the safet y of study  
participants in case of potential 
fluctuati ons in the NIHSS between 
screening and randomization.
Revised Protocol No.: 06
Date: 09-Oct-2020 149
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Summary of key changes for Revised Protocol 03
Section Number & 
TitleDescription of Change Brief Rationale
Removed aorti c arch athero ma 
>4mm as vascular imaging 
criteria and added criteria related 
to severit y of atheroscl erotic 
plaqueTo simplify  the cri teria used for 
the required evidence of large 
vessel atherosclerosis on vascular 
imaging, as an iso lated aortic arch 
atherom a is a rare imaging finding 
and therefore not routinely 
assessed wit h CTA/MRA or other 
modalities after TIA/stroke
Added requirement that pre -
morbid mRS m ust be ÔÇ£[ADDRESS_1230682] total duration 
of requi red contraceptive use
Secti on 6.2: 
Exclusio n Cri teria
and 
SynopsisAdded specifics regarding 
petechiae on brain imagingTo ensure participant safet y, the 
definit ion of petechiae was clarify 
to include only h emorrhagic 
infarcti on type 1 (HI1) defined 
petechiae on brain imaging
Added ‚Äúother PPIs‚Äù to acceptable 
concomitant medicat ions and
disallowed cimeti dine as an H2 
blockerTo allow for regional differences 
in PPI [INVESTIGATOR_880530] i t 
inhibits CYP2C19
Added reference to appendices 
including strong CYP3A 
inhibitors and inducersTo support sites in the quick 
ident ificat ion of strong CYP3A4 
inhibitors and inducers .
Secti on 7.1: 
Treatments 
Administered
Table 7.[ADDRESS_1230683] igational Products (IP s) in 
tableTo avoi d confusi on and allow 
flexibilit y for future revi sions to 
supplied IP .
Changed the clopi[INVESTIGATOR_880527] [ADDRESS_1230684] ices for 
clopi[INVESTIGATOR_880438].
Secti on 7.3: 
Selection and Added dosing instructions for 
missed dosesTo provi de detailed guidance for 
the handling of missed doses of 
blinded study  medicati on
Revised Protocol No.: 06
Date: 09-Oct-2020 150
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Summary of key changes for Revised Protocol 03
Section Number & 
TitleDescription of Change Brief Rationale
Timing of Dose for 
Each Parti cipant
Secti on 7.4: 
BlindingAdded scenarios where the DMC 
and the RAR vendor will receive 
unblinded data for safet y 
assessmentUpdated for consistency wit h 
DMC rol e and study  design
Secti on 7.7.1: 
Prohibited and/or 
Restricted 
TreatmentsShortened the time for collect ion 
of medicat ions taken prior to 
study  drug administrati on from 30 
days to 7 days 
Added reference to appendices 
including strong CYP3A 
inhibitors and inducersRevised to remove burden fro m 
sites and parti cipants
To support sites in the quick 
ident ificat ion of strong CYP3A4 
inhibitors and inducers
Secti on 8.1: 
BleedingRemoved m easures that m ay be 
considered for management of 
bleeding events and referred to 
Secti on 9.2.1To update the guidance for the 
handling of bleeding b ased on 
newly available informat ion
Secti on 8.4: 
Emergency  
ProceduresAdded guidance for use of 
thrombolytic therapy  for the 
treatm ent of new stroke, 
including possibilit y of 
unblindingBased on Invest igator feedback, 
added further guidance on the 
handling of the blinded study  
medicat ion if a subject qualifies 
for tPA treatm ent after a new 
stroke event.
Secti on 8.7: Post -
Study  Treatm ent 
Follow-upClarified requi red assessment for 
subjects who have study  drug 
discontinuedTo provi de further gui dance to 
sites regarding requi red study  
related activit ies in the case o f 
early  treatm ent di scont inuat ion.
Secti on 9.2.1:
BleedingAdded measures to consider for 
management of bleeding events 
requi ring interventionTo update the guidance for the 
handling of bleeding events that 
requi re intervent ion based on 
newly available informat ion.
Secti on 9.2.3:
Time Period and 
Frequency for 
Collect ing AE and 
SAE Inform ationModified required duration of 
SAE collect ion from 30 day s to 
7daysModified to coincide wit h 
BMS-986177 half -life
Revised Protocol No.: 06
Date: 09-Oct-2020 151
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Summary of key changes for Revised Protocol 03
Section Number & 
TitleDescription of Change Brief Rationale
Secti on 9.2.7: 
PregnancyUpdated l anguage for scenario 
where study  treatm ent m ay be re-
initiated fo llowing pregnancy Update to align wit h BMS 
protocol  model docum ent
Secti on 9.2.8: 
OverdoseUpdated definit ion of overdose to 
match Appe ndix 3To align the definit ion of overdose 
throughout the protocol
Secti on 9.2.13 Added details for brief physical 
examTo cl arify assessments that 
constitute protocol -requi red brief 
physical exam
Secti on 9.2.16: 
Clinical Safety  
Laboratory  
AssessmentsClarified collection schedule for 
clinical laboratory  samples; added 
Day 60 sampleDay 60 central  clinical  laboratory  
assessment added  
.
Secti on 9.3.1: PK 
Assessments
and
Secti on [IP_ADDRESS]: 
Biomarker Sam pling 
ScheduleChanged the c ollect ion window 
for the [ADDRESS_1230685] dose 
PK/PD sample on Day  1 from 
ÔÇ±4hours to -6/+4 hours.
Clarified the expectation for the 
protocol -specified 12- and 24 -
hour sam ple collection for 
participants wi th TIA and 
explained that the blood sample 
shoul d be collected pri or to 
hospi [INVESTIGATOR_880531] <24 hours 
after the index event. Broadened the sampling window 
from +4 hours to -6/+[ADDRESS_1230686] ice variat ion 
regarding hospi[INVESTIGATOR_880532] 9.4.2: 
Assessment of Risk 
for Subsequent 
Stroke Associated 
with Index TIAModified text to reflect that the 
presence of motor symptom s can 
also be used as one of the 
qualifying criteria for TIATo allow for enrollment of TIA 
patients wi th an ABCD2score of 
ÔÇ≥6 in the presence of motor 
symptoms
Secti on 10.1: 
Sample Si ze 
Determinat ion
and
SynopsisClarified the com posite event rate 
that is being used f or sam ple size 
determinat ion
Revised assumption for sample 
size determinat ion for subjects 
who discont inue early wit hout 
usable endpo int data fro m 5% to 
10%Added for clarit y of com posite 
event rate being used to determine 
sample size
Revised to align with RAR report
Revised Protocol No.: 06
Date: 09-Oct-2020 152
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Summary of key changes for Revised Protocol 03
Section Number & 
TitleDescription of Change Brief Rationale
Secti on 10.4.2:
Efficacy AnalysesModified sect ion to tabul ar form 
matching endpo ints and statist ical 
methodTo align with preferred 
presentation of endpo ints and 
methods
Secti on 10.4.3: 
Safety AnalysesModified section to tabul ar form 
matching endpo ints and statist ical 
method
Added new exploratory  object ive 
endpo intTo align with preferred 
presentation of endpo ints and 
methods
Secti on 10.4.7: 
Interim RAR 
AnalysesAdded scenarios where interim 
RAR will be used t o stop the tri al 
early  for futility or expected 
successTo cl early define early  stoppi[INVESTIGATOR_880533] 4Revised total durat ion of 
contraceptive use for WOCBP 
from 32days to 34 daysCorrected i nconsistency  for total  
durati on of  requi red contraceptive 
use
Appendix 11Added new appendix for strong 
CYP3A inhibitorsAdded to inform sites of 
commo nly administered 
medicat ions that m ay qualify
Appendix 12Added new appendix for strong 
CYP3A inducersAdded to inform sites of 
commo nly administered 
medicat ions that m ay qualify
Revised Protocol No.: 06
Date: 09-Oct-2020 153
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230687] 450 subjects complete the Day 21 visit.  
The PK sampling schedule was changed for Day s 21 and 90; PD sample co llection changed to be 
consistent with the revised PK sample times and sample collection window. The BMS -supplied 
aspi[INVESTIGATOR_880534] -Invest igational Product (Non -IP) to IP. 
INR was added to the blinded analytes on Days 21 and 90. Additionally, Appendix 3 (Adverse 
Events) was updated as part of standardi zation of AE collect ion procedures and details by [CONTACT_429].
No object ives or endpoints have been changed from the original protocol , except f or the rem oval 
of Barthel  Index. Other changes are administrative changes that do not impact the scient ific 
integrity of the study , such as typographical errors or clarificati ons and changes in termino logy. 
The changes made in the body  of the protocol  were also implemented in the Synopsis where 
applicable. The table below highlights the key changes made to the body  of the protocol starting 
at Secti on 2.
Summary of Key C hanges f or Revised Protocol 02
Section 
Number & 
TitleDescription of Change Brief Rationale
Secti on 2:
Table 2-2Updated table to reflect addit ion 
of central  clinical  laboratory  
sample collect ion at Day  60 si te 
visit with expanded visit window.
Added evaluat ion of MoCA and 
subset of WAIS -IV by  [CONTACT_880600] 60 central  clinical  laboratory  
assessment added  
.
The accuracy  and reliabilit y of 
cogni tive impairment instruments used 
in clinical trials is thought to be 
improved by [CONTACT_880601].
Secti on 5.1: 
Study  Design 
and SynopsisAdded DMC review after the first 
[ADDRESS_1230688] 450 subjects who complete 
the Day  21 visit will be reviewed by 
[CONTACT_880602] a recommendat ion 
about continuing central laboratory  
sampling on Day  60.
Secti on 5.1.1:
Data 
Moni toring and 
Other External 
CommitteesAdded key r esponsibili ties of the 
DMC to m ake recommendation 
for continued central clinical 
laboratory  testing.See above for rationale.
The RAR is being managed by [CONTACT_441895].: 06
Date: 09-Oct-2020 154
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Summary of Key C hanges f or Revised Protocol 02
Section 
Number & 
TitleDescription of Change Brief Rationale
Removed details about ADC. leading world experts for RAR design 
and they  will be checking the model 
simulat ion results and the algorithm 
outputs. The probabilit y of having an 
erroneous algorithm is very  low. In 
addition, the DMC will review the 
RAR results every  [ADDRESS_1230689] ician has sufficient experience to 
assess whether the algorit hm and 
rando mizat ion allocation are 
reasonable.
Secti on 7.1, 
Table 7.1 -1:
Study  
Treatments for 
CV010031Updated descript ion of placebo 
for BMS -[ADDRESS_1230690] (IP) to IPBecause BMS is providing the aspi[INVESTIGATOR_60463], the designation was 
updated to reflect standard process.
Secti on 7.2: 
Method of 
Treatment 
AssignmentClarified details related to the use 
of the IRT systemUpdated to reflect proper termino logy 
for use of the IRT system
Secti on 9.2.8: 
OverdoseUpdated overdose text to reflect 
new definit ions in the updated 
Appendix [ADDRESS_1230691] updated Appendix 3 
which describes AE collection, 
definit ion and reporting requirements
Secti on 9.2.16:
Clinical Sa fety 
Laboratory  
AssessmentsINR added to the blinded analytes 
on Day s 21 and 90Inconsistency  corrected for blinding of 
coagul ation factors
Secti on [IP_ADDRESS], 
Table [IP_ADDRESS] -1Modified PK co llection times 
relative to dose to 2 Hours ( -2/+4) 
for BMS -986177, aspi [INVESTIGATOR_880535] s [ADDRESS_1230692] ion times for 
BMS -986177 changed to align to ease 
site burden for Day  21 and 90 visits
Secti on [IP_ADDRESS], 
Table [IP_ADDRESS] -1Aligned bio marker collect ion 
schedule with PK sample 
collect ion schedule by  [CONTACT_880603] [ADDRESS_1230693] ion.
Revised Protocol No.: 06
Date: 09-Oct-2020 155
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Summary of Key C hanges f or Revised Protocol 02
Section 
Number & 
TitleDescription of Change Brief Rationale
Secti on 9.3.3: 
Addit ional 
Research 
Collect ionRemoved text i ndicating that end -
of-study  is defined as [ADDRESS_1230694] 
updated AE reporting definit ions 
and details.Appendix updated as part of 
standardization o f AE collection 
procedure and details by [CONTACT_2728].
Revised Protocol No.: 06
Date: 09-Oct-2020 156
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Overall Rationale for Revised Protocol 01, 20- Sept -2018
The purpose of this amendm ent is to update the protocol  in consideration of  
 further engagement with the Steering Committee (SC) and 
Key Opi[INVESTIGATOR_880536] (KOLs) which provi ded new insights into the target populat ion and 
operati onal feasibilit y of the protocol  as initially written. Key changes include the scenarios for 
clopi[INVESTIGATOR_880537] 600 mg 
to 300 mg. Some inclusio n/excl usion criteria were modified to better defi ne the target populat ion. 
The collect ion of Barthel  Index, to assess the impact of stoke on daily living, was removed from 
the protocol. The introducti on of the high-dose BMS [ADDRESS_1230695] the scient ific 
integrity of the study, such as typographical errors or clarificat ions and changes in termino logy for 
‚Äúnon -hemorrhagic stroke‚Äù to ‚Äúischemic stroke‚Äù and ‚Äúsilent‚Äù brain infarct ion to ‚Äúcovert‚Äù brain 
infarction .The changes made in the body  of the protocol  were also implemented in the Synopsis 
where applicable. The table below highlights the key changes made to the body of the protocol 
starting at Section 2.
Summary of Key C hanges for Revised Protocol 01
Section
Number & 
TitleDescription of Change Brief Rationale
Secti on 2:
Tables [ADDRESS_1230696] change 
to: NIHSS score for qualifying 
event fro m ÔÇ£7 to ÔÇ£5, scenarios 
where a clopi[INVESTIGATOR_880538], and revisio ns to the 
Day [ADDRESS_1230697] endpoi nt data.
Secti on 4: 
Objectives and 
Endpoints 
Table 4-1Updated object ives and 
endpo ints tabl e to refl ect 
removal of Barthel  Index and 
change in termino logy for ‚Äúnon -
hemorrhagic stroke‚Äù to 
‚Äúischemic stroke‚Äù and ‚Äúsilent‚Äù 
brain infarct ion to ‚Äúcovert‚Äù brain 
infarctionBarthel  Index was rem oved as i t was 
thought to offer minimal addit ional 
inform ation compared to other 
assessments being co llected, and the 
collect ion woul d be outwei ghed by  [CONTACT_880604] m ultiple assessments.
Termino logy was m odified to better 
align with more generally used terms.
Revised Protocol No.: 06
Date: 09-Oct-2020 157
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Summary of Key C hanges for Revised Protocol 01
Section
Number & 
TitleDescription of Change Brief Rationale
Secti on 5.1: 
Study  Design 
and SynopsisRevised clopi[INVESTIGATOR_880527] 600 mg to 300 mg 
and clarified scenarios under 
which clopi[INVESTIGATOR_880539].
Updated study  schematic (Fi gure 
5.1-1) and clarified the Day 90 
MRI window.
The enro llment of participant to 
the 200 m g QD or BID 
BMS -986177 doses was also 
changed to be implemented in a 
staggered mannerClopi[INVESTIGATOR_880540] 600 m g to 300 m g due to similar 
clinical outcomes between these two 
loading doses (i e, CHANCE vs. POINT) 
and concerns about site/country  
acceptabilit y since the study  is planned 
for global recrui tment.
The Day  90 MRI window was clarified 
to allow flexibilit y in an attempt to 
minimize Day  90 MRI data l oss.
As BMS -986177 has not been studied in 
this acute stroke populat ion in 
combinat ion with DAPT therapy , it is 
prudent for the Sponsor to take a 
staggered approach to ensure patient 
safet y. There fore, the high doses of 
BMS -986177 will not be started until 
some safety  data are obtained and 
reviewed by  [CONTACT_1363].
Secti on 6:
Study  
Popul ationVarious inclusio n and exclusio n 
criteria were m odified to reflect 
feedback fro m SC.
Other changes were made to 
align with allowance for pre -
rando mizat ion treatment with 
clopi[INVESTIGATOR_880541] a vis clopi[INVESTIGATOR_880542].
Concomitant pantoprazole use 
was allowed.
Scenarios where UFH or 
LMWH were allowed for post -
stroke DVT prophylaxis prior to 
rando mizat ion.NIHSS score for qualifying event was 
changed from ÔÇ£7 to ÔÇ£[ADDRESS_1230698] 
on cl opi[INVESTIGATOR_880543] a barri er 
to enrollment for participants who need 
treatm ent wi th acid -reducing agents
Revised Protocol No.: 06
Date: 09-Oct-2020 158
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Summary of Key C hanges for Revised Protocol 01
Section
Number & 
TitleDescription of Change Brief Rationale
Secti on 7.2:
Treatment 
AssignmentSecti on updated to reflect 
staggered approach for the 200 -
mgQD and/or BID dose groupsRandomization (previously  equally 
allotted to 8 doses) needed to be revised 
to 6 doses due to the staggered approach 
being emplo yed for the introduction of 
200 m g BMS -986177 QD and/or BID 
doses.
Secti on 7.3:
Selection and 
Timing of Dose 
for Each 
Parti cipantTiming of BMS -[ADDRESS_1230699] 
of food in the dose range being 
investigated for BMS -986177
Secti on 9.2.12:
Magnet ic 
Resonance 
Imaging (MRI)Clarified details for Day  90 MRI 
window.Expanded to Day  90 MRI window to 
+10 day s and reinforced the need for 
continued treatment if part icipants 
utilize the w indow. MRI window 
intended to allow site and machine 
scheduling flexibilit y to avoi d loss of  
data for the Day  90 MRI endpoint.
Secti on 9.2.16:
Clinical Safety  
Laboratory  
AssessmentsPT added to Clinical laboratory  
Assessments table for Day s 21 
and 90PT added to clinical laboratory  
assessments as bio marker to confirm 
target sel ectivity. Resul ts noted as 
‚Äúblinded to Invest igator, site staff and 
Sponsor‚Äù
Secti on [IP_ADDRESS], 
Table [IP_ADDRESS] -1Modified PK sample co llection 
times for BMS -[ADDRESS_1230700] ion at time o f outcom e 
event added to help characterize study  
drug exposure for participant having an 
outcom e event
Secti on [IP_ADDRESS], 
Table [IP_ADDRESS] -1Aligne d Biomarker collect ion 
schedule with PK sample 
collect ion schedule.Alignment of sampling schedules to 
increase site compliance and pair data 
Revised Protocol No.: 06
Date: 09-Oct-2020 159
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
Summary of Key C hanges for Revised Protocol 01
Section
Number & 
TitleDescription of Change Brief Rationale
Removed CRP from  biomarker 
assessment and added PT to 
sample collect ion schedulecollect ion timepo int for future P K-PD 
analyses.
CRP rem oved due to low value vs 
operati onal com plexi ty/blood volume 
considerations. 
PT added to assess target select ivity.
Secti on 9.4:
Other 
AssessmentsNIHSS score for qualifying 
event was changed from ÔÇ£7 to 
ÔÇ£5.
Added co llection of NIHSS , 
mRS, MoCA and DSST at the 
time of new stroke or major 
bleeding event.
Removed Bathel  Index from  
Secti on 9.4.4NIHSS score for qualifying event was 
changed from ÔÇ£7 to ÔÇ£5 based on 
feedback fro m SC. 
Added/clarified which assessments are 
to be collected at the time of a new 
stroke or m ajor bleeding event to 
provi de inform ation about cognit ive 
funct ion and stroke severit y close to the 
time of a new outcome event.
Barthel  Index was rem oved as i t was 
thought to offer minimal addit ional 
inform ation compared to o ther 
assessments being co llected, and the 
collect ion woul d be outwei ghed by  [CONTACT_880604] m ultiple assessments.
Secti on 10.2:
RandomizationSecti on updated to reflect 
staggered approach for 200 mg 
QD and/or BID BMS -[ADDRESS_1230701] ional 
Classificat ion, and ISTH, 
PLATO and B ARC Bleeding 
Criteria rem oved. Other re -
numbered accordingly.Barthel  Index rem oved from study  
assessments.
Addit ional risk criteria (including 
NYHA Score) for participants fro m 40 
to ÔÇ£54 years of age rem oved.
Bleeding defini tions to be provi ded 
separately  in the study  endpoints 
manual.
Revised Protocol No.: 06
Date: 09-Oct-2020 160
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230702]
1)If the participant is taking or has taken one of the combined P -gp and strong CYP3A inhibitors 
listed below in the 7 days prior to randomizat ion, do NOT randomize into the AXIOMATIC 
(CV010031) trial (as per Protocol, Section 6.2, Exclusion Criteria 2f).
2)The participant must discontinue the study drug (BMS -986177) if they require treatment wit h 
one of the strong CYP3A inhibitors listed below (as per Section 8.5, Other Reasons for 
Permanent Discontinuation from Study Treatment).
3)For questions, please submit quest ions to the  system at .If the 
 system  is unavailable at the time of your questi on, pl ease call the  Medical  Moni tor 
at .
Therapeutic Class Agent
Antibioticsclarithromycin
telithromycin
troleando mycin
Antifungalsitraconazo le
ketoconazo le
posaconazole
voriconazo le
Antiviralsboceprevir
danoprevir /ritonavir co mbination
ombitasvir/paritaprevir/ritonavir combinat ion
ombitasvir/partiaprevir/ritonavir/dasabuvir 
combinat ion
telaprevir
Calcium Channel Blockers mibefradil
Antidepressants nefazodone
Cancer Treatm ents idelalisib
Diuretics conivaptan
Food Products grapefruit juice double strength*
Kinase Inhibitors idelalisib
Treatments of HIV atazanavir
Revised Protocol No.: 06
Date: 09-Oct-2020 161
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -70033093 Factor XIa Inhibitor
cobicistat (GS -9350)
darunavir
elvitegravir /ritonavir co mbination
indinavir
indinavir /ritonavir co mbination
lopi[INVESTIGATOR_5326] r /ritonavir co mbination
nelfinavir
ritonavi r
saquinavir
saquinavir /ritonavir combinat ion
tipranavi r /ritonavir combinat ion
*made from frozen concentrate and reconstituted with half the normal amount of water
Listing provided by [CONTACT_880605] : UW Drug Interaction Database, FDA Database¬Æ, Lexicomp Database¬Æ Version 0.1
Revised Protocol No.: 06
Date: 09-Oct-2020 162
Approved
8.0
v
Approved
1.0
v
Clinical Protocol CV010031
BMS -986177/JNJ -[ADDRESS_1230703]
1) If the participant is taking or has taken one of the combined P -gp and strong CYP3A inducers 
listed below in the 7 days prior to randomizat ion, do NOT randomize into the AXIOMATIC 
(CV010031) tria l (as per Protocol, Section 6.2, Exclusion Criteria 2f).
2)The participant must discontinue the study drug (BMS -986177) if they require treatment wit h 
one of the strong CYP3A4 inducers listed below (as per Section 8.5, Other Reasons for 
Permanent Discontinuation from Study Treatment).
3)For questions, please submit quest ions to the  system at .If the 
 system  is unavailable at the time of your questi on, pl ease call the  Medical  Moni tor 
at .
Therapeutic Class Agent
Antiandrogensapalutamide
enzalutamide
Antibioticsrifabutin
rifampin
Anticonvulsantscarbamazepi[INVESTIGATOR_880544]'s Wort extract
Other Ant ilipemics avasimibe
Other Ant ineoplast ics mitotane
Listing provided by [CONTACT_880605] : UW Drug Interaction Database, FDA database¬Æ, Lexicomp¬Æ Database Version 1.0
Revised Protocol No.: 06
Date: 09-Oct-2020 163
Approved
8.0
v
Approved
1.0
v